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Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food
Allergens (NDA) derived dietary reference values (DRVs) for sodium. Evidence from balance studies on
sodium and on the relationship between sodium intake and health outcomes, in particular
cardiovascular disease (CVD)-related endpoints and bone health, was reviewed. The data were not
sufﬁcient to enable an average requirement (AR) or population reference intake (PRI) to be derived.
However, by integrating the available evidence and associated uncertainties, the Panel considers that a
sodium intake of 2.0 g/day represents a level of sodium for which there is sufﬁcient conﬁdence in a
reduced risk of CVD in the general adult population. In addition, a sodium intake of 2.0 g/day is likely to
allow most of the general adult population to maintain sodium balance. Therefore, the Panel considers
that 2.0 g sodium/day is a safe and adequate intake for the general EU population of adults. The same
value applies to pregnant and lactating women. Sodium intakes that are considered safe and adequate
for children are extrapolated from the value for adults, adjusting for their respective energy requirement
and including a growth factor, and are as follows: 1.1 g/day for children aged 1–3 years, 1.3 g/day for
children aged 4–6 years, 1.7 g/day for children aged 7–10 years and 2.0 g/day for children aged
11–17 years, respectively. For infants aged 7–11 months, an Adequate Intake (AI) of 0.2 g/day is
proposed based on upwards extrapolation of the estimated sodium intake in exclusively breast-fed
infants aged 0–6 months.
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Summary
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Food Allergens (NDA) was asked to deliver a Scientiﬁc Opinion on dietary reference values (DRVs) for
the European population, including sodium.
Sodium (Na+) is the dominant cation in the extracellular ﬂuid (ECF) of the body. The functions of
sodium lie in its participation in the control of the volume and systemic distribution of total body
water; enabling the cellular uptake of solutes; and the generation via interactions with potassium of
transmembrane electrochemical potentials.
Dietary sodium deﬁciency is rare in healthy European populations. Sodium chloride and other
sodium salts are ubiquitous in the diet, and there are adaptive physiological mechanisms that reduce
the losses of sodium in urine, faeces and sweat at low levels of sodium intake. Sodium chloride added
during industrial food processing and discretionary use or food preservation is the major source of
dietary sodium in Western diets. Other sources of sodium include inherently native sources and
sodium-containing food additives, in which sodium may be associated with anions other than chloride.
In healthy people, almost all dietary sodium is absorbed, even at very high level of intake.
Following absorption, sodium ions are distributed by portal and systemic circulations, where their
concentrations are maintained within a narrow range. Up to 95% of sodium body content is in the ECF,
including a large proportion in bone, skin and muscle. The pool of sodium in bone, muscle and skin
has been proposed to be a sodium depot or reserve, but could also have a homeostatic and adaptive
role as an extra-renal clearance depository for handling excessive systemic accumulation of sodium.
The excretion and retention (i.e. homeostasis) of sodium is effected by an integrated neurohormonal
control from centres located in the hypothalamus. The kidney is the main organ mediating the
excretion and retention of sodium. It efﬁciently excretes sodium in response to high dietary intakes
and salvages sodium when dietary intake is low. By contrast, sodium losses in the faeces are relatively
stable and typically limited to a few mmol/day. The amount of sodium lost in sweat can vary widely,
depending on, for example environmental conditions or the levels of physical activity.
The Panel reviewed the reliability of the methods and biomarkers used to assess sodium intake. Urinary
sodium excretion in 24-h collections is considered the most reliable biomarker of sodium daily intake.
However, a single 24-h urine collection may not reliably reﬂect an individual’s usual intake. Also, incomplete
collections of 24-h urine samples can introduce bias in measuring daily sodium excretion. Multiple collections
and quality control procedures are required to estimate an individual’s usual sodium intake reliably.
Homeostatic mechanisms maintain the plasma sodium concentration of healthy individuals within a
narrow range. Hyponatraemia and hypernatraemia are typically related to disorders affecting water
and electrolyte balances. They are seldom due to inappropriate sodium intake. The Panel considers
that there is no biomarker of sodium status that can be used for setting DRVs for sodium in the
general population.
Evidence from balance studies on sodium and on the relationship between sodium intake and
health outcomes, in particular cardiovascular disease (CVD)-related endpoints and bone health, was
reviewed.
Balance studies indicate that adaptation mechanisms enable the maintenance of sodium balance
over a wide range of sodium intakes. Recent data from a long-term study of sodium and other
electrolytes metabolism suggest that rhythmical variations in the sodium body pools may occur
independently from sodium intake. This complicates the interpretation of balance studies and of 24-h
urine collections. Overall, the Panel considers that balance studies cannot be used to determine sodium
requirements.
The literature on the relationship between sodium intake and selected health outcomes, i.e. blood
pressure, cardiovascular disease-related endpoints and bone health, was systematically reviewed. To
minimise the risk of bias in the evidence used in the assessment, the review was restricted to
randomised controlled trials (RCTs) and prospective studies, studies that excluded participants with
pre-existing medical conditions, and studies that used at least one 24-h urinary collection to estimate
sodium intake. Risk of bias in eligible studies was assessed using the OHAT-NTP critical appraisal tool.
Studies were categorised according to their risk of bias based on a three-tier system (i.e. at low,
moderate or high risk of bias).
Eligible studies on bone health provided limited and inconsistent evidence for an association
between sodium intake and bone mineral density and could not be used to set DRVs for sodium.
Meta-analyses and modelling of the dose–response between 24-h sodium urinary excretion (UNa)
and blood pressure were conducted. Random effects meta-analyses of the 32 eligible RCTs showed
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signiﬁcant effects of sodium reduction on systolic blood pressure (SBP) (3.9 (95% CI 5.1, 2.8)
mm Hg; I2 61.9%, p < 0.001) and diastolic blood pressure (DBP) (2.0 (2.8, 1.2) mm Hg; I2
60.6%, p < 0.001). Using mixed-effects meta-regression models, mean SBP increased by 5.3 mm Hg
(95% CI: 3.6–6.9 mm Hg) and mean DBP increased by 2.6 mm Hg (95% CI: 1.6–3.7 mm Hg) for
each 100 mmol (2.3 g)/24 h increase in mean UNa. The Panel considers that there is strong evidence
for a positive relationship between UNa and SBP and DBP over the range of mean UNa observed in the
studies (between 49 and 209 mmol/24 h (1.3–4.8 g/day)). This is also supported by an eligible
prospective observational study that investigated the long-term relationship between UNa and blood
pressure levels and by the eligible studies that assessed the relationship between UNa and risk of
hypertension (two RCTs and two prospective observational studies).
A small number of prospective observational studies assessing the relationship between UNa and CVD
risk was eligible for the assessment: three cohort studies investigated the association between UNa and
risk of stroke or coronary heart disease (CHD); three cohort studies investigated the association between
UNa and risk of total CVD. Overall, only limited conclusions can be drawn on the relationship between
UNa and risk of CVD. The Panel considers that, over the range of UNa observed in these studies:
• There is some evidence for a positive association between UNa and risk of CHD. The positive
relationship between UNa and blood pressure levels/incidence of hypertension, which is an
established independent risk factor for CHD, supports this association.
• There is some evidence for an inverse association between UNa and risk of stroke. However, the
number of eligible studies available investigating this outcome is small and the mechanisms by
which UNa could be inversely associated with the risk of stroke are unclear, particularly
considering the positive relationship between UNa and blood pressure, which is an established
risk factor for stroke.
• There is some evidence for a positive association between UNa and risk of total CVD, which is
consistent with the evidence for a positive association between UNa and risk of CHD and the
positive relationship between UNa and blood pressure levels/incidence of hypertension.
Overall, the Panel considers that the available evidence cannot be used to determine the sodium
requirement in the population; so, an average requirement (AR) and population reference intake (PRI)
for sodium cannot be established. Data on the relationship between sodium intake and blood pressure
or CVD risks could inform about the levels of sodium intake associated with a reduced risk of chronic
diseases. Balance studies could inform about the levels of sodium intake that are adequate to maintain
a null sodium balance. Expert judgement was used to weigh the available evidence and take account
of the associated uncertainties by means of a formal expert knowledge elicitation (EKE). The EKE
allows a representation of the uncertainty about the quantity (parameter) of interest using a
probability distribution.
Integrating the available evidence and associated uncertainties, the Panel considers that a sodium
intake of 2.0 g/day represents a level of sodium for which there is sufﬁcient conﬁdence in a reduced
risk of CVD in the general adult population. Also, a sodium intake of 2.0 g/day is likely to allow most of
the general adult population to maintain physiological sodium balance. Therefore, the Panel considers
that 2.0 g sodium/day is a safe and adequate intake for the general EU population of adults.
The requirement for the daily accretion rate of sodium in fetal and maternal tissues can be met by
the adaptive changes that maintain sodium homeostasis during pregnancy. There is no evidence that
the sodium requirement of lactating women differs from the requirement of non-lactating women. So,
2.0 g of sodium/day is a safe and adequate intake for pregnant and lactating women.
Sodium intakes that are considered safe and adequate for children are extrapolated from the value
for adults, adjusting for their respective energy requirement and including a growth factor, and are as
follows: 1.1 g/day for children aged 1–3 years, 1.3 g/day for children aged 4–6 years, 1.7 g/day for
children aged 7–10 years and 2.0 g/day for children aged 11–17 years, respectively.
For infants aged 7–11 months, an Adequate Intake (AI) of 0.2 g/day is proposed based on upwards
extrapolation of the estimated sodium intake in exclusively breast-fed infants aged 0–6 months, on the
basis of the energy requirements of the respective age groups.
The Panel notes that the mean/median intake of sodium in the European adult populations exceeds
the safe and adequate intakes set for sodium. The risk of inadequate (insufﬁcient) intake in European
populations is low. Concerns for European populations instead relate to excess intake of sodium.
Therefore, in practice, the values proposed can be used to inform the setting of population goals for
the reduction in sodium intake.
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Background as provided by the European Commission
The scientiﬁc advice on nutrient intakes is important as the basis of Community action in the ﬁeld
of nutrition, for example such advice has in the past been used as the basis of nutrition labelling. The
Scientiﬁc Committee for Food (SCF) report on nutrient and energy intakes for the European
Community dates from 1993. There is a need to review and if necessary to update these earlier
recommendations to ensure that the Community action in the area of nutrition is underpinned by the
latest scientiﬁc advice.
In 1993, the SCF adopted an opinion on the nutrient and energy intakes for the European Community.1
The report provided Reference Intakes for energy, certain macronutrients and micronutrients, but it did
not include certain substances of physiological importance, for example dietary ﬁbre.
Since then new scientiﬁc data have become available for some of the nutrients, and scientiﬁc
advisory bodies in many European Union Member States and in the United States have reported on
recommended dietary intakes. For a number of nutrients these newly established (national)
recommendations differ from the reference intakes in the SCF (1993) report. Although there is
considerable consensus between these newly derived (national) recommendations, differing opinions
remain on some of the recommendations. Therefore, there is a need to review the existing EU
Reference Intakes in the light of new scientiﬁc evidence, and taking into account the more recently
reported national recommendations. There is also a need to include dietary components that were not
covered in the SCF opinion of 1993, such as dietary ﬁbre, and to consider whether it might be
appropriate to establish reference intakes for other (essential) substances with a physiological effect.
In this context the EFSA is requested to consider the existing Population Reference Intakes for
energy, micro- and macronutrients and certain other dietary components, to review and complete the
SCF recommendations, in the light of new evidence, and in addition advise on a Population Reference
Intake for dietary ﬁbre.
For communication of nutrition and healthy eating messages to the public it is generally more
appropriate to express recommendations for the intake of individual nutrients or substances in food-
based terms. In this context the EFSA is asked to provide assistance on the translation of nutrient
based recommendations for a healthy diet into food based recommendations intended for the
population as a whole.
Terms of reference as provided by the European Commission
In accordance with Article 29(1)(a) and Article 31 of Regulation No 178/2002,2 the Commission
requests EFSA to review the existing advice of the Scientiﬁc Committee for Food on population
reference intakes for energy, nutrients and other substances with a nutritional or physiological effect in
the context of a balanced diet which, when part of an overall healthy lifestyle, contribute to good
health through optimal nutrition.
In the ﬁrst instance the EFSA is asked to provide advice on energy, macronutrients and dietary
ﬁbre. Speciﬁcally advice is requested on the following dietary components:
• Carbohydrates, including sugars;
• Fats, including saturated fatty acids, polyunsaturated fatty acids and monounsaturated fatty
acids, trans fatty acids;
• Protein;
• Dietary ﬁbre.
Following on from the ﬁrst part of the task, the EFSA is asked to advise on population reference
intakes of micronutrients in the diet and, if considered appropriate, other essential substances with a
nutritional or physiological effect in the context of a balanced diet which, when part of an overall
healthy lifestyle, contribute to good health through optimal nutrition.
Finally, the EFSA is asked to provide guidance on the translation of nutrient based dietary advice
into guidance, intended for the European population as a whole, on the contribution of different foods
or categories of foods to an overall diet that would help to maintain good health through optimal
nutrition (food-based dietary guidelines).
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Data and methodologies
The assessment is conducted in accordance with the NDA Panel’s Scientiﬁc Opinion on principles for
deriving and applying dietary reference values (DRVs), thereafter referred to as ‘the opinion on
principles’ (EFSA NDA Panel, 2010).
In addition, some parts of the assessment were undertaken by applying the four-step approach for
evidence use (i.e. plan/carry out/verify/report) described in the EFSA report on principles and process
for dealing with data and evidence3 (the ‘PROMETHEUS approach’) (EFSA, 2015).
The opinion is structured as follows:
 Sections 1–4 include relevant background information on sodium; this encompasses an
introduction (Section 1), information on chemistry, function, physiology, metabolism, interaction
with other nutrients and biomarkers of intake and status (Section 2), information on dietary
sources and intake data (Section 3) and an overview of DRVs and recommendations from other
bodies (Section 4).
 Section 5 covers the assessment of the evidence on the criteria (endpoints) on which to base
DRVs.
 Section 6 provides the integration of the available evidence and derivation of DRVs.
The data and methodologies used to inform the respective sections are described below.
1) Collection of relevant background information
To inform Sections 1–4 of the Scientiﬁc Opinion, a literature search covering sodium physiology and
metabolism in healthy adults, biomarkers of intake, and genotypes affecting sodium metabolism was
commissioned to the University of Hertfordshire (Lewis et al., 2015).
To complement the information gathered in a previous opinion (SCF, 2003), a comprehensive
review of the literature published from January 2000 on the concentration of sodium in breast milk
from healthy women living in Europe, North America and Australia was conducted by LASER Analytica
(LASER Analytica, 2014).
An ad hoc questionnaire developed by the members of the working group on DRVs for minerals
was disseminated to EFSA focal points and the members of the EFSA Food Consumption Network to
collect information on the levels of urinary sodium excretion, to ascertain current information on
sodium intake by European populations.
Additional background information was gathered by the members of the working group on DRVs
for minerals and EFSA staff. Recent textbooks, authoritative reviews and research papers were used as
sources of information. They were retrieved through searches in bibliographic databases, and were
selected on the basis of their relevance.
2) Identiﬁcation of the criteria on which to base DRVs
In Section 5, the NDA Panel assesses the evidence on possible criteria on which to base DRVs. To
that end, the Panel considers:
 biomarkers as indicators of sodium requirement (Section 5.1);
 studies on sodium balance (Section 5.2);
 indicators of sodium requirement in pregnancy and lactation (Section 5.3);
 indicators of sodium requirement in children (Section 5.4);
 sodium intake and health consequences (Section 5.5).
The NDA Panel assessed the suitability of each criterion to set DRVs for the nutrient on the basis of
considerations of the available evidence and its inherent uncertainty and the possibility of deriving
quantitative estimates.
Sections 5.1–5.4 draw from the background information gathered in Sections 2 and 4 of the
Scientiﬁc Opinion, expert knowledge from the members of the working group on DRVs for minerals,
and targeted searches in bibliographic databases.
In line with the PROMETHEUS approach, a draft protocol (Annex A) was developed for Section 5.5
of the Scientiﬁc Opinion. Systematic reviews were conducted on the relationship between sodium
intake and selected health outcomes. The protocol describes the steps followed for the collection,
selection, appraisal and synthesis of evidence.
Dietary Reference Values for sodium
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3) Integration of the available evidence and derivation of DRVs
Section 6 outlines the criteria considered by the NDA Panel as themost appropriate for setting DRVs, and
provides DRVs for sodium. To that end, the Panel considered the quantitative relationships between sodium
intake and the selected criteria together with the related uncertainties. The principles of the EFSA Scientiﬁc
Committee guidance documents on uncertainties analysis and on the use of weight of evidence approaches
in scientiﬁc assessments (EFSA Scientiﬁc Committee et al., 2017; EFSA Scientiﬁc Committee et al., 2018a;
EFSA Scientiﬁc Committee et al., 2018b) were applied. In view of the limited evidence available and of the
associated uncertainties, a formal expert knowledge elicitation (EKE) was undertaken by the members of
the working group on DRVs for minerals to integrate the evidence and express related uncertainties. EKE is a
systematic, documented and reviewable process to retrieve expert judgements from a group of experts in
the form of a probability distribution. Several methods are described in the EFSA guidance to elicit
knowledge of the experts (EFSA, 2014). For the sodiummandate, the roulette method was chosen. This is a
formal approach that allows the experts to draw their own distribution of uncertainty on the parameter to be
estimated by placing different numbers of plastic counters along the range of possible parameter values
conveniently split in subintervals. The judgements were elicited following the Shefﬁeld protocol, in which
experts ﬁrst make separate judgements about the distribution, then share and discuss their distributions,
and ﬁnally develop a consensus distribution and document their reasoning (EFSA, 2014).
4) Public consultations
In September 2017, Sections 1–5.4 of the draft Scientiﬁc Opinion, as well as the draft protocol
developed for Sections 5.5 and 6 (Annex A), were published for public consultation.4 This was to
receive input from stakeholders on the parts of the opinion that have been used to inform the draft
protocol, and on the methodology foreseen to inform the parts covered by the protocol. The draft
opinion and draft protocol were revised in the light of the comments received. A technical report which
addresses the comments received during the consultation has been published (EFSA, 2017b).
Following the public consultation, the protocol was implemented and the opinion was completed. In
April 2019, the draft Scientiﬁc Opinion was published for public consultation to collect comments on the new
sections that had been integrated (Sections 5.5 and 6, conclusions and recommendation for research).5
The opinion was then ﬁnalised considering the comments received, where appropriate. A technical report
which addresses the comments received during the consultation has been published (EFSA, 2019).
Assessment
1. Introduction
In 1993, the SCF adopted an opinion on the nutrient and energy intakes for the European
Community. For sodium, an acceptable range of intakes (0.575–3.5 g/day, corresponding to 25–150
mmol/day) was set for adults. For children, pregnant and lactating women, no value was set.
2. Deﬁnition/category
2.1. Chemistry
Sodium (Na+) is an alkali metal with an atomic mass of 22.99 Da (Lide, 2009; Wieser et al., 2013).
Only one sodium isotope (23Na) is stable in nature. At normal temperature and pressure, sodium is a solid
metal; it is highly reactive in both water and air and is not found naturally in its elemental form. In the
Earth’s crust, there is an abundance of sodium salts such as those with carbonate, nitrate, sulfate,
borate, and particularly with halogens, especially chloride (Greenwood and Earnshaw, 1997; Lide, 2009).
Sodium chloride (NaCl) is the main constituent of table salt. One gram of sodium chloride provides
0.4 g of sodium and 0.6 g of chloride (17 mmol sodium and chloride).
2.2. Function of the nutrient
2.2.1. Biochemical functions
Sodium exists as the electrolyte Na+ in body ﬂuids; it is the dominant cation in the extracellular
ﬂuid (ECF). Chloride (Cl–) is its accompanying extracellular anion and together they contribute the
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major component of the extracellular osmolality of 275–295 mOsm/kg of water. The principal elements
of the corresponding intracellular osmotic activity are contributed by potassium (K+), chloride and low
molecular organic metabolites. The ECF sodium content approximates to 135–145 mmol/L and that of
potassium is 3.5–5.5 mmol/L, whereas within cells sodium and potassium contents approximate
15 mmol/L and 150 mmol/L, respectively (Heer et al., 2000; Gropper et al., 2009; Bailey et al., 2014).
The homeostasis of water and sodium, and to an extent that of chloride and potassium, are
interdependent and integrated to maintain these conditions (Sterns, 2015). The functions of sodium lie
in: (i) its participation in the control of the volume and systemic distribution of total body water; (ii)
enabling the cellular uptake of solutes; and (iii) the generation via interactions with potassium of
transmembrane electrochemical potentials.
The systemic control of ECF volume, and the maintenance of osmotic equilibrium between the ECF
and the intracellular ﬂuid depends on the mechanisms and transport systems that control the entry of
Na+ into cells and the energy-dependent extrusion of Na+ out of cells. This function is seen in
epithelial polarised cells (e.g. the intestinal and renal tubular epithelia). Such cells have an energy-
dependent sodium pump (Na+/K+-ATPase) on their basolateral membrane that exchanges three
intracellular molecules of Na+ for two extracellular K+ molecules entering the cells. This creates a
gradient between intracellular and extracellular sodium ionic concentrations and activities, and the
passive ﬂow of Na+ down this gradient is enabled and regulated by speciﬁc cellular membrane pores
and carriers that couple the ﬂow of Na+ to the entry of water and of solutes (e.g. amino acids,
monosaccharides) into the cells (Section 2.3.1). The link between sodium transport and co-transport
systems underpins cellular uptake and transport of water and solutes in all organs; the energy
expended in these processes represents around 25% of the metabolic rate of a human at rest (EFSA,
2005a).
The differential transmembrane distribution and activity gradients of sodium and potassium induced
by carrier proteins and Na+/K+-ATPase create a polarised cell membrane potential. This is present in
most cells but is particularly evident in muscle (of all types) and in neurones. In these cells, the
membranes have ion channels that, in response to stimuli, open to allow the ions to ﬂow across and
depolarise the membrane. So, Na+ and K+ in tandem are fundamental for electrical signalling in the
nervous system, muscle and heart; the sodium channels involved are classiﬁed as voltage gated
channels (Campbell and Reece, 2002).
2.2.2. Health consequences of deﬁciency and excess
The health consequences of both chronic and acute deﬁciencies and excesses of sodium are related
to the distribution of total body water and sodium in the extracellular and intracellular ﬂuid
compartments. This is more obvious in acute deﬁciency and excess (Sections 2.2.2.1 and 2.2.2.2) than
it is for long-term excessive exposure to sodium accompanied by its systemic accumulation in bone,
connective tissue, muscle and skin (Titze et al., 2014) (Section 2.3.3).
The features of acute sodium excess and deﬁciency are predominantly neurological and arise from
exceeding the homeostatic systems controlling hydration of the central nervous system. Sodium is
generally enabled to pass easily across vascular endothelia and, as a result, the sodium concentrations
(i.e. activities) of plasma and ECF, including interstitial ﬂuid, are virtually identical. However, in the
central nervous system, the capillaries have tight endothelial junctions that block sodium movements.
So, changes in plasma and ECF sodium concentrations can create osmotic gradients causing water to
move in or out of the cerebral spinal ﬂuid (Sterns, 2015). This phenomenon affects other tissues and
organs. However, organs such as the liver or the kidney can swell, or shrink, to accommodate changes
in volume induced by redistribution of water within them, whereas the brain, being encased within the
skull, is more susceptible to extreme changes in volume. This is probably why the brain has sensors of
plasma osmolality and blood pressure to exercise control of body water, and of intracellular and
extracellular tonicity (Section 2.3.4).
2.2.2.1. Deﬁciency
Dietary sodium deﬁciency is rare in healthy European populations. Sodium chloride and other
sodium salts are ubiquitous in the diet (Sections 3.1 and 3.2), and there are adaptive physiological
mechanisms that reduce the losses of sodium in urine, faeces and sweat at low levels of sodium intake
(Section 2.3.4).
Hyponatraemia, deﬁned as a serum sodium concentration less than 135 mmol/L (Sterns, 2015), is
indicative of systemic sodium imbalance but not necessarily of systemic sodium deﬁciency (Andersson
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et al., 1982; Speedy et al., 2000). The threshold of 135 mmol/L is the lower point of the reference
range and, as such, is indicating potential sodium depletion and deﬁciency. However, because of the
systemic interaction of sodium with water balance, the serum sodium concentrations at which
symptoms of sodium deﬁciency become apparent are not well characterised. Severe neurological
symptoms are generally associated with serum sodium concentrations < 120 mmol/L, at which level
cerebral oedema develops. Overall, the symptoms progress from malaise, nausea, vomiting and
headache to lethargy, impaired consciousness, seizures and coma (Adrogue and Madias, 2000a;
Sterns, 2015).
2.2.2.2. Excess
Rapid onset of sodium excess secondary to dietary sodium intake is also uncommon, but acute
toxicity may arise from high exposures to sodium, usually as sodium chloride, from ingestion (e.g. self-
poisoning) or from parenteral administration in clinical care. Hypernatraemia, deﬁned as a serum
sodium concentration > 145 mmol/L, is typically a consequence of dehydration rather than of excessive
sodium intake. The symptoms of hypernatraemia are similar to those of hyponatraemia and also
include non-speciﬁc features such as headache, confusion, fever, nausea and vomiting (Adrogue and
Madias, 2000b; Sterns, 2015).
In 2005, the NDA Panel explored the relationship between high exposures to sodium (usually as
sodium chloride) and hypertension (EFSA, 2005a, 2005b). For groups of individuals, there was strong
evidence for an exposure-dependent rise in blood pressure. The Panel noted that this is a continuous
relationship that embraces the whole range of habitual sodium intakes and considered that it was not
possible to determine a threshold of habitual sodium consumption below which adverse effects on
blood pressure were unlikely. The Panel also noted that epidemiological studies indicated a positive
association between sodium intake and risk of morbidity and mortality from cardiovascular diseases.
Evidence for a direct adverse effect of high sodium intake on heart function (i.e. independent of raised
blood pressure) was inconclusive. The Panel concluded that sodium itself was not carcinogenic but that
high intakes of sodium chloride could increase susceptibility to carcinogens such as nitrosamines,
gastric infection with Helicobacter pylori, or give inadequate protection against free radical-induced
damage. Overall, the NDA Panel did not set a tolerable upper intake level (UL) for sodium because of
insufﬁcient data. However, the Panel noted that there was strong evidence for the contribution of
sodium to high blood pressure in European populations, and that high blood pressure has been directly
related to the development of cardiovascular and renal diseases.
2.3. Physiology and metabolism
As sodium is integral for the homeostasis of total body water, its absorption, distribution and
excretion are controlled by systems that monitor and regulate ECF osmolality (tonicity) and volume.
2.3.1. Intestinal absorption and secretion
Sodium is absorbed throughout most of the length of the small and large intestine, with the quantity
and mechanism of absorption varying with intestinal sites (Chang and Leung, 2014). In the small
intestine, epithelial uptake of sodium is facilitated by speciﬁc co-transporters on the apex of the
enterocytes. These co-transporters couple the ﬂow of sodium into the enterocytes to facilitate the
uptake of low molecular solutes and micronutrients. The ﬂow of sodium is generated by an electrolyte
concentration gradient that is created by the extrusion of sodium by Na+/K+-ATPase on the basolateral
membranes of the cells (Section 2.2.1). This transfers the solutes out of the gut lumen into the
enterocytes on the gut villi and into the portal plasma. The vascular structure creates a countercurrent
system dependent on the osmotic activity that results from the localised accumulation of solutes and
sodium in the villi. This increased osmotic activity, in turn, draws water into and across the epithelium
by paracellular pathways, and the ﬂow drags other luminal solutes across the epithelium (solute drag).
Sodium is recycled into the small intestinal lumen via the gastric, intestinal, pancreatic and hepatic
secretions that accompany digestion and absorption.
The small intestine is estimated to handle 8–10 L of water in the course of a day. This comprises
water from endogenous secretions and from the diet (1–1.5 L/day). More than 98% of the ﬂuid load is
absorbed in the gut. About 1–2 L daily enter in the distal ileum and colon, which are the regions
where net absorption of sodium and water occurs. These distal processes also include adjustments
involved with the homeostasis of potassium, chloride and bicarbonate, as well as the uptake and
transfer of intraluminal fermentation products from the colon (Sandle, 1998; Kato and Romero, 2011).
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In the distal bowel, other carriers are responsible for the uptake of sodium. These include sodium
exchange for hydrogen ions (Na+/H+ exchangers) (Pan et al., 2012) and/or absorption of anions,
chloride and bicarbonate, to maintain electroneutrality (Fordtran et al., 1968; Turnberg et al., 1970;
Chang and Leung, 2014). The sodium secretion that accompanies active chloride secretion is a passive
process, driven by the transepithelial potential difference resulting from chloride secretion (Kato and
Romero, 2011; Chang and Leung, 2014). In the rectum, active sodium absorption occurs against large
electrochemical gradients through electrogenic sodium channels (Levitan et al., 1962; Sandle, 1998;
Chang and Leung, 2014) (Table 1).
Four 7-day balance studies spaced seasonally over a year in healthy young adults consuming self-
selected diets, with a mean daily intake of 3.4 g (148 mmol) of sodium, indicated that approximately
98.5% of ingested sodium is absorbed (Holbrook et al., 1984) (Section 5.2.1). Shorter balance studies
(5–12 days following 2–4 days of adaptation) in Japanese adults with a wider range of intakes showed
that the absolute amount of sodium absorbed increases linearly with increasing sodium intake. Mean
sodium absorption was 97.8  1.9% for daily intakes of 39–142 mg/kg body weight (bw) or 2.2–6.8 g
(95–295 mmol)/day of sodium (Kodama et al., 2005). Mean 24-h urinary sodium excretion was
33.2  0.8 g (1,443  35) after 72 h in 14 healthy men consuming 34.5 g (1,500 mmol) of sodium/
day, indicating that sodium absorption is maintained at approximately 96% even at very high intake
(Luft et al., 1979).
2.3.2. Transport in blood
Following absorption, sodium ions are distributed by portal and systemic circulations, where their
concentrations are maintained within a narrow range by the mechanisms described below
(Section 2.3.4). In healthy adults, serum sodium concentrations are between approximately 135 and
145 mmol/L (Heer et al., 2000; Gropper et al., 2009; Bailey et al., 2014). Reference ranges vary
slightly among different laboratories depending on the measurement technique used (Morimatsu et al.,
2003).
2.3.3. Distribution to tissues
Typical total body content of sodium is 1.3–1.5 g (55–65 mmol)/kg bw, equivalent to a total of
85–96 g (3,700–4,200 mmol) for a 70-kg man (Penney, 2008; James and Reid et al., 2011), 95% of
which is in the ECF. A large proportion of body sodium is in bone, skin and muscle (Bie, 2018). Within
cells (e.g. myocytes), sodium is present at a lower concentration, approximately 3 mmol/L (Bailey
et al., 2014), with some variation depending on cell types (Yunos et al., 2010). These pools of sodium
have different turnover times, with the most exchangeable pools being ECF and intracellular sodium,
and the pool of sodium bound to connective tissue is slower (Titze et al., 2014; Rakova et al., 2017;
Bie, 2018).
The pool of sodium in bone, muscle and skin has been proposed to be a sodium depot or reserve,
but it could have other roles. Sodium bound to proteoglycans in connective tissue creates a high
osmotic force that supports the hydration of these tissues and enables them to withstand high-
pressures. This sodium pool could also have a homeostatic and adaptive role as an extra-renal
clearance depository for handling excessive systemic accumulation of sodium (Titze et al., 2014;
Rakova et al., 2017; Selvarajah et al., 2017; Bie, 2018) which is discussed below.
The deposition of sodium in bone, muscle and skin could explain why an increase in sodium intake
is not necessarily associated with a change in body weight, an increase in ECF volume, nor with an
increase in plasma sodium concentration or its renal loss (Heer et al., 2000; Titze et al., 2014; Sterns,
2015; Rakova et al., 2017). A study by Heer et al. (2000) found that, compared with a sodium intake
of 1.2 g (50 mmol)/day, a daily sodium intake of 12.7 g (550 mmol) was associated with an increase
in plasma volume of approximately 300 mL, but with no change in body weight. This implies that there
was a redistribution of water from the interstitial ECF to plasma. It is proposed that total body sodium
‘ﬂuctuates’ independently of sodium intake (Titze et al., 2014). Long-term balance studies in men with
constant and controlled daily sodium intakes of 2.5 g (110 mmol), 3.6 g (155 mmol) and 4.8 g
(210 mmol) demonstrated weekly and half-weekly cycles of urinary sodium excretion that were
inversely related to urine content of aldosterone and its metabolites (as marker of aldosterone
production) and directly related to glucocorticoid/cortisol production (Rakova et al., 2013). This pattern
of sodium excretion was accompanied by a monthly cycle of changes in total body sodium content of
 4.6–9.2 g (200–400 mmol), without parallel changes in total body water content. These studies
indicated that osmolyte and water balance are regulated by a rhythmical release of mineralocorticoids
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and glucocorticoids, the accrual of endogenous water (i.e. water released as a product of systemic
metabolism) to adjust ECF osmolality, and by weekly and monthly cyclical excretions of sodium (Titze
et al., 2014; Rakova et al., 2017).
There is evidence that sodium accumulates in the connective tissue of bone, muscle and skin with
age. In a cross-sectional study, 23Na magnetic resonance of the midcalf showed higher sodium
concentrations in the tissues of 57 hypertensive subjects as compared with the 56 normotensive
controls. In men (with or without hypertension), but not in women, muscle content of Na increased
with age, with no associated increase in muscle water content, whereas water content in the skin
increased with that of sodium. Generally, these compositional age-related changes were larger in men
than in women (Kopp et al., 2013; Titze, 2015) and have been associated with increased vascular
stiffness (Safar et al., 2009; Olde Engberink et al., 2015).
Collectively, the above observations contribute to the biological mechanistic plausibility of the
positive association of sodium intakes/exposure with systemic blood pressure. Also, cyclic hormonal
regulatory processes may contribute to the inherent within-person variability in 24-h urine sodium
excretion, beyond daily variations in intake.
2.3.4. Elimination
The excretion and retention (i.e. homeostasis) of sodium and water are effected by an integrated
neurohormonal control from centres located in the hypothalamus (Lowell, 2019). Plasma osmolality
and volume are sensed by four interdependent sensor systems. These comprise a group that detects
plasma osmolality, and a system of pressure-sensitive receptors (baroreceptors).
ECF osmolality is sensed by the circumventricular organs (CVOs), which are highly vascularised
areas in the hypothalamus. Neuronal osmoreceptors in CVOs have direct exposure to the ECF through
gaps in the blood–brain barrier. The osmoreceptors shrink when exposed to increased ECF osmolality,
e.g. as would result from a decrease in total body water. This shrinkage is relayed to the hypothalamic
supraoptic nucleus, which stimulates thirst and the release of antidiuretic hormone (ADH) by the
pituitary gland. ADH enables water retention by increasing the number of water permeable channels
(aquaporins) in the luminal cell membranes of the renal collecting ducts. ADH has a half-life of 20 min
and it is continuously secreted to maintain the physiological range of osmolality. So, the supraoptic
nucleus reacts to increased osmolality by increasing water intake and by reducing renal water
excretion (Sterns, 2015). When serum sodium concentration falls below 135 mmol/L, ADH secretion
and thirst are inhibited.
Plasma volume is sensed by two types of pressure-sensitive receptors (or baroreceptors) that
respond to either high or low vascular pressure. ‘High-pressure’ baroreceptors are located in the
cerebral and carotid arteries, aortic arch and the juxta glomerular apparatus of renal glomeruli,
whereas ‘low-pressure’ baroreceptors lie in the thoracic veins, the cardiac atria and right ventricle, and
the pulmonary (thoracic) veins.
Collectively, these sensors regulate the neurohumoral control of total body water and ECF. The
osmosensors operate by mediating changes in water intake and renal distal tubule retention or loss of
water through aquapores. The baroreceptors induce changes in renal retention or loss of sodium to
mediate water homeostasis. The mediators include the sympathetic nervous system (SNS) and
catecholamines; atrial natriuretic peptide; and the renin–angiotensin–aldosterone system (RAAS).
The renin–angiotensin–aldosterone pathway is active in several different tissues, but most notably
the kidney (Penney, 2008; Hamlyn, 2014; Lowell, 2019). Renin is released from the juxtaglomerular
apparatus in response to reduced pressure in the afferent renal arterioles, increased sympathetic nerve
activity and decreased sodium and chloride concentrations in the distal tubular ﬂuid. Renin hydrolyses
angiotensinogen into angiotensin I that is converted by the angiotensin-converting enzyme into
angiotensin II. Angiotensin II stimulates: (i) sodium, and therefore water, reabsorption in the proximal
tubule; (ii) constriction of the arterioles; and (iii) the release of aldosterone from the adrenal cortex.
Aldosterone stimulates renal recovery of sodium in exchange for excreted potassium in the epithelia of
the distal tubule and collecting ducts, and in the distal colon. Aldosterone also facilitates the
simultaneous reabsorption of water with that of sodium by stimulating the release of ADH (which
increases the number of aquaporins in the distal tubules) and stimulates sodium intake via neuronal
control of salt appetite (Lowell, 2019).
As with sodium kinetics (Section 2.3.3), the regulation of electrolyte and water homeostasis exhibits
a circadian rhythm affecting blood pressure, glomerular perfusion and ﬁltration rate, which results in a
variable rate of urinary excretion of sodium and potassium. This biological clock is mediated by
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regulation of the expression of genes responsible for the neuroendocrine control of the renal handling
of sodium (Gumz et al., 2015; Solocinski and Gumz, 2015).
2.3.4.1. Urine
The kidney is the main organ mediating the excretion and retention of sodium and, so, water
homeostasis, as outlined above. It efﬁciently excretes sodium in response to high dietary intakes, and
salvages sodium when dietary intake is low (Section 5.2).
In experiments in which subjects at a steady state were shifted to a lower level of sodium intake,
the half-life for the reduction in renal sodium excretion was about 24 h (Strauss et al., 1958; Epstein
and Hollenberg, 1976) and, consequently, a steady state between sodium intake and urinary sodium
excretion is considered to be achieved within a few days (Cogswell et al., 2013).
A meta-analysis investigating urinary sodium excretion relative to sodium intake included 35 studies
in which a constant quantity of dietary sodium was provided to participants for a minimum of 3 days
(Lucko et al., 2018). This was considered to be the minimum duration to ensure that participants were
at a steady state of urine sodium excretion relative to sodium intake. In a subgroup analysis, the
length of this stabilisation period (categorised as a minimum 3, 5 or 7 days) was not found to alter the
percentage of dietary sodium excreted. On average, 92.8% of daily dietary sodium was excreted in
24-h urine (95% CI 90.7, 95.0; I2 95.1%, p < 0.001). The average excretion of ingested sodium varied
from 76% to 122% across studies. The pooled estimate was similar when the analysis was restricted
to studies conducted in healthy people (93.7%, 95% CI 90.5, 96.8; I2 97.1%, p < 0.001). Comparable
excretion rates have been reported in studies in which people consumed their usual diet: 86% of the
sodium ingested over 4 weeks (1 week per season over a year, to cover variability) was excreted in
24-h urine samples collected during the same period (Holbrook et al., 1984) and 98% of dietary
sodium was excreted in 24-h urine in another 3-day study (Schachter et al., 1980).
The nephron, under the neurohormonal control systems described above, is the key organ
regulating sodium excretion and maintaining normal ECF and plasma volumes. Glomerular ﬁltration
allows a ﬁltrate free of cells and macromolecules (the electrolyte content of which resembles that of
plasma) to pass into the proximal tubules. The glomerular ﬁltration rate (measured as creatinine
clearance, with a usual value of around 125 mL/min) decreases with age.
The kidney has the capacity to ﬁlter large amounts of sodium, more than 99% of which is then
reabsorbed in the renal tubules via co-transporters driven by the basolateral Na+/K+-ATPase.
Approximately 60–70% of sodium reabsorption occurs via co-transporters in the proximal tubule, along
with organic molecules (amino acids, glucose and organic acids), mediated by membrane Na+/H+
exchange (Greger, 2000). Water follows this movement of solutes. In the ascending limb of the loop of
Henle, 20–30% of the ﬁltered sodium chloride is absorbed via the Na+/2Cl–/K+ co-transport system.
However, this loop is impermeable to water and the ﬁltrate becomes less concentrated. In the early
distal tubule, another 6% of the ﬁltered sodium is recovered, and this further dilutes the ﬂuid. About
5–10% of sodium reabsorption occurs in the distal tubule, through active sodium transport via the
Na+-Cl– co-transporter (Greger, 2000). In the distal tubule of the nephron, aldosterone enhances
sodium reabsorption and potassium excretion.
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Table 1: Regulation of sodium excretion in the kidney and distal bowel
Site
Na reabsorbed
(%)
Mechanism Water transfer
Regulating
factors
Proximal
renal tubule
60–70 Co-transporters with solutes.
Active Na+/K+ ATP-ase
dependent
Some Na/H+
Principal site for water
reabsorption
Highly permeable driven by
osmolality
Angiotensin II
SNS
catecholamines
Loop of
Henle
20–30 Na+/K+/2Cl– co-transport Impermeable to water Flow dependent
Pressure
Natriuresis
Distal tubule 5–10 Na+-Cl– co-transport Impermeable to water Aldosterone
Flow dependent
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2.3.4.2. Faeces
The efﬁciency of distal intestinal absorption of intraluminal sodium is responsive to aldosterone
(Sandle, 1998) and has been described in Section 2.3.1.
Balance studies have shown that sodium losses in the faeces were relatively stable and limited to a
few mmol/day for sodium intakes over a range between 1.2 and 12.7 g/day (50 and 550 mmol/day)
(Holbrook et al., 1984; Heer et al., 2000; Palacios et al., 2004). For example, in the balance study by
Holbrook et al. (1984) in which sodium losses were estimated for four periods of 7 days in 28 US men
and women consuming their usual diet (Section 5.2), mean ( SD) sodium losses in faeces were
56  26 mg/day (2.4  1.1 mmol/day), representing less than 2% of sodium intake.
2.3.4.3. Dermal losses
Sodium concentration in sweat varies widely. Values between 10 mmol/L (0.23 g/L) and 180 mmol/L
(4.20 g/L) have been reported in adults (IOM, 2005; Bates and Miller, 2008; Kaptein et al., 2016).
Inﬂuencing factors include levels of sodium intake, sweat rate, hydration status and degree of heat
acclimation (Allan and Wilson, 1971; Allsopp et al., 1998; Bates and Miller, 2008). Interindividual
variability may also be inﬂuenced by physiological determinants of sodium reabsorption in the sweat
gland (Brown et al., 2011). Sodium concentration in sweat decreases following heat acclimation
(Consolazio et al., 1963; Allsopp et al., 1998; Buono et al., 2007; Bates and Miller, 2008), contributing
to the maintenance of sodium balance under conditions of high sweat excretion (Consolazio et al.,
1963; Allsopp et al., 1998) (Section 5.2).
Studies conducted under conditions of moderate temperature and exercise levels indicate small
sodium losses via sweat across a wide range of sodium intake levels (Barr et al., 1991; Heer et al.,
2000; Palacios et al., 2004). In the balance study by Palacios et al. (2004) in 36 female adolescents
under sedentary conditions (see Section 5.2), sweat losses represented ca. 3% of total sodium losses
under the ‘high’ sodium diet (4 g (174 mmol)/day) and 10% under the ‘low’ sodium diet (1.3 g
(56 mmol)/day). Sodium losses via sweat can be considerably higher in situations of exercise and heat
(Sharp, 2006; Bates and Miller, 2008; Cogswell et al., 2015).
2.3.4.4. Breast milk
Colostrum has higher concentrations of sodium than mature milk (Koo and Gupta, 1982; Atkinson
et al., 1995). The sodium content of breast milk decreased rapidly in the ﬁrst days post-partum, as the
mammary gland undergoes the transition between pregnancy and lactation (i.e. closure of the
intercellular junctions) (Atkinson et al., 1995). This is followed by a gradual decline in the sodium
concentration of mature milk.
The concentration of electrolytes, including sodium, in human milk is lower than in plasma. It is
determined by an electrical potential gradient in the mammary epithelial cells regulated through
membrane transport pathways (Wack et al., 1997; Truchet and Honvo-Houeto, 2017). It is not
inﬂuenced by maternal sodium intake (Filippi et al., 1981; Keenan et al., 1982; Ereman et al., 1987).
Diurnal variations in breast milk sodium concentration, reciprocal to potassium concentration, have
been reported (Keenan et al., 1982, 1983). Factors that have been associated with increased sodium
concentration in breast milk include pathological processes such as mastitis or localised inﬂammation
of breast tissue (Morton, 1994), premature birth (Gross et al., 1980) and manual compared with
mechanical (pump) expression (Lang et al., 1994).
Based on 11 studies on sodium concentration in breast milk from 511 women in the USA, the UK
and Canada, Atkinson et al. (1995) reported mean sodium concentrations across studies between 17.1
and 22.3 mmol/L (393 and 513 mg/L) at day 3 (colostrum), 9.4 and 13.1 mmol/L (216 and 301 mg/L)
at day 14 (transitional milk), 5.9 and 17.1 mmol/L (136 and 393 mg/L), 4.7 and 8.0 mmol/L (108 and
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Site
Na reabsorbed
(%)
Mechanism Water transfer
Regulating
factors
Collecting
ducts
5 Na+ exchange K+ channels ADH-mediated permeability
via aquaporins
Aldosterone
Atrial natriuretic
peptide
Distal bowel Na+ channels Aquaporins Aldosterone
ADH: antidiuretic hormone; Cl: chloride; K: potassium; Na: sodium; SNS: sympathetic nervous system.
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184 mg/L), and 3.6 and 6.0 mmol/L (83 and 138 mg/L) at days 30, 90 and 180 of lactation (mature
milk), respectively.
Appendix A reports data on sodium concentration in breast milk from additional studies that
involved mothers of term infants in Western populations. Mean sodium concentrations are between 3.0
and 10.6 mmol/L (70 and 244 mg/L) from eight studies that analysed mature breast milk (Keenan
et al., 1982; Koo and Gupta, 1982; Parr et al., 1991; Holt, 1993; Motil et al., 1997; Wack et al., 1997;
Fly et al., 1998; Bjorklund et al., 2012) and 11.2 mmol/L (257 mg/L) in one study that used mixed
samples (collected between 1 and 8 weeks post-partum) (Bauer and Gerss, 2011).
Based on the data presented in Appendix A, the Panel considers an approximate midpoint of
sodium concentration in mature breast milk of women from Western countries as 150 mg/L
(6.5 mmol)/L. Based on a mean milk transfer of 0.8 L/day (Butte et al., 2002; FAO/WHO/UNU, 2004;
EFSA NDA Panel, 2009) during the ﬁrst 6 months of lactation in exclusively breastfeeding women, the
Panel estimates the maternal loss of sodium through breast milk to be 120 mg (5.2 mmol)/day.
2.4. Modiﬁcation of sodium metabolism during pregnancy
During pregnancy, there is an expansion of the ECF, including the plasma volume, starting within
2 weeks of conception. Expansion of the plasma volume is between 1 and 1.6 L. These changes occur
irrespective of the mother’s size, are usually larger in multigravida, and are accompanied by a fall in
both plasma osmolality and plasma sodium concentrations (Davidson and Repke et al., 1998). The
expansion of the ECF represents a change in the homeostasis of total body water that is accompanied
by increased cardiac output, increased vascular perfusion of organs and tissues, and reduced SBP in
the ﬁrst half of pregnancy. As a consequence, the volume of the kidneys increases by around 30%.
The renal blood ﬂow almost doubles, the glomerular ﬁltration rate is increased by 50%, and these
changes are accompanied by an increased tubular reabsorption of sodium. Simultaneously, there is an
increased renal clearance of low-molecular-weight solutes such as proteins, amino acids and glucose.
Creatinine clearance is increased by 25% in the fourth week of gestation and by 45% in the ninth
week (Cheung and Lafayette, 2013).
Progesterone has a major inﬂuence on these changes. This hormone induces smooth muscle
relaxation and vasodilation and it reduces the response of the distal tubules to aldosterone, even
though aldosterone production is also increased early in pregnancy. However, there are other
adaptations, which have been poorly characterised, namely the production of hormones involved in the
regulation of body water and a reduced responsiveness of receptors, particularly the RAAS, to these
hormones (Brown, 1989; Wintour, 1998; Cheung and Lafayette, 2013). The ECF changes disappear by
1 month after delivery but the reversal of the renal adaptations may take up to 6 months post-partum.
2.5. Interaction with other nutrients
2.5.1. Potassium
The metabolism of potassium and sodium are strongly interrelated, in part due to Na+/K+-ATPase
exchange mechanisms (Adrogue and Madias, 2014) (Section 2.2.1). Additionally, and importantly, the
efﬁciency of sodium homeostasis, particularly its renal regulation, is related to that of potassium.
In its previous assessment of DRVs for potassium, the Panel concluded that dietary potassium
intake modulates the inﬂuence of sodium on blood pressure (EFSA NDA Panel, 2016). There is also
evidence that the effect of potassium intake on blood pressure may be higher in individuals with high
sodium chloride intake compared with those with low sodium chloride intake. In a meta-analysis of
randomised controlled trials (RCTs) on the effect of potassium intake on blood pressure, Aburto et al.
(2013) conducted subgroup analyses according to levels of sodium intake, as assessed through
baseline urinary sodium excretion. The largest blood pressure-lowering effect of potassium was
associated with the highest category of sodium intake (greater than 4 g (174 mmol)/day) compared
with the lower categories (< 2 g (87 mmol)/day and 2–4 g (87–174 mmol)/day).
In its opinion on DRVs for potassium (EFSA NDA Panel, 2016), the Panel considered whether the
sodium-to-potassium intake ratio could inﬂuence blood pressure outcomes more than either potassium
or sodium intakes alone. According to the systematic review by Perez and Chang (2014), evidence
from RCTs carried out in hypertensive subjects suggests that the sodium-to-potassium excretion ratio,
on a molar basis, is more strongly associated with blood pressure outcomes than either sodium or
potassium alone. Only four RCTs were conducted in normotensive subjects. The Panel notes, however,
that none of the RCTs included in the review was designed to assess the effect of a change in the
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sodium-to-potassium ratio vs a change in either nutrient alone on blood pressure outcomes. This
systematic review also included one prospective cohort study that reported that the sodium-to-
potassium ratio, on a weight basis (assessed through 3-day weighed records), was more strongly
associated with hypertension and/or systolic and diastolic blood pressure levels than either sodium or
potassium alone (Du et al., 2014). The Panel notes that additional prospective cohort studies have
investigated the association between the sodium-to-potassium intake or excretion ratio, assessed
through variable methods (dietary questionnaire, spot or 24-h urine excretion), and blood pressure
and CVD outcomes with inconsistent results (Chien et al., 2008; Kieneker et al., 2014; Okayama et al.,
2016; Tabara et al., 2017; O’Donnell et al., 2019).
A possible moderating effect of potassium intake on the relationship between sodium and blood
pressure was explored in the meta-analyses of RCTs conducted for the present opinion
(Section 5.5.1.2 and Appendix I). Stratiﬁed analysis by levels of potassium intake/excretion are
presented in Tables I.1 and I.2. When building the meta-regression models, potassium intake was not
retained as it did not explain a signiﬁcant proportion of the heterogeneity. Such analyses were, in
addition, limited by the number of studies for which information on potassium intake/excretion was
missing (13 out of 35 studies).
The Panel concludes that the interrelationship between sodium, potassium and blood pressure or
CVD outcomes has not been sufﬁciently characterised to inform the DRVs for sodium.
2.5.2. Chloride
The interaction between sodium and chloride is biologically crucial in that they, with potassium,
diffuse freely in aqueous medium. In biological systems the three ions are compartmentalised by lipid
membranes in such a way that their individual physicochemical properties maintain osmotic balance,
electroneutrality, and acid–base balance between intracellular compartments and the cytoplasm, and
between the cytoplasm and ECF. Regulated changes in the transmembrane balance for these ions in
particular are fundamental for the transport of solutes across membranes (e.g. in intestinal
absorption), and the generation of electrical signals in the muscle, and in the peripheral and central
nervous systems (Berend et al., 2012; Imbrici et al., 2015). So, the functions of sodium depend on the
availability of chloride as a counter-ion (Section 2.2.1).
Chloride is rate limiting for the transport of sodium and chloride in the thin ascending loop of
Henle, because of the differences in the afﬁnities of sodium and chloride for the co-transporters.
Therefore, the availability of chloride has a determinant effect on the release of renin (Kotchen et al.,
1987). Although chloride has biological functions independent of sodium, any direct role, independent
of sodium or potassium, in modulating blood pressure has not been established (McCallum et al.,
2015; EFSA NDA Panel, 2019).
Data from studies on hypertensive rats, a limited number of clinical observations, and accumulating
reports on putative mechanisms suggest that the full-expression of sodium chloride-dependent
elevation in blood pressure relies on the concomitant presence of both sodium and chloride (Kurtz
et al., 1987; Shore et al., 1988; Luft et al., 1990; Kotchen and Kotchen, 1997; McCallum et al., 2015).
It is noteworthy that dietary sodium chloride causes a greater rise of mean blood pressure, in
both normotensive and hypertensive subjects, than does sodium combined with other anions (e.g.
citrate, phosphate, bicarbonate) (Shore et al., 1988; McCallum et al., 2015; EFSA NDA Panel, 2019).
The Panel notes that there is evidence that chloride can contribute to the effect of sodium chloride
on blood pressure.
2.5.3. Calcium
Calcium and sodium share common transport mechanisms in the kidney; the reabsorption of
calcium parallels the reabsorption of sodium at the renal tubular level (Yu, 2015; Moor and Bonny,
2016). There is consistent evidence that an increase in sodium intake increases urinary calcium
excretion, while a reduction in sodium intake lowers urinary calcium excretion (Afssa, 2001; EFSA,
2005a; IOM, 2005).
In a cross-sectional study of 484 post-menopausal women, Nordin and Polley (1987) reported that
urinary calcium excretion was positively and independently related to calculated 24-h urinary sodium
excretion. The correlation between urinary calcium and urinary sodium was stronger in those on lower
dietary calcium intakes (less than 1,250 mg/day), as assessed by food frequency questionnaires (FFQs).
Subsequently, two RCTs have assessed whether the quantitative relationship between sodium intake
and calcium excretion, and the effect of increasing calcium excretion on calcium balance, depend on
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background calcium intake (Lin et al., 2003; Teucher et al., 2008). In a 2 9 3 factorial design, Lin et al.
(2003) randomised 186 adult men and women to a control diet, supplying 450 mg calcium/day, or the
Dietary Approaches to Stop Hypertension (DASH) diet, supplying 1,250 mg calcium/day, and to three
sodium intake levels of 1.1 g (50 mmol), 2.3 g (100 mmol) and 3.4 g (150 mmol)/day for 30 days. In a
crossover design, Teucher et al. (2008) assigned 11 postmenopausal women to dietary interventions
characterised by calcium intakes of 518 versus 1,284 mg/day and by sodium chloride intakes of 3.9 g
(170 mmol) vs 11.2 g (487 mmol)/day) for four 5-week periods. The two studies provided consistent
evidence that sodium intake affects urinary calcium excretion both at ‘low’ and ‘high’-calcium intake.
Teucher et al. (2008) estimated bone calcium balances using a compartmental model. With the ‘low’-
calcium diets, negative bone calcium balances were estimated at both levels of sodium intakes. A
negative bone sodium balance was also estimated on the ‘high’-calcium/’high’-sodium chloride diet, while
bone calcium balance was positive on the ‘high’-calcium/’low’-sodium chloride diet. The only kinetic
parameter signiﬁcantly affected by sodium chloride intake was urinary calcium excretion.
The Panel notes that increasing sodium intake induces an increase in urinary calcium excretion that
may negatively affect bone calcium balance, even when dietary calcium intake is above the PRI for
calcium (EFSA NDA Panel, 2015).
2.6. Biomarkers
2.6.1. Biomarkers of intake
In healthy people, almost all dietary sodium is absorbed (Section 2.3.1) and urine is the major
route of sodium excretion (Section 2.3.4.1). Urinary sodium excretion has traditionally been used as a
biomarker of sodium intake, as it is considered to be more reliable than estimates of intake based on
dietary assessments (Section 3.2).
2.6.1.1. Measurements in 24-h urine collection
Twenty-four-hour urinary sodium excretion is used as a measure of average sodium intake at the
population level (WHO, 2011). In a recent meta-analysis of 35 studies (Lucko et al., 2018), mean 24-h
urine sodium was a close (93% on average) estimate of mean 24-h dietary intake of sodium
(Section 2.3.4.1). Adjustments to account for sodium excretion through sweat or in stools have been
made only in a few studies, and in most cases, 24-h urinary sodium excretion is used as a marker of
daily sodium intake, without correction for other routes of sodium losses (Cogswell et al., 2015).
Incomplete collections of 24-h urine samples can, however, introduce bias in measuring daily
sodium excretion, and investigators need to implement quality control procedures (Cobb et al., 2014;
Lucko et al., 2018). Several markers exist to assess and ensure complete collections, including: (i)
urinary recovery of ingested para-aminobenzoic acid (PABA) (usual criterion ≥ 85%), which is
considered as the reference method; (ii) 24-h urinary creatinine excretion; (iii) self-report of missed
voids; (iv) total urine volume (less than a speciﬁc threshold); and (v) duration of collection time
(typically accepted range between 20 and 28 h); or (vi) combinations of the above (e.g. ratio of
urinary to predicted creatinine excretion with total urine volume).
In eight studies using PABA, the percentage of incomplete collections ranged between 6% and 47%
(John et al., 2016). Based on 24-h urinary samples from 507 subjects, Wielgosz et al. (2016) assessed
the impact of different methods of assessing completeness of collection on sodium intake estimates.
Methods such as exclusion of individuals who collected urine for more than or less than 24 h, time-
adjustment of urine collections that varied from 24 h and creatinine-based exclusion criteria were
assessed. Estimated mean daily sodium intake varied between 3.6 g (156 mmol) and 7.3 g (317 mmol)
in the same set of urine samples depending on the method used to exclude or correct incomplete 24-h
urine collections.
John et al. (2016) reviewed the literature to evaluate the validity of various methods using PABA
recovery as the referent marker. The indices that were based on creatinine excretions had a moderate
sensitivity (6–63% in four studies), but higher speciﬁcity (57–99.7%) to identify incomplete collection.
Taking PABA recovery as the reference, the most valid method for identifying incomplete collections
was the ratio of observed to predicted creatinine excretion (ratio < 0.7). The Panel acknowledges the
risk that incomplete collection of 24-h urine can lead to underestimated urinary sodium excretions. The
Panel notes that assessments of the reliability of daily sodium intake estimates based on urinary
excretion need to take into account the quality control measures that were applied by the researchers
to ensure and assess the completeness of urine collections.
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Sodium levels in 24-h urine collections are inherently variable. This variation is usually assumed to
reﬂect daily variations in intake, although considerable day-to-day variability has also been observed in
24-h sodium excretion of individuals under conditions of well controlled, ﬁxed sodium intakes (Rakova
et al., 2013; Weaver et al., 2016; Lucko et al., 2018) (Section 2.3.3).
The number of 24-h urine collections needed to cover intraindividual variability range between 5
and 10 (Luft et al., 1982; Siani et al., 1989; Lerchl et al., 2015; Weaver et al., 2016). Luft et al. (1982)
conducted a study among 43 free-living individuals to examine the utility of 24-h urine collections in
capturing variations in sodium intake. They reported that nine 24-h collections were optimal to predict
usual intake (r = 0.75). According to two prolonged balance studies (105 and 250 days) that involved
10 healthy young men, Lerchl et al. (2015) concluded that a single, accurately collected, 24-h urine
sample was not able to detect a 3 g difference in the individual sodium chloride intake (corresponding
to a difference of 1.2 g of sodium) among men with sodium chloride intakes of 6, 9 or 12 g/day
(corresponding to 2.5 (110 mmol), 3.6 (155 mmol) and 4.8 g (210 mmol) of sodium). This resulted in
a misclassiﬁcation of half of the study participants with respect to their usual sodium intake. A
collection of three consecutive 24-h urine samples reduced the number of misclassiﬁed individuals to
25%, and a collection of seven samples to 8%. In the study by Weaver et al. (2016), at least 10
repeated 24-h samples were required on an average sodium intake of about 4 g (175 mmol)/day to
reach a level of 75% reliability in the estimation of individual levels of sodium excretion.
In their review of observational cohort studies evaluating the association between sodium intake and
health-related outcomes, Cobb et al. (2014) noted that the error introduced by the high day-to-day
variability in sodium intake appears to be random and does not lead to biased estimates of the overall
mean intake, when a single 24-h urine collection is used. It limits, however, the accurate classiﬁcation of
study participants on the basis of their individual usual sodium intakes, which additionally leads to an
overestimation of the proportion of individuals being classiﬁed in the tails of the intake distribution
(Cogswell et al., 2015). In an analysis based on follow-up data from the US Trials of Hypertension
Prevention that included multiple 24-h urine collections per subject, the use of the single (ﬁrst)
measured 24-h urinary sodium collection ﬂattened the relationship between sodium intake and overall
mortality compared with the average of multiple (three to seven) measured 24-h collections (He et al.,
2018). The Panel notes that a single 24-h urine collection does not reliably reﬂect an individual’s usual
intake, primarily due to within-person day-to-day variability in sodium intake and excretion.
The Panel therefore considers that a single 24-h collection can be used to estimate average group
sodium daily intakes, but a single 24-h urine collection can lead to random misclassiﬁcation of study
participants in relation to their usual sodium intake. In addition, the Panel notes that incomplete 24-h
urine collections can introduce bias in intake estimates.
2.6.1.2. Casual spot urine collections and timed spot collections
Other methods such as casual spot and timed spot urine collections (i.e. collection during the day,
evening, or overnight) have also been used as indicators of sodium intake. Day-to-day and diurnal
variations in sodium excretion render these measures highly variable at the individual level; hence,
these methods are subject to greater within-person variability in sodium excretion than 24-h urine
collections (Ji et al., 2012; Wang et al., 2013). Predictive equations have been developed to estimate
24-h urinary sodium excretion from spot urine samples (Kawasaki et al., 1993; Tanaka et al., 2002;
Brown et al., 2013). Their validity has been assessed in a number of studies (Kawasaki et al., 1993;
Tanaka et al., 2002; Brown et al., 2013; Cogswell et al., 2013; Ji et al., 2014; Mente et al., 2014;
Pﬁster et al., 2014; Polonia et al., 2017; Zhou et al., 2017) (Appendix B). Associations between these
estimates and 24-h urinary excretions have primarily been assessed through correlation coefﬁcients,
which ranged between +0.33 (one timed morning urine collection in a sample of 297 white women in
the UK and application of the Tanaka formula (Ji et al., 2014)) and + 0.53 (one morning urine
collection in a sample of 159 men and women in Japan and application of the Kawasaki formula
(Kawasaki et al., 1993)). In more recent studies, agreement between predicted and observed
excretions has also been assessed through Bland–Altman plots, which indicate overestimation of
predicted 24-h excretions at lower levels and underestimation at higher levels of observed 24-h urinary
excretions for both men and women (Brown et al., 2013; Cogswell et al., 2013; Ji et al., 2014; Mente
et al., 2014; Polonia et al., 2017).
Cogswell et al. (2013) undertook a study to assess the validity of various equations predicting 24-h
urinary sodium excretion based on spot urine concentrations (Appendix B). A sample of 407 adults aged
18–39 years provided one sample of 24-h urine collection, from which four timed voids (morning,
afternoon, evening and overnight) were selected. The published Kawasaki, Tanaka and INTERSALT
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equations were used to predict 24-h sodium excretion with spot urine by specimen timing and race–sex
subgroups. Bias was assessed through calculating the mean differences between estimated and
measured 24-h sodium excretion and with the use of Bland–Altman plots. The authors concluded that the
INTERSALT equation when applied to sodium concentration in morning, afternoon and evening (but not
overnight) samples provided the least biased estimates of population mean sodium intakes. The Tanaka
equation was more reliable for mean population estimates when applied to overnight samples. However,
the authors observed signiﬁcant overestimation and underestimation among individuals and concluded
that none of the equations provided unbiased estimates of individual 24-h sodium excretion. The use of
spot vs 24-h urine samples for measuring differences in mean sodium excretion between population
samples was assessed in the China Salt Substitute and Stroke Study (Huang et al., 2018). The Tanaka,
Kawasaki and INTERSALT equations provided substantially underestimated differences between
intervention and control groups compared with the values obtained using 24-h urine samples.
Spot urine collections are, however, considered useful for trend analysis at group/population level
(WHO, 2011; Ji et al., 2012; Cogswell et al., 2013).
The Panel notes that the reliability of both overnight and spot urine collections to estimate daily
sodium intake is largely affected by circadian variations in individual sodium excretion. The
Panel further notes that estimates of individual daily intakes from predictive equations based on spot
urine samples can be biased, particularly at the lower and higher ends of the distribution and can
therefore substantially misclassify exposure.
2.6.2. Biomarkers of status
Homeostatic mechanisms maintain plasma sodium concentration of healthy individuals within a
narrow range (Sterns, 2015) (Section 2.3.2). Red blood cells concentrations are around 11 mmol/L
(Cox, 1995; Penney, 2008). Differences by sex have been observed (Beilin et al., 1966). Slightly
elevated plasma sodium concentration (by about 1–3 mmol/L) is often observed in hypertensive
subjects (de Wardener et al., 2004; Blaustein et al., 2012).
The plasma sodium concentration is closely related to overall sodium balance, as well as potassium
and water homeostasis. So, changes in plasma sodium concentration are related to the overall
osmolarity of the diet, blood and gastrointestinal ﬂuids, sweat and urine (Sterns, 2015).
Hyponatraemia and hypernatraemia are typically related to disorders affecting water and electrolyte
balances, and are seldom due to inappropriate sodium intake (Section 2.2.2). Plasma sodium
concentration does not accurately reﬂect sodium body content.
The Panel considers that there is no biomarker of sodium status that can be used for setting DRVs
for sodium in the general population.
2.7. Effects of genotype
There is heterogeneity in sodium-dependent trafﬁcking systems, much of which is not noticed
because of the redundancy in many metabolic pathways that enable compensatory systems.
Nonetheless, many genotypic variants that affect sodium-dependent solute carriers for amino acids,
monosaccharides, vitamins, potassium, calcium and bile acid, for example, have been reported.
Additionally, there are monogenic defects affecting voltage-gated sodium channels in neurons, and all
types of muscle. Depending on the channel affected, the clinical features embrace cardiac conductivity
defects, myopathies, increased sensitivity to pain, paroxysmal extreme pain, neuropathies, epilepsy
and autonomic dysfunction (OMIM on line6).
Many monogenic changes affecting the renal excretion and salvage of sodium, chloride and water
have also been identiﬁed, and these constitute a spectrum of defects involving both hypotension and
hypertension (Schafer, 2002; Padmanabhan et al., 2015). Inherited defects in sodium reabsorption in
the loop of Henle are associated with increased loss of sodium and chloride (salt-losing tubulopathies)
accompanied by hypokalaemia and alkalosis (e.g. Bartter’s syndrome, Gitelman’s syndrome). These
genotypes are usually associated with normal or reduced blood pressure (Schafer, 2002; Padmanabhan
et al., 2015). Other genotypes are associated with increased epithelial Na channel (ENaC) function
causing syndromes involving excess aldosterone and mineralocorticoid activity leading to volume
expansion and hypertension, hypokalaemia and, occasionally, alkalosis (e.g. Liddle’s syndrome). In
some instances, these syndromes include increased mucus viscosity and bronchiectasis. Other
syndromes involve loss of ENaC activity resulting in a syndrome of pseudohypoaldosteronism with
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reduced ECF volume, sodium loss with hyperkalaemia and hypotension (Schafer, 2002; Padmanabhan
et al., 2015).
‘Salt sensitivity’ is deﬁned as a trait present in humans, by which the blood pressure of some
members of the population exhibits changes parallel to changes in salt intake (Elijovich et al., 2016).
As a response to ‘high’ exposure to sodium or sodium chloride in the population at large is a rise in
blood pressure levels, the distinctiveness of a ‘salt-sensitive’ individual lies in the immediacy of the
observed changes in blood pressure levels induced by alterations in sodium chloride intake. ‘Salt
sensitivity’ can be regarded as one end of a Gaussian distribution of blood pressure responses to
change in dietary sodium chloride, while the other extreme has been termed ‘salt resistant’
(Weinberger, 1996; Strazzullo et al., 2000; He et al., 2009). The range of responses depends on the
balance of environmental, dietary, for example potassium intake, and lifestyle factors with individuals’
physiological characteristics and genetic proﬁles (Lupoli et al., 2013; Luzardo et al., 2015;
Padmanabhan et al., 2015; Elijovich et al., 2016). Although there is evidence for a genetic basis of ‘salt
sensitivity’, the identiﬁcation of genetic variants associated with ‘salt sensitivity’ is challenging (Elijovich
et al., 2016). The Panel notes that, as yet, there is no consensus on the characterisation of ‘salt
sensitivity’ (Luzardo et al., 2015; Elijovich et al., 2016).
The Panel considers that as yet no genotype has been characterised sufﬁciently to merit
consideration about the estimation of DRVs for sodium in the general population.
3. Dietary sources and intake data
3.1. Dietary sources
All unprocessed foods contain sodium, although at low levels. The sodium content of unprocessed,
raw meat and ﬁsh is typically between 30 and 150 mg (1.3 and 6.5 mmol)/100 g, and fruits and
vegetables generally contain less than 50 mg (2.2 mmol)/100 g (UK Food Standards Agency, 2002;
Anses, 2016c; National Institute for Health and Welfare, 2016).
Sodium is present in variable amounts in water, with mineral deposits, seawater spray, sewage
efﬂuents, and salt used in road de-icing contributing signiﬁcant quantities of sodium to water (WHO,
2003). Water treatment chemicals, such as sodium ﬂuoride, sodium bicarbonate and sodium
hypochlorite, can also increase the sodium content of water. Median (25–75th) sodium concentrations
in tap water sampled in 30 European countries was 0.4 (0.2–0.9) mmol/L (9.5 (4.3–20.0) mg/L)
(n = 579 samples) (Banks et al., 2015). High variability was found in European samples of bottled
mineral water, from 0.04 mmol (1 mg) to 61.7 mmol (1,419 mg)/L (n = 73) (Azoulay et al., 2001). So,
the contribution of drinking water to dietary sodium intake may vary substantially depending on the
source and quantity of the water that is consumed.
Sodium is added to food mostly as sodium chloride during processing. In addition, sodium may be
added in the form of sodium-containing food additives, such as sodium bicarbonate in ﬁne bakery wares
or sodium nitrate in processed meat. Authorised sodium-containing food additives include riboﬂavin
50-phosphate sodium, D-pantothenate sodium, sodium-L-ascorbate, ferric sodium diphosphate, ferric
sodium ethylenediaminetetraacetate (EDTA), sodium iodide, sodium iodate, sodium bicarbonate, sodium
carbonate, sodium citrate, sodium gluconate, sodium lactate, sodium hydroxide, sodium salts of
orthophosphoric acid, sodium selenate, sodium selenite, sodium hydrogen selenite, sodium ﬂuoride,
sodium molybdate and sodium borate, which can be added to both foods7 and food supplements.8 Sodium
sulfate and sodium monoﬂuorophosphate are authorised for use in food supplements only.7 The sodium
content of infant and follow-on formulae9 and processed cereal-based foods and baby foods for infants and
young children10 is regulated.
The sodium content of processed foods can vary substantially between countries, reﬂecting dietary
habits and taste preferences. In addition, large variations have been observed in the sodium content
of food items belonging to the same food group. Studies conducted in the Netherlands, Australia and
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the UK agree on the wide range of sodium content among similar food items. Based on these
estimations, food groups with the highest sodium content are sauces (particularly Asian ones),
processed meat, cheese and canned ﬁsh, whereas food groups with the lowest sodium content are
rice, pasta, cereal products (excluding bread) and processed fruits and vegetables (Webster et al.,
2010; Ni Mhurchu et al., 2011; Capuano et al., 2013; Eyles et al., 2013). In European populations, the
main contributors to sodium intake are bread, meat and meat products, and cheese and dairy
products (European Commission, 2012; Kloss et al., 2015).
The relative contributions of different sodium sources (inherently food-borne, processing-added, table
salt, cooking salt) to intake is variable, as illustrated by studies conducted in the UK (Farrimond et al.,
1995; Henderson et al., 2003), Denmark (Andersen et al., 2009) and Italy (Leclercq and Ferro-Luzzi,
1991). Estimates of the mean contribution of discretionary sodium chloride (i.e. added during the
preparation of the meals or at the table) vary from 10% in the study in Denmark to more than one third
of the total intake in the study in Italy. The Panel however notes the substantial uncertainty associated
with these estimates.
The Panel notes that sodium chloride added during industrial food processing, discretionary use or
food preservation is the major source of dietary sodium in Western diets. Other sources of sodium
include inherently native sources, and sodium-containing food additives, in which sodium may be
associated with anions other than chloride.
3.2. Dietary intake
3.2.1. Methodological considerations
In dietary surveys, sodium intake is estimated through recalls (of recent or usual diet) or food
diaries capturing intakes in real-time. In addition to the limitations inherent to the use of dietary
questionnaires, i.e. the inaccurate reporting of participants and the use of incomplete or outdated food
composition tables to determine the sodium content of food, errors in estimating sodium intake can be
introduced by the failure to capture the sodium chloride added at the table and/or during cooking.
These errors can result in biased estimates of sodium intake, which if they differ by exposure or
disease status (i.e. high consumers or hypertensive subjects may misreport more often than individuals
with lower intakes or normal blood pressure, respectively), can have an unpredictable impact on the
estimated association between sodium intake and disease risk.
In a pooled analysis of data collected in ﬁve large validation studies conducted in the USA,
Freedman et al. (2015) assessed the relative validity of FFQs and 24-h dietary recalls (DRs) in
capturing sodium intake through comparisons with 24-h urinary sodium levels. On average, weighted
by the inverse of the variance, underreporting was 28% (men) and 39% (women) with a FFQ and 4%
(men) and 13% (women) with a single 24-h DR. Underreporting of sodium was strongly associated
with higher body mass index (BMI) for both instruments and also with being black, male, and having a
high school education versus a college education or higher for FFQs. Correlation coefﬁcients between
self-reported questionnaires and 24-h urinary estimates improved when sodium intake was expressed
in relation to total energy intake (i.e. as sodium density) and when multiple 24-h DRs were collected
as compared with a single 24-h DR.
Two recent reviews of validation studies compared estimates of sodium intakes based on dietary
questionnaires (24-h dietary recalls, food diaries or FFQs) with 24-h urinary sodium excretion (McLean
et al., 2017, 2018). Studies were quite heterogeneous in the period covered, i.e. number of days
covered by 24-h DRs or records, of months captured by FFQs and the number of 24-h urine samples
collected; in whether sodium chloride used for preparation or added at the table was taken into
consideration; in considering participants’ characteristics in the analysis; and in the way the data were
analysed. In most studies, correlation coefﬁcients were estimated and ranged from 0.11 to 0.49 for
food diaries (six studies) and from 0.16 to 0.72 for 24-h DRs (10 studies) (McLean et al., 2018). The
results of Bland–Altman analysis performed in two studies generally point to poor agreement between
estimations based on 24-h DRs and urine collections. In particular, one study reported a negative
association (increasing urinary sodium excretion was associated with increasing underestimation by
dietary method) but the limits of agreement were not reported. The second study reported a mean
difference of 0.087 g/day, but with 95% limits of agreement ranging from 3.1 to +3.3 g/day,
indicating a wide range of bias in the estimations. The correlation coefﬁcients between intakes
assessed through FFQs and 24-h urines ranged from 0.07 to 0.36 across 16 eligible validation studies
(McLean et al., 2017). Concurrent urine collections did not substantially improve the correlations. One
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eligible study indicated poor agreement between estimates from a FFQ and 24-h urine collection based
on the Bland–Altman method. There was no obvious bias at low or high sodium intakes in that study.
The Panel notes that there is generally poor agreement between sodium intake estimates based on
dietary questionnaires and 24-h urine collections. The Panel considers that estimates of sodium intake
based on 24-h urinary excretion are more accurate than estimates of intake based on dietary
questionnaires (Section 2.5.1). Twenty four-hour urine collection is the recommended method for
assessing population mean sodium intake. There are limitations, however, in the use of this method,
including potential bias due to inaccurate collection. The Panel additionally considers that when
estimates of individual intakes are based on single measurements or the average of a small number of
urine collections, they may be prone to random errors due to within-individual day-to-day variability in
sodium excretion, which may result in the estimation of inaccurate percentiles of sodium intake.
3.2.2. Sodium urinary excretion in European populations and abroad
In 2016, an overview of sodium intake in European populations was prepared based on data on
sodium urinary excretion in European populations collected through EFSA focal points and the
members of the EFSA Food Consumption Network.11 Data were collected from 18 countries, and the
most recent surveys, conducted between 2002 and 2014, were selected. Appendix C provides urinary
sodium excretion data in children in four countries (Austria, Iceland, Italy, Spain). Appendices D and E
provide urinary sodium excretion data of adult men and women in 17 countries (Austria, Belgium,
Croatia, the Czech Republic, Finland, Germany, Greece, Hungary, Ireland, Italy, Norway, Slovenia,
Spain, Sweden, Switzerland, the Netherlands and the United Kingdom). Most countries used 24-h urine
collection, while three countries collected spot or timed urine collection and estimated daily sodium
excretion through arithmetic extrapolation. Studies using 24-h urine collection were heterogeneous
with respect to the methods and criteria applied for the assessment and exclusion of incomplete or
unreliable urine collections (e.g. PABA recovery, creatinine excretion levels, urinary volume, self-
reporting of incomplete samples). Some studies were designed as national monitoring surveys, while
others were conducted as part of broader observational studies. Sample sizes also varied widely, from
tens to thousands of people.
Mean sodium urinary excretion levels across countries ranged between 3.2 and 6.1 g/day (141 and
266 mmol/day) in adult men, and between 2.6 and 4.2 g/day (112 and 182 mmol/day) in adult
women. Across all countries, mean sodium excretion levels were higher in men than in women. In
children, values ranged between 1.7 g/day (72 mmol/day) in 6-year-old boys and girls in Iceland and
2.8 and 3.5 g/day (122 and 154 mmol/day) in Austrian boys and girls aged 13–14 years old.
Powles et al. (2013) combined data from national and subnational adult population surveys of 24-h
urinary sodium excretion and dietary sodium intake, conducted in 187 countries (21 regions) between
1980 and 2010. Dietary estimates were converted into urine equivalents based on surveys having data
for both measurements from the same individuals, and mean sodium intake was estimated through
Bayesian hierarchical modelling. Across European countries, mean (95% uncertainty interval) sodium
intake estimates ranged from 3.27 (2.98–3.58) g/day (Denmark) to 4.42 (4.22–4.61) g/day (Italy) for
men and women combined. World-wide, sodium intakes were the highest in East and Central Asia and
Eastern Europe (mean > 4.2 g/day), and in Central Europe and Middle East/North Africa sodium intake
ranged between 3.9 and 4.2 g/day. Regional mean intakes in North America, Western Europe and
Australia/New Zealand ranged between 3.4 and 3.8 g/day. Intakes were lower (< 3.3 g/day) in sub-
Saharan Africa and Latin America, but more uncertain due to the few data sources available.
In the INTERSALT study, an international study undertaken in 1982–1985 in which 52 centres from
32 countries participated, 200 men and women (aged 20–59 years) equally distributed in age and sex
groups were recruited in each centre. Participants were asked to provide a 24-h urine collection,
following a standardised protocol. Urine analyses were conducted in the same laboratory. The study
pointed to a large variation in the sodium intake of free-living healthy individuals, with median urinary
sodium excretion ranging between 0.005 g (0.2 mmol)/day in Yanomamo Indians in Brazil and 5.6 g
(242.1 mmol)/day in China (Intersalt Cooperative Research Group, 1988).
Dietary Reference Values for sodium
11 In addition, data were received during the public consultation on the intermediate draft of the Opinion. EFSA (European Food
Safety Authority), 2017. Outcome of a public consultation on the Scientiﬁc Opinion of EFSA Panel on Dietetic Products,
Nutrition and Allergies (NDA) on Dietary Reference Values for sodium (intermediate draft) and related protocol. EFSA
supporting publication 2017:1356.
www.efsa.europa.eu/efsajournal 23 EFSA Journal 2019;17(9):5778
4. Overview of dietary reference values and recommendations
4.1. Adults
For adults aged 19 and older, the US National Academies of Sciences, Engineering, and Medicine
(NASEM) set an adequate intake (AI) of 1.5 g/day (NASEM, 2019). The lowest levels of sodium intake
evaluated in randomised trials conducted among adults (DASH-sodium trial and eight other trials) and
the balance study from Allsopp et al. (1998) which indicated neutral balance with heat stress at this
level of intake were considered in setting the AI. The NASEM concluded that evidence of harmful
effects of low sodium intake on type 2 diabetes, glucose tolerance, and insulin sensitivity, blood
pressure, plasma lipid concentrations, cardiovascular disease and all-cause mortality was insufﬁcient
and inconsistent. The NASEM also established a Chronic Disease Risk Reduction Intake (CDRR) for
sodium, deﬁned as the lowest level of intake for which there was sufﬁcient strength of evidence to
characterise a chronic disease risk reduction. In the sodium intake range of 2.3–4.1 g/day (100–
178 mmol/day), the strength of evidence was considered high that reducing sodium intake reduces
chronic disease risk, based on evidence of reduction in cardiovascular disease incidence, reduction in
hypertension incidence, and lowering of systolic and diastolic blood pressure. A sodium CDRR of
reducing intakes if above 2.3 g/day (100 mmol/day) was proposed, which is applicable to adults with
and without hypertension, irrespective of sex, age or race/ethnicity. The 2015–2020 Dietary Guidelines
for Americans recommended that adults limit sodium intake to less than 2.3 g/day (HHS/USDA, 2015).
The German-speaking countries (D–A–CH, 2016; Strohm et al., 2018) based their DRVs on data
from the balance study by Allsopp et al. (1998) in which male subjects achieved a positive sodium
balance with sodium intake of 1.5 g/day after 8 days, under conditions of moderate physical activity
and heat exposure. In addition, it was noted that the requirements of other nutrients, with the
exception of iodine and ﬂuoride, can be achieved with a diet providing 1.5 g sodium/day (Deutsche
Gesellschaft f€ur Ern€ahrung, 2015). An AI of 1.5 g/day was set for all adults. In a separate statement,
the German Nutrition Society (DGE) emphasised the relationship between sodium chloride intake and
blood pressure, and that a high consumption of sodium chloride is associated with an elevated or
‘suboptimal’ blood pressure while a low consumption is associated with blood pressure in the normal or
‘optimal’ range (Strohm et al., 2016). This association was considered a convincing proof of an indirect
effect of high sodium chloride intake via hypertension on the risk of CVD, while the evidence for a
direct effect of sodium chloride intake on CVD risk was considered inconsistent. A target value for
dietary sodium chloride of 6 g/day (2.4 g sodium) for adults was recommended.
The Nordic countries (Nordic Council of Ministers, 2014) acknowledged that trials showed a
decrease in blood pressure when sodium intake was reduced, and that blood pressure is a risk factor
for CVD (Bibbins-Domingo et al., 2010). It was stated that recommended intakes for sodium should be
based on public health considerations rather than actual requirements. A sodium chloride intake of less
than 6 g/day or a sodium intake of less than 2.4 g/day was considered a population goal.
In 2014, the Italian Society of Nutrition (SINU) set an AI of 1.5 g sodium/day for adults aged
18–59 years, in line with IOM’s conclusions (IOM, 2005). A suggested dietary target (SDT) of 2 g
sodium/day was proposed for this age group for the prevention of cardiovascular and other chronic
diseases, consistent with the recommendation from the WHO (2012b). It was stated that the target
for the population is a sodium intake below the SDT. For older adults (≥ 60 years), SINU proposed a
decrease in the AI and SDT compared with younger adults, in proportion with the requirement for
energy. This was taking into consideration the fact that the sensitivity of blood pressure to sodium
chloride intake increases with age (Khaw and Barrett-Connor, 1990; Vollmer et al., 2001), and also
accounted for reduced renal and cardiovascular functions in older adults.
The WHO (2012b) has not set DRVs for sodium but recommends a reduction in sodium intake to
< 2 g/day sodium (5 g/day sodium chloride) in adults (≥ 16 years of age) (strong recommendation12).
This was based on evidence from systematic reviews on the relationship between sodium and blood
pressure and risk of cardiovascular disease, stroke and coronary heart disease in adults (WHO, 2012a,c).
The Health Council of the Netherlands concluded that, in a large number of RCTs, lowering sodium
intake reduces blood pressure, which is a causal risk factor of cardiovascular diseases (Kromhout et al.,
2016). The Committee observed that the protective effect of a low intake of sodium was stronger in
hypertensive than in normotensive people (Graudal et al., 2011; Aburto et al., 2013; He et al., 2013).
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The guideline could not be quantiﬁed because of insufﬁcient data from high-quality cohort studies on
sodium intake and cardiovascular risk. Therefore, the Committee decided to maintain its previous
guideline to limit salt intake to 6 g/day (2.4 g sodium) (Health Council of the Netherlands, 2006).
Afssa (2001) did not set a PRI for sodium because of a lack of intervention studies (in particular on
cardiovascular morbidity and mortality) to deﬁne a PRI. A lack of consensus was noted on the
relationship between sodium intake and blood pressure (Alderman et al., 1997; Stamler et al., 1997;
Weinberger, 1997; McCarron, 1998; Taubes, 1998; MacGregor and de Wardener, 1999; Swales, 1999).
Afssa (2001) suggested that healthy adults should not consume more than 12 g/day and not less than
5 g/day of sodium chloride (corresponding to 4.8 and 2.0 g/day of sodium). In 2016, Anses considered
recent literature on the relationship between sodium intake and blood pressure (Mente et al., 2014)
and cardiovascular risk (IOM, 2013; Adler et al., 2014; Graudal et al., 2014; O’Donnell et al., 2014;
Pﬁster et al., 2014) and noted a lack of consensus; the experts concluded that current data were
insufﬁcient to set a UL, a PRI or an AI for sodium (Anses, 2016b). In its update of the food-based
dietary guidelines for the French population, Anses selected the median consumption of sodium as the
maximum value not to be exceeded, which amounts to reducing intake in the half of the population
with higher intake levels, in agreement with public health policies. The French consumption survey
INCA2 reported median daily intakes of sodium of 2,273 mg for women and 2,994 mg for men
(excluding sodium from salt added at the table) (Anses, 2016a).
The SCF (1993) did not set a PRI for sodium but an acceptable range of intakes of 0.575–3.5 g
sodium/day. The lower intake took into account reports on maintenance of sodium balances at intakes
as low as 0.069–0.46 g/day, and observed habitual intakes in some populations of 0.23–0.92 g/day
(Glieberman, 1973; INTERSALT Cooperative Research Group, 1988; Law et al., 1991a), allowing for
changes in physical activity and ambient temperature. The upper intake was based on evidence that
an intake higher than 4.6 g/day may be associated with increased risk of hypertension, especially in
older adults (Frost et al., 1991; Law et al., 1991a,b), and the public health consideration that intakes
should be lower than this amount to reduce the risk of hypertension and CVD.
The UK COMA (DH, 1991) set DRVs based on the balance of ‘risks and beneﬁts’ of sodium intakes.
The COMA was unable to derive an estimated average requirement (EAR) but set a lower reference
nutrient intake (LRNI) for sodium at 25 mmol/day (0.575 g/day) and a reference nutrient intake (RNI)
at 70 mmol/day (1.6 g/day). It was noted that a reduction in sodium intake decreases blood pressure
in people with established hypertension, but this may not be seen in people with normal blood
pressure. The COMA was unable to determine a potentially toxic threshold for sodium intake. It was
noted that 10% of the population may be affected by a genetic susceptibility to sodium-related
hypertension apparent at sodium intakes of 3.2–4.7 g/day. In 2003, the UK Scientiﬁc Advisory
Committee on Nutrition (SACN) endorsed the RNI of 70 mmol/day (1.6 g/day) and recommended a
target sodium chloride intake of less than 6 g/day (2.4 g (100 mmol) sodium)) for the adult population
by multiplying the RNI by a factor of 1.5 (SACN, 2003). The Committee noted that this is higher than
the RNI and substantially greater than the sodium chloride intake required to maintain the sodium
content of the body. It noted that the target salt intakes set for adults do not represent ideal or
optimum consumption levels, but an achievable population goal as part of a public health strategy.
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Table 2: Overview of dietary reference values (adequate intakes) for sodium for adults
NASEM (2019) D–A–CH (2016) SINU (2014) SCF (1993)
DH (1991);
SACN (2003)
Age (years) ≥ 19 ≥ 19 ≥ 19 ≥ 18 ≥ 19
AI
Men (g/day)
Women (g/day)
1.5
1.5
1.5
1.5
1.5
1.5
0.575–3.5(a)
0.575–3.5(a)
1.6
1.6
Age (years) ≥ 60
AI
Men (g/day)
Women (g/day)
1.2
1.2
AI: adequate intake; D–A–CH: Deutschland–Austria–Confoederatio Helvetica; DH: Department of Health; NASEM: National
Academies of Sciences, Engineering, and Medicine; SACN: Scientiﬁc Advisory Committee on Nutrition; SCF: Scientiﬁc Committee
for Food; SINU: Italian Society of Nutrition.
(a): Acceptable range of intakes.
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4.2. Infants and children
For infants aged 7–12 months, the NASEM (2019) set an AI of 370 mg/day (16.1 mmol/day) based
on the sodium intake from breast milk (approximately 70 mg/day (3.0 mmol/day)) and from
complementary foods (300 mg/day (13.0 mmol/day)). For children and adolescents 1–18 years of age,
the AIs were derived by extrapolating from the sodium AI for adults based on average Estimated
Energy Requirements for sedentary children, as compared to an Estimated Energy Requirement for
adults. Regarding CDRR intake, the NASEM noted that evidence to assess the relationship between
sodium intake and chronic disease in children and adolescents was insufﬁcient and the uncertainties
about the long-term chronic disease beneﬁts of reduced sodium intake beginning in childhood.
However, the committee considered that the risk of not setting a CDRR for children outweighed the
risk of setting a sodium CDRR intake for children based on evidence of blood pressure tracking to
adulthood, the public health importance, and consideration of salt-taste sensitivity and preferences
starting to develop as early as 3–4 months of age. The sodium CDRRs for children were extrapolated
from the adult sodium CDRR, based on energy requirements, and were set as follows: 1.2 g/day for
children aged 1–3 years, 1.5 g/day for children aged 4–8 years, and 1.8 g/day for children aged
9–13 years and 2.3 g/day for children aged 14–17 years. The 2015–2020 Dietary Guidelines for
Americans (HHS/USDA, 2015) recommended that children limit sodium intake to less than the ULs
established by the IOM in 2005.
For infants aged 4–11 months, the German-speaking countries (D–A–CH, 2016) derived an AI of
0.2 g/day. This was based on an estimated sodium intake from breast milk of 0.13 g/day for infants
aged 0–4 months (considering a sodium content of breast milk of 0.170 g/L and assuming an average
breast milk intake of 0.75 L/day) and upward extrapolation considering differences in body weight. AIs
for children were extrapolated down from the AI of adults, based on difference in body weight and
applying a growth factor.
For children, Nordic countries stated that data suggest that a reduction in sodium intake at an early
age is associated with a lower blood pressure in later life. For children below 2 years of age, it was
recommended to limit sodium chloride intake to below 0.5 g/MJ (equivalent to 0.2 g/MJ of sodium), to
avoid developing a preference for a diet with a high sodium chloride level. From 2–9 years, it was
recommended not to exceed a sodium chloride intake of about 3–4 g/day (Nordic Council of Ministers,
2014).
For infants aged 7–12 months, SINU (2014) set an AI based on the sodium intake from breast milk and
from complementary foods, in line with the approach taken by IOM (2005). For children aged 1–10 years,
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Table 3: Overview of population goal/target for sodium and sodium chloride intake for adults
Strohm
et al.
(2016)
(DGE)
Anses
(2016a)
HHS/
USDA
(2015)
Nordic
Council of
Ministers
(2014)
SINU
(2014)
WHO
(2012b)
Health
Council of
the
Netherlands
(2006)
SACN
(2003)
Age
(years)
≥ 18 ≥ 19 ≥ 18 ≥ 18 ≥ 16 ≥ 18 ≥ 19
Sodium
chloride
(g/day)
6 – 5.75 6 5 5 6 6
Sodium
(g/day)
2.4 M: ≤ 2,994 mg/day
W: ≤ 2,273 mg/day
2.3 2.4 2.0 2.0 2.4 2.4
Age
(years)
≥ 60
Sodium
chloride
(g/day)
4
Sodium
(g/day)
1.6
Anses: French Agency for Food, Environmental and Occupational Health and Safety; DGE: German Society of Nutrition; HHS/
USDA: Health and Human Services/United States Department of Agriculture; M: men; SACN: Scientiﬁc Advisory Committee on
Nutrition; SINU: Italian Society of Nutrition; W: women; WHO: World Health Organization.
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AIs and SDTs were extrapolated down from the AI for adults in proportion of the energy requirement of
the respective age groups. For children and adolescents aged 11–18 years, the same AI and SDT as for
adults were proposed.
The WHO (2012b) has not set DRVs for sodium but recommends a reduction in sodium intake to
control blood pressure in children aged 2–15 years of age (strong recommendation). The
recommended maximum level of intake of 2 g/day sodium in adults should be adjusted downward
based on the energy requirements of children relative to those of adults.
Afssa (2001) and the SCF (1993) did not set DRVs for sodium in infants and children due to
insufﬁcient evidence.
The UK COMA (DH, 1991) set LRNIs and RNIs for infants and children. For infants and children
above 6 months, RNIs were derived factorially by calculating the daily increase in total body sodium
content allowing for the declining proportion with age of ECF in body mass (Friis-Hansen, 1961), with
an allowance for dermal, faecal and urinary losses. So, LRNIs between 0.2 g sodium/day (7 months to
3 years) and 0.575 g sodium/day (15 to 18 years) were set. In 2003, the UK Scientiﬁc Advisory
Committee on Nutrition endorsed the RNI proposed by COMA and multiplied them by a factor of 1.5 to
set daily target average sodium chloride intake (SACN, 2003). The Committee noted that target
sodium chloride intakes do not represent ideal or optimum consumption levels, but an achievable
population goal.
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Table 4: Overview of dietary reference values (adequate intakes) for sodium for infants and
children
NASEM (2019) D–A–CH (2016) SINU (2014) DH (1991)
Age (months) 0–6 4–11 4–6
AI (g/day) 0.11 0.2 0.28(a)
Age (months) 7–12 6–12 7–9
AI (g/day) 0.37 0.4 0.32(a)
Age (months) 10–12
AI (g/day) 0.35(a)
Age (years) 1–3 1–3 1–3 1–3
AI (g/day) 0.8 0.4 0.7 0.5(a)
Age (years) 4–8 4–6 4–6 4–6
AI (g/day) 1.0 0.5 0.9 0.7(a)
Age (years) 7–9 7–10 7–10
AI (g/day) 0.75 1.1 1.2(a)
Age (years) 9–13 10–12 11–14 11–14
AI (g/day) 1.2 1.1 1.5 1.6(a)
Age (years) 14–18 13–14 15–17 15–18
AI (g/day) 1.5 1.4 1.5 1.6(a)
Age (years) 15–18
AI (g/day) 1.5
AI: adequate intake; D–A–CH: Deutschland–Austria–Confoederatio Helvetica; DH: Department of Health; NASEM: National
Academies of Sciences, Engineering, and Medicine; SINU: Italian Society of Nutrition.
(a): Reference nutrient intake (RNI).
Table 5: Overview of population goal/target for sodium and sodium chloride intake for children
HHS/USDA (2015)
Nordic Council
of Ministers (2014)
SINU (2014) SACN (2003)
Age (months) 0–6
Sodium chloride (g/day) 1
Sodium (g/day) 0.4
Age (months) 0–24 7–12
Sodium chloride (g/day) 0.5(a) 1
Sodium (g/day) 0.2(a) 0.4
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4.3. Pregnancy and lactation
The NASEM considered that there was a lack of evidence to suggest that sodium requirements of
pregnant women differ from that of non-pregnant women and proposed a sodium AI for pregnant
women of 1.5 g/day (65 mmol/day) (NASEM, 2019). Regarding lactating women, the NASEM noted
that sodium is excreted in breast milk but the concentrations are determined by an electrical potential
gradient, rather than by maternal dietary intake. The sodium requirements for lactating women does
not appear to differ from that of non-pregnant, non-lactating women and the same AI of 1.5 g/day
(65 mmol/day) was set for this group. The NASEM considered that there was insufﬁcient evidence that
a different sodium CDRR is needed for pregnant or lactating females compared to their non-pregnant,
non-lactating age group counterparts. The same sodium CDRR of 2.3 g/day was proposed for these
groups.
D–A–CH (2016) considered that the extra sodium requirement of 0.07 g/day (3 mmol/day) during
pregnancy, due to the expansion of ECF volume, can be covered by homeostatic mechanisms. The
same was considered to be true for the additional requirement of 0.13 g/day (6 mmol/day) during
lactation due to sodium losses with breast milk.
SINU (2014) considered that the AI for non-pregnant non-lactating women was sufﬁcient to cover
the increase in sodium requirement during pregnancy and lactation; the same AI as for other adults
(1.5 sodium/day) was maintained for these population groups. SINU recommended that the SDT for
other adults (2 g sodium/day) also applies to pregnant and lactating women.
The Nordic countries (Nordic Council of Ministers, 2014) concluded that there was a lack of
evidence to suggest that the sodium requirement during pregnancy and lactation differs signiﬁcantly
from that of non-pregnant women; no DRVs for sodium were set for these population groups.
Likewise, the SCF (1993) and the UK COMA (DH, 1991) did not set speciﬁc DRVs for sodium for
pregnant and lactating women.
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HHS/USDA (2015)
Nordic Council
of Ministers (2014)
SINU (2014) SACN (2003)
Age (years) 1–3 2–9 1–3 1–3
Sodium chloride (g/day) 3.75 3–4 2.25 2
Sodium (g/day) 1.5 1.2–1.6 0.9 0.8
Age (years) 4–8 10–18 4–6 4–6
Sodium chloride (g/day) 4.75 6 3 3
Sodium (g/day) 1.9 2.4 1.2 1.2
Age (years) 9–13 7–10 7–10
Sodium chloride (g/day) 5.5 3.75 5
Sodium (g/day) 2.2 1.5 2.0
Age (years) 14–18 11–17 11–18
Sodium chloride (g/day) 5.75 5.0 6
Sodium (g/day) 2.3 2.0 2.4
HHS/USDA: Health and Human Services/ United States Department of Agriculture; SACN: Scientiﬁc Advisory Committee on
Nutrition; SINU: Italian Society of Nutrition.
(a): Expressed as nutrient density, i.e. g of sodium/MJ of energy intake.
Table 6: Overview of dietary reference values (adequate intakes) for sodium for pregnant and
lactating women
NASEM (2019) D–A–CH (2016) SINU (2014)
Age (years) 14–50
AI pregnancy (g/day) 1.5 1.5 1.5
AI lactation (g/day) 1.5 1.5 1.5
AI: adequate intake; D–A–CH: Deutschland–Austria–Confoederatio Helvetica; g: gram; NASEM: National Academies of Sciences,
Engineering, and Medicine; SINU: Italian Society of Nutrition.
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5. Criteria (endpoints) on which to base dietary reference values
5.1. Biomarkers as indicators of sodium requirement
As stated in Section 2.4, the Panel considers that there are no appropriate biomarkers of sodium
status that can be used for deriving DRVs for sodium.
5.2. Balance studies
Balance studies are based on the assumption that a healthy subject on an adequate diet maintains
equilibrium or a null balance, between nutrient intakes and nutrient losses. At this null balance, the
intake matches the requirement determined by the physiological state of the individual. When intakes
exceed losses (positive balance), there is nutrient accretion that may be attributable to growth or
weight gain, anabolism, or repletion of stores; when losses exceed intakes (negative balance), nutrient
stores are progressively depleted, resulting in clinical symptoms of deﬁciency in the long term. In
addition to numerous methodological concerns about accuracy and precision in the determination of
nutrient intakes and losses (Baer et al., 1999), the validity of balance studies to calculate nutrient
requirements has been questioned. Differences between intakes and losses of a nutrient may only
reﬂect adaptive changes before a new steady state is reached (Young, 1986), or the conditions for the
maintenance of nutrient ‘stores’ in the context of a given diet, whereas the health relevance of the size
of body pools still needs to be established for each nutrient (Mertz, 1987).
Although the term ‘balance studies’ is used in this section, the Panel considered studies that
describe comparative assessments between sodium intake and sodium excretion provided that their
designs allowed for an adaptation period (see Section 2.3.4.1). The key characteristics and results of
eligible balance studies are tabulated in Appendix F.1 and summarised below.
5.2.1. Balance studies in adults
Holbrook et al. (1984) aimed to assess sodium ‘balance’ in 28 United States healthy (20–53 years),
free-living men and women consuming self-selected diets. For 1 week in each season of the year (four
7-day periods), participants collected duplicate samples of food and beverages consumed and 24-h
urine and faecal samples for sodium content analysis. Sodium ‘balance’ was calculated as the
difference between sodium intake (including salt added during preparation and at the table) and
sodium excretion through urine and faeces. Dermal losses were not measured. Results are given for
the four 7-day periods combined (28 days). Most participants decreased their energy intake, as
assessed by dietary records (mean decrease of about 17% for men and 13% for women), during the
collection periods. Mean sodium intake was 3.4 g (148 mmol)/day. Mean  SD difference between
sodium intake and excretion was +0.47  0.32 g (+20  14 mmol)/day. The 95% CI of the mean did
not include zero. The mean difference between sodium intake and excretion was more positive during
the summer (+0.6 g (26 mmol)/day versus +0.4 g (17 mmol)/day in other periods). The Panel notes
the positive difference between sodium intake and excretion in these free-living individuals with a
mean sodium intake of 3.4 g (148 mmol)/day. The Panel also notes that dermal losses were not
assessed, which may have contributed to the positive difference.
One study (Allsopp, 1997; Allsopp et al., 1998) investigated sodium balance in 25 men (18–
40 years, BMI 20–34 kg/m2, not on regular strenuous physical training), who were conﬁned to an
experimental chamber at 25°C for 3 days (days 1–3), followed by 5 days at 40°C from 08:00 to
18:00 h and then at 25°C from 18:00 to 08:00 h (days 4–8). Relative humidity and air velocity were
kept constant. Sodium intake was controlled and kept constant throughout the study at doses of 1.5 g
(65 mmol)/day (n = 9), 4 g (174 mmol)/day (n = 9) or 8 g (348 mmol)/day (n = 7). Sodium losses
were estimated from daily 24-h urine collections, faecal samples and whole-body wash-downs on days
3, 4 and 8. Plasma aldosterone concentration was measured from morning blood samples. On day 8,
mean  SD sodium balance was +0.04  0.35 g/day, +0.79  0.64 g/day and +0.67  1.19 g/day in
the groups of men consuming 1.5, 4 and 8 g sodium/day, respectively. On day 8, no two groups were
dissimilar with respect to net sodium balance. In the group consuming 1.5 g of sodium/day, mean
plasma levels of aldosterone had increased by day 3 (vs no increase in the other two groups). During
the heat exposure period, such an increase was observed in all groups, but it was more apparent in
the group consuming 1.5 g of sodium/day.
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The Panel notes that men with low physical activity and a daily exposure to prolonged heat were
on average in balance, partly mediated by changes in aldosterone secretion, after 8 days of a
controlled diet that provided 1.5 g (65 mmol) of sodium/day.
A series of studies addressing Na, K, Ca, Mg, P, Fe, Zn, Cu and Mn was conducted in Japan and
have been collectively analysed on several occasions (Kodama et al., 2005; Nishimuta et al., 2005,
2006, 2012, 2018). Nishimuta et al. (2012) calculated the ‘estimated equilibrated dietary intakes
(EEDI)’ for sodium (the intercept of a linear regression equation between intake and balance) using
data from 13 ‘balance’ studies conducted in young Japanese women (n = 131, 18–26 years). Daily
sodium intake, assessed through duplicate diet samples, ranged between 2.5 g (107 mmol) and 4.8 g
(209 mmol). Each study included an adaptation period of 2–4 days. Sodium concentration in urine and
faeces were measured. Sodium losses in sweat during exercise were measured in ﬁve studies by
collecting sweat from the arm. The duration of the balance periods ranged from 8 to 12 days.
Notwithstanding the uncertainty induced by measurements of sweat losses, the Panel notes that, in
this collective analysis of primary studies among Japanese women, mean sodium ‘balance’ was
‘positive’ (+6.07  4.06 mg/kg bw) with sodium intakes above 2.5 g (107 mmol).
Other sodium balance studies or experiments assessing sodium excretion in different circumstances
are also available in the literature (McCance, 1936; Falconer and Lyall, 1937; Dole et al., 1950; Heer
et al., 2000, 2009; Rakova et al., 2013). The Panel considers that these ‘balance studies’ cannot be
used for setting DRVs for sodium due to the very small number of study participants (two in McCance
(1936); three in Falconer and Lyall (1937)), the inclusion of participants with pre-existing medical
conditions (Dole et al., 1950), the absence of adaptation periods (Heer et al., 2000, 2009), or the lack
of measurements of both faecal and dermal losses (Rakova et al., 2013).
5.2.2. Balance studies in children
Using a randomised cross-over design, Palacios et al. (2004) assessed sodium retention in 14 white
and 22 black US girls (11–15 years) during 3 weeks on a ‘low’ (mean  SEM: 1.31  0.04 g
(57  2 mmol)/day) and 3 weeks on a ‘high’ (3.95  0.05 g (172  2 mmol)/day)) sodium intake,
separated by a 2-week wash-out in which participants consumed self-selected diets. The ﬁrst week of
each period served as an equilibration period. The study was conducted in summer time. Eight white
and 15 black girls completed both periods, while six white and seven black girls completed one of the
two periods only. Before the study initiation, subjects completed six 24-h dietary recalls. Dietary
intakes of protein, fat, ﬁbre, potassium, calcium and phosphorus were controlled, at levels
representative of usual intakes in this population. Faecal and 24-h urine samples were collected daily
for 20 days during each study period. Corrections for incomplete samples were applied based on the
excretion of creatinine in urine and polyethylene glycol in faeces (‘normalised’ 24-h pools). Whole-body
sweat was collected after 2 weeks of acclimatisation to the diet for 24 h by a whole-body scrub-down
procedure, taking measures to minimise the contribution of exfoliated skin to the estimate. Mean
sodium balance over the last 2 weeks of each period was calculated including sodium losses in sweat.
Aldosterone concentration and renin activity were measured in plasma sampled upon awakening
(‘resting’ samples) and 2 h later (‘stimulated’ samples).
Mean ( SD) sodium balance was positive during ‘low’ and ‘high’ sodium intakes (+0.4  0.31 g/day
among blacks (n = 19) and +0.2  0.14 g/day among whites (n = 12) on ‘low’ intake and
+1.0  0.61 g/day among blacks (n = 19) and +0.3  0.28 g/day among whites (n = 10) on ‘high’
intake). Results were similar when urine and faecal samples were not normalised and when only subjects
completing both dietary periods were analysed. The Panel notes that this study in adolescent girls reports
positive mean sodium balances with a daily sodium intake of 1.31 g (57 mmol). Plasma aldosterone
concentrations were elevated at the end of the ‘low’ sodium period compared with the ‘high’ sodium
period (Appendix F.1).
5.2.3. Mechanistic considerations
In daily life, the body constantly adapts to maintain sodium (and water) homeostasis in response to
changing environmental conditions. Sodium balance is tightly regulated through neural and hormonal
mechanisms (including the SNS and the RAAS) affecting its renal reabsorption and intake (‘salt
appetite’) (Section 2.3.4). Several meta-analyses of human intervention studies have investigated the
effect of a reduction in sodium intake on these systems (Graudal et al., 2011; WHO, 2012c; He et al.,
2013) (Table F.1 in Appendix F.2). In the meta-analysis from He et al. (2013), which included most of
the studies that were also considered in the other two meta-analyses, a reduction in sodium intake,
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resulting in 24-h urinary sodium excretion in the range of 50–100 mmol (1.2–2.3 g)/day, was
associated with mean increases in plasma renin activity of 0.26 (95% CI 0.17, 0.36) ng/mL per h,
plasma aldosterone concentration of 73.20 (95% CI 44.92, 101.48) pmol/L and plasma noradrenaline
concentration of 31.67 (95% CI 6.57, 56.77) pg/mL). The effect estimate on plasma adrenaline
concentration was 6.70 (95% CI –0.25, 13.64) pg/mL (He et al., 2013). The trials included in these
analyses lasted from 4 to 11 weeks.
Cross-sectional analyses of data from subjects with different levels of sodium intake indicate
curvilinear relationships between sodium intake, plasma renin activity and urinary aldosterone
excretion; both increased sharply with 24-h urinary sodium excretion < 50 to 100 mmol/day (1.2 to
2.3 g/day) (Laragh et al., 1972; Laragh and Sealey, 2011).
In a study of sodium metabolism in young men consuming controlled amounts of sodium for
several weeks (Rakova et al., 2013), average daily urinary excretion of aldosterone increased with
gradual sodium restriction from 4.9 g/day to 2.5 g/day, each level maintained constant for > 29 days
(Table F.2 in Appendix F.2). In contrast, a decrease in urinary levels of glucocorticoids in urine was
observed. On average, 95% of dietary sodium was recovered in urine over each dietary phase, which
suggests that sodium balance was achieved at each level of sodium intake, through the activation of
hormonal regulatory mechanisms. A high day-to-day variability in urinary excretion of sodium was also
observed, as well as weekly and monthly rhythms of ﬂuctuations in aldosterone and glucocorticoids
that correlated with body sodium accumulation (apparent positive balance) and release (apparent
negative balance), independent of sodium intake.
5.2.4. Conclusions
Mean sodium intake assessed in eligible balance studies ranged between 1.5 g and 4.9 g/day in
adults (three studies) and between 1.31 and 3.95 g/day in adolescents (one study). No data are
available for sodium intakes below 1.3 g/day (adolescents) and 1.5 g/day (adults).
The Panel notes that adaptation mechanisms triggered by neural and hormonal signals enable the
maintenance of sodium balance over a wide range of sodium intakes. The concerns about using
balance studies to establish nutrient requirements are particularly relevant for sodium. Recent data
from a long-term study of sodium metabolism suggest that rhythmical variations in the sodium body
pools independent of sodium intake may occur. This complicates the interpretation of balance studies.
Overall, the Panel considers that balance studies cannot be used to determine sodium requirements,
but could be used to inform about the levels of sodium intake that are adequate to maintain a null
sodium balance. The Panel also notes the lack of data on the health effects of a sustained activation of
the SNS and the RAAS system in the general population.
5.3. Indicators of sodium requirement in pregnancy and lactation
Total body sodium is estimated to increase by 23 g (1,000 mmol) during pregnancy, and has been
assumed to represent an additional daily requirement of 70–90 mg (3–4 mmol) of sodium (Pitkin et al.,
1972). However, the increase is not evenly distributed throughout pregnancy. The need arises from the
expansion of the maternal ECF volume (approximating 3.0 L) that comprises 60% of the extra
requirement, and the remaining 40% meets the compositional requirements of the fetus, placenta and
the amniotic ﬂuid. The changes in the volume and distribution of body water start early in pregnancy
and are associated with the initial endocrine response to pregnancy that, among other things,
increases the homeostatic retention of sodium (Section 2.4).
Oliver et al. (1981) undertook a comparative study among women of two South American tribes to
understand how hormonal adaptation impacts on sodium balance during pregnancy and lactation. The
ﬁrst group consisted of pregnant (n = 4), non-pregnant/lactating (n = 16) and non-pregnant/non-
lactating (n = 16) Yanomamo Indian women living in villages in northern Brazil and southern Venezuela
with no access to sodium chloride. The second group included pregnant (n = 7) and non-pregnant
(n = 9) Guaymi Indian women of Panama, who had free access to sodium chloride and used it to cook
vegetables and preserve meat. The second (control) group was included to address concerns about
genetic susceptibility. In both groups, measurements of arterial blood pressure, blood and spot urine
samples were collected between 08:00 and 10:00 h in the morning. Breast milk samples were
collected only among the Yanomamo women. Urinary sodium concentrations among Yanomamo
women ranged between 0.7 mmol/L (pregnant) and 1.4 mmol/L (non-pregnant/non-lactating women)
and between 77.8 mmol/L (pregnant) and 119.0 mmol/L (non-pregnant) among Guaymi women. In
breast milk, the concentrations of sodium ranged between 5 and 9 mmol/L (0.1–0.2 g/L) meaning that
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it was comparable to the sodium concentration in sodium-afﬂuent regions. The pregnant Yanomamo
had high urinary concentrations of aldosterone, associated with higher plasma renin activities and
serum aldosterone concentrations than in all other subjects. Pregnant Guaymi also had elevated serum
and urinary aldosterone concentrations, but signiﬁcantly lower (p < 0.001) than in Yanomamo women.
Prolonged lactation in the Yanomamo was associated with elevation of plasma renin activity, serum
and urinary aldosterone concentration compared with the Guaymi, but was not higher than in non-
lactating Yanomamo women. Based on evidence from two Indian tribes living in South America, the
Panel notes that pregnancy in a salt-poor environment is associated with hormonal adaptation
associated with sodium retention, similar to non-pregnant adults (Allsopp et al., 1998).
The Panel considers that the requirement for the daily accretion rate of sodium in fetal and
maternal tissues can be met by the adaptive changes that maintain sodium homeostasis during
pregnancy.
Sodium losses in human milk are relatively small (a few mmol/day). The concentration of sodium in
human milk is not inﬂuenced by maternal sodium intake (Section 2.3.4.4). The Panel notes that there is
no evidence that sodium requirement of lactating women differs from the requirement of non-lactating
women.
5.4. Indicators of sodium requirement in infants and children
Sodium is retained with growth of tissues during child development (Section 5.2.2).
The neonate is in a state of relative total body water and ECF excess, and the typical diuresis
accompanied by sodium loss, which occurs immediately after birth, is considered physiological. During
the ﬁrst days of postnatal life, fractional excretion of sodium decreases progressively, and a state of
positive balance is reached (Ross et al., 1977; Al-Dahhan et al., 1984). Multiple endocrine systems are
integrated with the renal regulatory mechanisms to enhance sodium retention in infants, in part
through an activation of the RAAS (Al-Dahhan et al., 1983; Chevalier, 2001).
As few data were available to calculate reference values for infants, the UK COMA Panel on Dietary
Reference Values (1991) used a factorial approach based on intracellular and ECF concentrations of
sodium with allowances for growth-related changes in the volumes of these compartments according to
body compositional reference data (Widdowson, 1980). Values for the ﬁrst 6 months of life were also
based on reference values for the composition of breast milk and a presumed intake of 850 mL/day. As
there was appreciable uncertainty in these data, the derived values were regarded as LNRIs rather than
ARs. The SCF (1993) considered these data as too uncertain to set reference intakes for sodium in
infants and young children.
Fomon (1993) also attempted to estimate the physiological requirement for sodium of infants via a
factorial approach by adding requirements for growth to obligatory losses. Sodium accretion with
growth was estimated from data on sodium content of the whole body and of cellular and extracellular
water, taking into account the quantities of these ﬂuids at different ages of reference infants, and from
the amount of sodium in osseous mineral at different ages (Pitts, 1974; Forbes, 1975; Fomon et al.,
1982; Widdowson, 1982; Boskey, 1988). It resulted in a sodium requirement for growth of 27 mg
(1.2 mmol)/day for infants aged 0–4 months and 16 mg (0.7 mmol)/day for infants aged 4–
12 months, respectively. Sodium losses via the skin, dependent on the body surface area, were
estimated to be 24 mg (1.0 mmol) from 0 to 4 months and 30 mg (1.3 mmol)/day from 4 to
12 months, respectively (Forbes, 1975). Assuming an absorption of 95%, 54 mg (2.3 mmol) of dietary
sodium/day were calculated to be needed at the age of 0–4 months, to account for growth demands
and replace losses, and 48 mg (2.1 mmol)/day for the age 4–12 months. Fomon (1993) proposed a
daily recommended intake of 80 mg (3.5 mmol) of sodium for infants throughout the ﬁrst year of life
in consideration of both the uncertainty created by the limited data available and the need for
assumptions to be made, and the necessity to provide for individual variability in requirements. The
Panel notes that the quantity of sodium provided by human milk during the ﬁrst 6 months of life (i.e.
120 mg/day assuming a volume of 0.8 L/day and a sodium concentration of 150 mg/L (see
Section 2.3.4.4)) is higher than this calculated physiological requirement.
5.5. Sodium intake and health consequences
Three categories of health outcomes were selected as the most suitable to inform the setting of
DRVs: blood pressure, cardiovascular disease-related endpoints and bone health. They were selected
on the basis of their biological relevance for the general healthy population, the biological plausibility of
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their relationship with sodium intake, and the type of evidence (i.e. RCTs and/or prospective
observational studies) (see protocol, Annex A). Systematic reviews of the literature were conducted to
characterise the relationship between sodium intake and these outcomes. The subquestions addressed
by the systematic reviews are reported in Table 7.
Eligible study design included randomised controlled parallel (RCTs) or crossover trials (with a
wash-out period of any duration) and prospective studies including cohort studies, nested case–control
and case–cohort studies. Trials were eligible if the intervention consisted in a change in sodium intake
compared with usual diet or placebo.
In relation to blood pressure and CVD-related outcomes, trials with concomitant interventions
deemed to affect the outcome of interest were excluded. For bone-related outcomes, trials in which
the same concomitant intervention was applied to all study groups were included. On study duration,
trials on blood pressure with a minimum duration of 4 weeks and trials on CVD outcomes with a
minimum duration of 6 months were eligible. Trials on BMD or risk of osteoporotic fractures in adults
had to last at least 1 year.
On subject characteristics, eligible studies involved adults (≥ 18 years) and children (6 months to
< 18 years) from the general population. Trials including diseased individuals, individuals on a
therapeutic diet (including weight loss diet), hypertensive subjects on blood pressure-lowering
medications, trials in pregnant women and trials with specialised exercise (e.g. athletes, militaries) and
extreme environmental conditions (e.g. prolonged exposure to unusually high temperature) were
excluded. Observational studies that did not explicitly exclude prevalent (i.e. pre-existing) cases of the
outcome of interest at baseline were excluded.
Studies were eligible if sodium intake was assessed based on urinary sodium excretion calculated from
single or multiple 24-h urine collection(s). Other types of sodium intake measurements were excluded.
The literature searches were conducted in three electronic bibliographic databases (Cochrane
library, Embase, PubMed) and two resources indexing PhD theses (DART, PQDT Open) in February
2018, and updated in October 2018. Search strings are described in the protocol (Annex A). Two
separate searches were performed to address subquestions 1 and 2 (Appendix G.1) and subquestions
3–5 (Appendix G.2). Two independent reviewers screened the literature identiﬁed through the
searches.
In relation to subquestions 1 and 2 (blood pressure, hypertension and CVD outcomes), 7,141
unique references were identiﬁed after removing duplicates (see PRISMA Chart, Appendix G.1.1). The
title and abstract screening left 402 relevant articles that underwent a full-text review. Of those, 357
were excluded (Appendix G.1.2). A total of 45 publications reporting on 36 RCTs and 9 prospective
observational studies were included. Screening of the reference lists of these publications (877
references) did not yield additional eligible studies. Also, no additional eligible studies were identiﬁed
among the studies included in similar systematic reviews (Appendix G.1.3).
In relation to subquestions 3–5 (bone health), 1,732 unique references were identiﬁed after
removing duplicates (see PRISMA Chart, Appendix G.2.1). The title and abstract screening identiﬁed
40 articles that underwent a full-text review. In total, 38 articles were excluded (Appendix G.2.2). A
ﬁnal two articles were included (Devine et al., 1995; Ilich et al., 2010). No additional eligible study was
found from the reference lists of the two eligible articles or from the list of articles included in a
systematic review with a similar research question identiﬁed through the search (Appendix G.2.3).
Risk of bias (RoB) in eligible studies was appraised using tailored versions of the OHAT-NTP RoB
tool (OHAT/NTP, 2015) and studies were classiﬁed as being at low (tier 1), moderate (tier 2) or high
(tier 3) RoB (Appendix G.3).
Dietary Reference Values for sodium
Table 7: Subquestions addressed by the systematic reviews on sodium
No Subquestion
1 What is the relationship between sodium intake and blood pressure in humans?
2 What is the relationship between sodium intake and cardiovascular disease-related outcomes in humans?
3 What is the relationship in children(a) between sodium intake and bone mineral density (BMD) and/or
bone mineral content (BMC)?
4 What is the relationship in adults(b) between sodium intake and BMD?
5 What is the relationship in adults(b) between sodium intake and the risk of osteoporotic fractures?
(a): 6 months to < 18 years.
(b): ≥ 18 years.
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5.5.1. Blood pressure and hypertension
5.5.1.1. Ofﬁce blood pressure in children
The characteristics of eligible studies and the outcome of the RoB appraisal are presented in
Appendices H.1 and H.2, respectively.
Experimental studies
Two RCTs met the eligibility criteria described in the review protocol (Miller et al., 1988; He et al.,
2015).
In a 12-week trial in the UK, school-age identical pairs of twins and their families received instructions
to restrict their sodium intake (Miller et al., 1988). During the middle 4-week period, one member of
each twin pair, chosen at random, received a daily NaCl supplement designed to return sodium intake to
baseline levels. In total, 88 twins completed the study. During the supplement period, higher UNa was
observed in the sodium-supplemented group (72.1 mmol/24 h) compared with the control group
(44.4 mmol/24 h), while there were no between-group differences in SBP (mean (SEM) 0.3 (0.6) mm
Hg) and DBP (0.2 (0.7) mm Hg). Overall, this study was judged to be at low RoB (tier 1).
In a cluster-randomised controlled study, 28 primary schools in China were randomly assigned to an
intervention consisting of a ‘low-salt’ education programme for 3.5 months (n = 141 children, mean
(SD) age: 10.2 (0.5) years) or to their usual nutrition education programme with no particular
reference to sodium chloride intake (n = 138 children, 10.0 (0.5) years) (He et al., 2015). Baseline
mean (SE) UNa were 116.7 (5.2) mmol/day and 124.2 (5.1) mmol/day in the control and intervention
group, respectively. A reduction in UNa was observed in the intervention group (12.1 (95% CI
19.9, 4.2) mmol/24 h), whereas sodium excretion increased in the control group (+20.5 (12.6,
28.4) mmol/24 h). The adjusted difference between the two groups in the change of sodium excretion
was 33.3 (44.2, 22.3) mmol/24 h (p < 0.001). In both groups, SBP and DBP increased between
baseline and the end of intervention. The adjusted difference between the two groups in the blood
pressure change from baseline (intervention vs control) was 0.8 (3.0, 1.5) mm Hg for SBP
(p = 0.51) and 1.2 (3.7, 1.2) mm Hg for DBP (p = 0.33). This study was judged to be at moderate
RoB (tier 2), in particular due to a potential RoB in relation to the outcome assessment (unblinded
outcome assessors).
Observational studies
Two publications from the DONALD prospective cohort study met the eligibility criteria set out in
the review protocol (Shi et al., 2014; Krupp et al., 2015). DONALD is an open cohort study
implemented in Germany since 1985. Examinations are conducted at ages 3, 6, 9, 12, 18 and
24 months and then annually until young adulthood and comprise anthropometry, a 3-day weighed
dietary record, a 24-h urine sample (from age 3–4 years onwards), medical examinations and parental
interviews.
Shi et al. (2014) analysed data from 435 healthy participants, for whom at least three repeated
measurements of blood pressure had been taken and who had provided three parallel 24-h urine
samples. The median age was 6 years at baseline and 16 years during the last assessment. In boys,
the median (25–75th percentile) UNa was 67.4 (50.6–89.9) mmol/day and 131 (96.9–176) mmol/day
during the ﬁrst and last assessment, respectively. Corresponding values in girls were 58.7 (45.9–74.5)
mmol/day and 108 (81.7–133) mmol/day. In the prepubertal stage, no association between changes in
UNa and SBP or DBP was observed. In the pubertal stage, the association (b (95% CI)) between
intraindividual changes in UNa and blood pressure was 0.1 (0.004, 0.2) mm Hg for SBP (p = 0.06)
and 0.1 (0.02, 0.2) mm Hg for DBP (p = 0.09) by 1 mmol/MJ per day increase in UNa. When
analysing differences in UNa and mean blood pressure between the subjects, the associations were
0.1 (0.1, 0.4) mm Hg for SBP (p = 0.3) and 0.2 (0.4, 0.04) mm Hg for DBP (p = 0.1). This study
was judged to be at low RoB (tier 1).
Among the DONALD participants who had already reached adult age, Krupp et al. (2015) selected
206 participants who had three repeated urinary, dietary and blood pressure measurements during
adolescence (11–16 years) and one blood pressure measurement in young adulthood (18–25 years).
The estimated mean (SD) sodium chloride excretion was 116 (27) and 105 (32) mmol/day in boys and
girls, respectively. In multivariable linear regression models, there was a positive association between
UNa (per 1 mmol/day increase) and adult SBP in boys (b (95% CI) = 0.10 (0.03, 0.18), p = 0.01) but
not in girls (0.05 (0.11, 0.02), p = 0.1). No association was found between UNa during
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adolescence and adult DBP (boys: 0.02 (0.08, 0.04), p = 0.6; girls: 0.02 (0.03, 0.08), p = 0.4).
This study was judged to be at low RoB (tier 1).
Conclusion
The Panel notes that two RCTs (tiers 1 and 2) did not provide evidence for an effect of sodium
reduction on blood pressure in school-age children. The observational study (tier 1) showed no
signiﬁcant association between UNa and blood pressure in pre-pubertal and pubertal children and
provided weak evidence for a positive association between UNa during adolescence and SBP in
adulthood.
5.5.1.2. Ofﬁce blood pressure in adults
The characteristics of eligible studies and the outcome of the RoB appraisal are presented in
Appendices I.1 and I.2, respectively.
Experimental evidence
In line with the protocol (Annex A), eligible RCTs were used to conduct quantitative analyses with
the aim to characterise the dose–response relationship between sodium intake and blood pressure.
The analysis report is provided in Annex B. The main results are outlined below and Appendices I.3
and I.4.
In total, 32 RCTs, providing 35 comparisons, met the eligibility criteria. Seven were parallel RCTs,
including one cluster-randomised trial and 25 were crossover RCTs. In total, 25 trials modiﬁed sodium
intake by providing subjects with NaCl or placebo tablets or a controlled diet with various amounts of
Na (‘feeding trials’), while seven trials used sodium reduction counselling (‘counselling trials’). The
between-group differences in mean UNa ranged from 13.3 to 285 mmol/day, with a median mean
value of 72 mmol/day. The study size ranged from 11 to 1,159 participants and the duration of the
intervention lasted from 4 weeks to 36 months. In total, 17 studies involved hypertensive individuals,
eight studies involved normotensive individuals and seven studies involved mixed populations. In total,
27 studies were classiﬁed in tier 1 and ﬁve studies in tier 2.
1) Meta-analyses at study level
The results of the random-effects meta-analyses of trials of effects of sodium reduction on blood
pressure are presented in Appendix I.3 and Annex B.
A random-effects meta-analysis of the 32 eligible RCTs showed signiﬁcant effects of sodium
reduction on SBP (3.9 (95% CI 5.1, 2.8) mm Hg; I2 61.9%, p < 0.001) and DBP (2.0 (2.8,
1.2) mm Hg; I2 60.6%, p < 0.001) (Figures I.1 and I.5).
Contextual sources of heterogeneity were explored in subgroup analyses. A larger effect was found
in hypertensive than normotensive individuals, for both SBP (hypertensive: 5.6 (8.1, 3.1) mm Hg
vs normotensive: 2.0 (3.3, 0.7) mm Hg) and DBP (hypertensive: 2.9 (4.2, 1.6) mm Hg vs
normotensive: 0.9 (1.6, 0.2) mm Hg) (Figures I.2 and I.6). The effect of reduction in sodium
intake was higher among subjects aged 50 years or more (SBP 6.1 (8.2, 4.1) mm Hg; DBP 2.9
(4.0, 1.9) mm Hg) than among subjects younger than 50 years (SBP 2.2 (3.3, 1.1) mm Hg;
DBP 1.0 (2.0, 0.0) (Figures I.3 and I.7). With respect to sex, a higher effect was found in studies
which consisted mostly of men (i.e. > 55% of total sample) than in studies which consisted mostly of
women. The exploration of the potential moderating effects of ethnicity, BMI or potassium intake was
limited by the small number of studies for which information on these factors was available (Tables I.1
and I.2 in Appendix I.3).
On the identiﬁed methodological sources of heterogeneity, larger effects were found in crossover
compared with parallel trials, when measuring blood pressure in supine position compared with sitting
position, (Tables I.1 and I.2). The effect of sodium reduction was smaller in trials of longer duration
(≥ 1 year) compared with trials of shorter duration (4 weeks) (Figures I.4 and I.8). After exclusion of
the van Berge-Landry and James (2004) study as an outlier, the effect of sodium reduction on SBP was
1.8 (2.9, 0.8) mm Hg in ‘counselling’ trials and 4.0 (5.3, 2.7) mm Hg in ‘feeding’ trials. The
respective values for DBP were 1.7 (2.6, 0.9) mm Hg and 1.8 (3.2, 0.5) mm Hg.
2) Meta-analyses, meta-regression and dose–response modelling at arm level
The results of the mixed-effects meta-regression models of the relationship between 24-h urinary
sodium excretion and absolute blood pressure levels are presented in Appendix I.4 and Annex B.
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To investigate the dose–response association between mean absolute values of 24-h urinary sodium
excretion and mean absolute values of blood pressure, all arms (68) from the eligible RCTs (32) were
subjected to meta-analysis assuming a random-effects model.
The pooled mean estimate across arms was 137.1 (134.2–140.1) mm Hg for SBP and 84.0 (82.0–
85.9) mm Hg for DBP; subgroup analyses were repeated at the arm level applying the same a priori
categorisations of relevant potential modiﬁers to identify candidate moderators to be included in the
multivariable models, producing comparable results to those from the meta-analyses at study level.
In total, 60 points (arms as unit of analysis) from 28 RCTs were included in the ﬁnal dose–response
models. Two RCTs were excluded from the meta-analysis pool because of missing information on age
(Puska et al., 1983; Richards et al., 1984). One (Alli et al., 1992) was excluded after thorough
consideration of some inconsistencies in the design and results of the study. Van Berge-Landry and James
(2004) were selected only for sensitivity analysis, given the fact that it was the only study with UNa values
in the control and intervention arms well beyond the range covered by all other trials (achieved urinary
excretion: 309 and 24 mmol/day at the end of the ‘high’ and ‘low’ sodium interventions, respectively).
Two arms were included from all trials except for MacGregor et al. (1989) (three arms), Sacks et al.
(2001) (three arms) and Watt et al. (1985) (four arms). After the exclusion of the eight arms, 14 were
from parallel RCTs, 46 were from crossover RCTs and none from cluster-randomised trials.
Fifty-two arms were from ‘feeding trials’ and eight arms from ‘counselling trials’. Mean 24-h sodium
excretion, once van Berge-Landry was excluded, ranged from 49.0 to 202.9 mmol/day, with a median
of 126.7 mmol/day. The arm size ranged from 10 to 515 participants, who were hypertensive in 33 out
of the 60 arms.
Mixed-effects meta-regression models were ﬁtted to account for the multilevel structure in the data,
with arms nested within studies; two random effects (intercepts) on arm and study were speciﬁed and
ﬁve ﬁxed effects were included from the list of potential moderators tested in univariate meta-
regressions.
Different functional forms were explored for the shape of the dose–response relationship; non-
linearities as tested by ﬁtting restricted cubic and linear splines were not statistically signiﬁcant once
both random effects were speciﬁed in the models.
The ﬁnal set of moderators included in both SBP and DBP models was: age at baseline (< 40 years old
(reference), 40–49, 50–59, ≥ 60 years old); blood pressure status at baseline (normotensive (reference)
hypertensive); blood pressure measurement method (supine (reference), sitting); mean urinary sodium
excretion at baseline (< 100 mmol/day (reference), 100–149, ≥ 150 mmol/day); and speciﬁc trial design
(no run-in (reference), run-in normal diet, run-in low-sodium diet) (Tables I.3 and I.4 in Appendix I.4).
Other variables, including potassium intake, BMI and ethnicity, did not explain a signiﬁcant
proportion of heterogeneity in a consistent manner in both SBP and DBP analyses and/or suffered from
a high proportion of missing data, so they were not retained in the ﬁnal models.
For each 100 mmol (2.3 g)/24-h increase in mean UNa, holding all other covariates constant, mean
SBP increased by 5.3 mm Hg (95% CI: 3.6–6.9 mm Hg) and mean DBP increased by 2.6 mm Hg
(95% CI: 1.6–3.7 mm Hg) (Figures I.9 and I.10 in Appendix I.4). Similar effects were estimated in
crude models (with no other covariates than mean sodium excretion).
Mean sodium excretion explained only 4% of the heterogeneity across trials in the SBP model and
3% in the DBP model. However, in both models the set of moderators explained more than 85% of
the between-study heterogeneity.
Moderating effects of age and hypertensive status were explored in stratiﬁed analyses. A larger
association was found in hypertensive than normotensive individuals, for both SBP (hypertensive: 6.4
(4.3, 8.6) mm Hg vs normotensive: 4.4 (2.1, 6.6) mm Hg) and DBP (hypertensive: 3.7 (2.5, 5.0) mm
Hg vs normotensive: 1.7 (0.1, 3.3) mm Hg) (Annex B). The effect of sodium was higher among
subjects aged 50 years or more (SBP 7.1 (5.0, 9.2) mm Hg; DBP 3.8 (2.6, 5.0) mm Hg) than among
subjects younger than 50 years (SBP 3.5 (1.5, 7.4) mm Hg; DBP 1.2 (0.4, 2.9) (Annex B).
3) Limitations of the models
Sources of uncertainty speciﬁc to the statistical analysis and their potential impact on the ﬁnal
estimates, where possible, were identiﬁed and described (see Annex B).
Using arms’ absolute values generated in controlled settings was expected to allow a better
characterisation of the dose–response relationship between sodium intake and blood pressure levels
than using data from observational studies (potential confounding). Still, relationships described via
meta-regression are observational in nature as they do not have the beneﬁt of randomisation to
support a causal interpretation (Thompson and Higgins, 2002). The models are representations of the
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relationship between mean UNa and mean SBP or DBP at ‘group’ level (potential aggregation bias).
Also, some potential moderators could not be explored (e.g. BMI, ethnicity, potassium intake and
energy intake13) due to missing information.
Given the inﬂuence of the design of the trials on data structure and incompleteness of information
there was a strong ‘methodological’ component (covariates that are linked to the experimental setting)
speciﬁed in the models to reach a good ﬁtting and contributing to explain a large part of the
heterogeneity between studies (random effects). This added challenges on the interpretation of the
models. Constants (intercepts) and predictions were substantially inﬂuenced by experimental factors
and were difﬁcult to reconcile with ‘populations’ values. So, the model cannot be used to make
predictions at population level, but it provides evidence for a positive linear relationship between mean
sodium excretion and mean levels of SBP and DBP.
Observational studies
One prospective cohort study met the inclusion criteria (Stolarz-Skrzypek et al., 2011). The analysis
combined data from 1,499 participants aged ≥ 20 years from Belgium, the Czech Republic, Italy, Poland
and the Russian Federation of the European EPOGH and FLEMENGHO cohorts, without antihypertensive
treatment and CVD history at baseline. During a follow-up of 6.1 years, a 100 mmol increase in sodium
excretion was associated with a 1.71 mm Hg (95% CI 0.79, 2.64) increase in SBP. The value for DBP
was 0.38 mm Hg (95% CI –0.31, 1.07). This study was judged to be at moderate RoB (tier 2), in
particular due to the lack of adjustment for signiﬁcant confounders (energy intake, smoking and physical
activity), potential misclassiﬁcation of participants in the lowest category of sodium excretion related to
the apparent undercollection of urine samples compared with the other categories (i.e. lower urinary
volume and creatinine excretion) and substantial attrition during follow-up.
Conclusion
Based on data from RCTs, the Panel considers that there is strong evidence for a positive relationship
between UNa and SBP and DBP over the range of mean UNa observed in the studies (between 49 and
209 mmol/24 h (1.3 to 4.8 g/day)). One eligible prospective observational study (tier 2) investigating
the long-term relationship between UNa and blood pressure levels supports such relationship.
5.5.1.3. Hypertension
The characteristics of eligible studies, the outcome of the RoB appraisal and descriptive forest plots
are presented in Appendices J.1, J.2 and J.3, respectively.
Experimental studies
Two RCTs assessed the effect of sodium reduction on the incidence of hypertension, namely the
Trials of Hypertension Prevention (TOPH), phases I and II (The Trials of Hypertension Collaborative
Research Group, 1997; Whelton et al., 1997). Both trials were conducted in the USA and involved
individuals aged 35 to 54 years with ‘high-normal’ blood pressure at baseline (DBP of 80–89 mm Hg in
TOPH I; DBP of 83–89 mm Hg and SBP < 140 mm Hg in TOPH II), not taking antihypertensive
treatment. TOPH II selected overweight individuals (BMI 110–165% of desirable body weight).
Participants were randomised to a dietary sodium reduction counselling programme or a usual care
group. TOPH I lasted 18 months, while TOPH II lasted 36–48 months. The incidence of hypertension
in the intervention group vs control group during follow-up was compared. In TOPH I, baseline mean
(SD) UNa was 154.6 (77.9) and 156.4 (60.5) mmol in the sodium reduction group (n = 326) and usual
care group (n = 417), respectively, while values were 186.1 (80.7) mmol and 188.0 (80.9) mmol/day
in the sodium reduction group (n = 581) and usual care group (n = 576) in TOPH II.
In TOPH I (Whelton et al., 1997), UNa decreased to 99.4 (60.0) mmol/day in the intervention
group compared with 146.5 (79.2) mmol/day in the control group after 18 months, corresponding to a
net (between groups) difference of 47.2 mmol (p < 0.0001). During follow-up, the incidence of
hypertension was 8.6% in the sodium reduction group compared with 11.3% in the usual care group
(RR (95% CI) = 0.76 (0.49, 1.18)). This study was judged to be at low RoB (tier 1).
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In TOPH II (The Trials of Hypertension Collaborative Research Group, 1997), the estimated net
reduction in UNa was 40 mmol/day (p < 0.001) after 36 months. Through 48 months, the incidence of
hypertension was 38.1% in the intervention group compared with 44.4% in the usual care group
(RR = 0.82, p = 0.05). This study was judged to be at low RoB (tier 1).
Observational studies
Two prospective cohort studies assessed the association between UNa and the incidence of
hypertension (Stolarz-Skrzypek et al., 2011; Forman et al., 2012). The EPOGH/FLEMENGHO
‘hypertension cohort’ followed up individuals aged ≥ 20 years from Belgium, the Czech Republic, Italy,
Poland and the Russian Federation (Stolarz-Skrzypek et al., 2011). The PREVEND cohort investigated
the natural course of albuminuria and its relationship with renal and cardiovascular diseases in Dutch
subjects aged 25–75 years and was characterised by an oversampling of participants with elevated
albumin excretion at baseline (> 10 mg/L) (Forman et al., 2012). At baseline, mean (SD) 24-h sodium
excretion was 174.2 (74.1) mmol in the EPOGH/FLEMENGHO cohort, while median (interquartile range
(IQR)) sodium excretion was 137 (106–171) mmol/day in the PREVEND cohort.
In the PREVEND cohort (Forman et al., 2012), hazard ratio (HR) (95% CI) for incident hypertension
was 1.05 (1.00–1.10) for each 43 mmol (1 g) higher UNa (5,556 men and women; 878 cases; median
follow-up 6.4 years). The HR was 1.21 (0.98–1.51) comparing the highest (median (IQR) UNa:
271 (242–316) mmol) to the lowest quartile (97 (79–110) mmol) of UNa. The association of UNa with
incident hypertension was modiﬁed by serum uric acid (SUA) and albumin urine excretion (UAlbumin).
The adjusted HRs were 0.98 (0.89–1.08), 1.05 (0.96–1.15) and 1.09 (1.02–1.16) per each 1 g
(43 mmol) increase in UNa in the lowest, middle and highest tertiles of SUA, respectively.
Corresponding HRs were 0.99 (0.93–1.06), 1.02 (0.92–1.12) and 1.18 (1.07–1.29) per each 1 g
(43 mmol) increase in UNa among those with UAlbumin < 10 mg/day, between 10 and 15 mg/day,
and > 15 mg/day, respectively. This study was judged to be at low RoB (tier 1).
In the EPOGH/FLEMENGHO cohort (Stolarz-Skrzypek et al., 2011) HRs (95% CI) for the incidence
of hypertension were 1.00 (0.87–1.16), 1.02 (0.89–1.16) and 0.98 (0.86–1.12) in the low (mean (SD)
UNa: women 94.4 (21.5) mmol; men 121.3 (27.9) mmol), medium (women 147.4 (14.3) mmol; 185.3
(16.1) mmol) and high (women 222.1 (47.2) mmol; men 282.2 (56.4) mmol) sex-speciﬁc tertiles of
sodium excretion, respectively, compared with the whole population (2,096 men and women; 552
events; median follow-up 6.5 years). This study was judged to be at moderate RoB (tier 2), in
particular due to the overadjustment for SBP, potential misclassiﬁcation of participants in the lowest
category of sodium excretion related to the apparent undercollection of urine samples compared with
the other categories (i.e. lower urinary volume and creatinine excretion) and substantial attrition
during follow-up.
Conclusion
A small number of studies, two RCTs (tier 1) and two prospective observational studies (tiers 1 and
2) investigating the relationship between UNa and risk of hypertension were eligible for the
assessment. Overall, the Panel considers that these studies support a positive relationship between
UNa and blood pressure.
5.5.2. Cardiovascular disease
Six publications, pertaining to ﬁve different cohort studies, were eligible (Tuomilehto et al., 2001;
Stolarz-Skrzypek et al., 2011; Cook et al., 2014; Joosten et al., 2014; Kieneker et al., 2018; Lelli et al.,
2018). Three cohorts were based on random samples of adult populations: (i) the EPOGH/FLEMENGHO
‘outcome cohort’ involved individuals aged ≥ 20 years from Belgium, the Czech Republic, Italy, Poland
and the Russian Federation (Stolarz-Skrzypek et al., 2011); (ii) the ‘Finnish cohort’ involved individuals
aged 25–64 years (Tuomilehto et al., 2001); and (iii) the InCHIANTI cohort involved individuals
aged ≥ 65 years in Italy (Lelli et al., 2018). Another cohort was constituted of the control groups of the
TOPH I and TOPH II sodium reduction trials that involved United States individuals aged 30–54 years with
‘high-normal’ blood pressure at baseline (post-trials follow-up) (Cook et al., 2014). Finally, the PREVEND
cohort involved subjects aged 25–75 years and was characterised by an oversampling of participants
with elevated albumin excretion at baseline (> 10 mg/L) (Joosten et al., 2014; Kieneker et al., 2018).
These publications addressed the association between sodium intake and risk of stroke (three
papers), risk of CHD (three papers) and risk of total CVD (three papers) (Table 8). As per the protocol
eligibility criteria, only analyses that excluded prevalent cases at baseline were considered. Two
Dietary Reference Values for sodium
www.efsa.europa.eu/efsajournal 38 EFSA Journal 2019;17(9):5778
publications reported HRs for sodium excretion expressed as a continuous variable, one publication
reported HRs by categories of sodium excretion, and three publications reported both. One publication
used the whole study population as reference group to calculate HR in each sodium excretion
category, which hindered its inclusion in pooled analyses. Because of the small number of eligible
studies available for pooling for each outcome type, meta-analyses were not conducted.
The study characteristics, the outcome of the RoB appraisal and descriptive forest plots, are
presented in Appendices K.1, K.2 and K.3.
In relation to sodium exposure measurement, multiple 24-h urine samples were collected in the
PREVEND and TOPH cohorts, while single 24-h urine collections were available in the other three
cohorts. In four publications, quality measures have been applied to deal with inaccurate urine
collections. Two papers excluded samples deemed to be incomplete from their analyses a priori
(Stolarz-Skrzypek et al., 2011), based on sex-speciﬁc creatinine cut-offs and urine volume; (Tuomilehto
et al., 2001), based on self-reporting); two papers excluded samples in sensitivity analyses (Cook
et al., 2014), based on intraindividual variability in creatinine/body weight ratio; (Joosten et al., 2014)
based on estimated urine volume vs actual).
The overall RoB was judged to be low for four publications (tier 1), and moderate for three
publications (tier 2). For the three papers for which the overall RoB was judged moderate (tier 2), the
main concerns related to: (i) overadjustment for blood pressure (Tuomilehto et al., 2001; Lelli et al.,
2018); (ii) potential for reverse causality due to the inclusion of hypertensive subjects in the sample
(Tuomilehto et al., 2001; Stolarz-Skrzypek et al., 2011; Lelli et al., 2018); (iii) potential misclassiﬁcation
of participants in the lowest category of sodium intake related to the apparent undercollection of urine
samples compared with the other categories (i.e. lower creatinine excretion relative to body weight)
(Stolarz-Skrzypek et al., 2011); and (iv) higher attrition rate in the highest category of sodium intake
compared with the other categories (Stolarz-Skrzypek et al., 2011).
At baseline, median (IQR) UNa was 137 (106–171) mmol (min–max: 50–315 mmol) in the
PREVEND cohort, 205 mmol in men (IQR Not Reported (NR); min–max: 25–552) and 154 mmol in
women (IQR NR; min–max: 12 to 512 mmol) in the Finnish cohort, 236 (160–306) mmol in the
InCHIANTI cohort, and 158 (127–194) mmol in the TOPHI/II cohort (min–max: NR). The mean (SD)
UNa was 178.0 (74.8) mmol (min–max: 50–400 mmol) in the EPOGH/FLEMENGHO cohort.
5.5.2.1. Stroke
In the PREVEND cohort (7,330 men and women), 183 fatal and non-fatal stroke events occurred
during a median follow-up of 12.5 years (Kieneker et al., 2018). The HR (95% CI) was 1.44 (1.14–
1.82) per 51 mmol/24 h decrement in UNa. By sex-speciﬁc quintiles of UNa, HRs were 1.45 (0.92–
2.29) (57 cases, 16,272 person-years) in Q1, 1.13 (0.71–1.79) (49 cases, 16,515 person-years) in Q2,
1.04 (0.64–1.71) (25 cases, 16,720 person-years) in Q4 and 0.81 (0.46–1.41) in Q5 (19 cases, 16,908
person-years), with Q3 taken as the reference category (33 cases, 16,774 person-years). Similar HRs
for the risk of fatal and non-fatal stroke were estimated after adjustment for potential mediators, i.e.
SBP and antihypertensive medication (1.44 (1.14–1.82)), plasma renin (1.50 (1.18–1.90)), aldosterone
(1.54 (1.21–1.97)), and sodium levels (1.49 (1.17–1.90)), respectively. In sensitivity analyses, the
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Table 8: Outcomes and references of prospective cohort studies on CVD
Outcome type No. publications References (cohort name)
Stroke Non-fatal 1 Tuomilehto et al. (2001) (Finnish cohort)
Fatal and non-fatal 2 Stolarz-Skrzypek et al. (2011) (EPOGH/FLEMENGHO)
Kieneker et al. (2018) (PREVEND)
CHD Non-fatal 1 Tuomilehto et al. (2001) (Finnish cohort)
Fatal and non-fatal 2 Stolarz-Skrzypek et al. (2011) (EPOGH/FLEMENGHO)
Joosten et al. (2014) (PREVEND)
CVD (total) Fatal 1 Stolarz-Skrzypek et al. (2011) (EPOGH/FLEMENGHO)
Non-fatal 1 Lelli et al. (2018) (InCHIANTI)
Fatal and non-fatal 2 Cook et al. (2014) (TOPH I/TOPH II)
Stolarz-Skrzypek et al. (2011) (EPOGH/FLEMENGHO)
CHD: coronary heart disease; CVD: cardiovascular disease; EPOGH/FLEMENGHO: European Project on Genes in Hypertension/
Flemish Study on Genes and Health Outcomes; InCHIANTI: Invecchiare in Chianti; PREVEND: Prevention of Renal and Vascular
End-stage Disease; TOPH: Trials of Hypertension Prevention
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association did not change after exclusion of individuals who were taking antihypertensive drugs at
baseline (6,388 subjects (126 events)) and those with malignancies, type 2 diabetes, or chronic kidney
disease at baseline (6,054 subjects (112 events)). In a weighted analysis, that accounted for the
sampling design of the study, the HR was 1.68 (1.12–2.50) per 51 mmol/24 h decrement in UNa. This
study was judged to be at low RoB (tier 1).
In the Finnish cohort (2,420 men and women), 84 non-fatal stroke events occurred during 8 to
13 years follow-up (Tuomilehto et al., 2001). The HR (95% CI) was 1.13 (0.84–1.51) per 100 mmol/
24 h increase in UNa. This study was judged to be at moderate RoB (tier 2).
In the EPOGH/FLEMENGHO cohort (3,681 men and women), 33 fatal and non-fatal stroke events
occurred during a median follow-up of 7.9 years (Stolarz-Skrzypek et al., 2011). The HRs (95% CI)
were 1.05 (0.56–1.96) (13 events), 1.28 (0.75–2.17) (13 events) and 0.78 (0.46–1.33) (7 events) in
the low, medium and high sex-speciﬁc tertiles of UNa, respectively, compared with the overall risk in
the entire cohort. This study was judged to be at moderate RoB (tier 2).
5.5.2.2. Coronary heart disease
In the PREVEND cohort (7,543 men and women), 452 fatal and non-fatal CHD events occurred
during a median follow-up of 10.5 years (Joosten et al., 2014). The HR was 1.07 (0.98–1.18) for each
1 g/day (43 mmol/24 h) increment in UNa. In stratiﬁed analysis, each 1 g/day increment in UNa was
associated with an increased risk for CHD in subjects with hypertension (1.14 (1.01–1.28); n = 2,363)
and in subjects with plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations
above the sex-speciﬁc median (1.16 (1.03–1.30); 320 events; n = 3,771). This study was judged to be
at low RoB (tier 1).
In the Finnish cohort (2,402 men and women), 128 non-fatal CHD events occurred during 8 to
13 years follow-up (Tuomilehto et al., 2001). The HR (95% CI) was 1.34 (1.08–1.67) per 100 mmol/
24 h increase in UNa. This study was judged to be at moderate RoB (tier 2).
In the EPOGH/FLEMENGHO cohort (3,681 men and women), 98 fatal and non-fatal CHD events
occurred during a median follow-up of 7.9 years (Stolarz-Skrzypek et al., 2011). HRs (95% CI) were
1.41 (0.99–2.01) (45 events), 1.15 (0.87–1.52) (34 events) and 0.87 (0.66–1.15) (19 events) in the
low, medium and high sex-speciﬁc tertiles of UNa, respectively, compared with the overall risk in the
entire cohort. This study was judged to be at moderate RoB (tier 2).
5.5.2.3. Cardiovascular disease (composite outcome)
In a 10–15 years post-trial follow-up, the association between UNa and risk of fatal and non-fatal
CVD events was assessed among subjects who had not been assigned to an active sodium reduction
intervention group in the TOPH I and TOPH II trials (Cook et al., 2014). In total, 193 events occurred
(68 myocardial infarctions, 77 coronary revascularisations, 22 strokes (1 participant reported both
myocardial infarction and stroke), and 27 CVD deaths). Four categories of UNa were deﬁned as
follows: < 100 mmol (< 2.3 g), 100 to < 157 mmol (2.3 to < 3.6 g), 157 to < 209 mmol (3.6 to
< 4.8 g) (reference category), and ≥ 209 mmol (≥ 4.8 g) sodium/24 h. HRs were 0.68 (0.34–1.37; 15
events/189 total) and 0.75 (0.50–1.11; 48/590) for the two lowest categories compared with the
reference category (40/427), while it was 1.05 (0.68–1.62; 23/191) for the highest category compared
with the reference category (p for trend = 0.13). There was a linear 17% increase in risk per 43 mmol
(1 g)/24 h increase in UNa (p = 0.054). Spline curves supported a linear association of UNa with CVD
events (p value for linearity = 0.044; p value for nonlinearity = 0.76). This study was judged to be at
low RoB (tier 1).
In the InCHIANTI cohort (514 men and women), 169 non-fatal CVD events (CVD types no
reported) occurred during a median follow-up of 9 years (Lelli et al., 2018). A RR (95% CI) of 0.96
(0.90–1.02) was reported (reference unit of UNa not reported). This study was judged to be at
moderate RoB (tier 2).
In the EPOGH/FLEMENGHO cohort, 232 fatal and non-fatal CVD events occurred during a median
follow-up of 7.9 years (non-fatal events included: 43 heart failures, 33 coronary revascularisations, 27
myocardial infarctions (MI), 14 pulmonary heart diseases, 13 strokes, 9 pulmonary embolisms, 4
coronary syndrome, 3 ischaemic heart diseases (IHD) and 2 aortic aneurysms; fatal events included:
29 heart failure, 20 stroke, 19 MI, 6 IHD, 6 sudden deaths, 2 pulmonary embolisms, 1 arterial
embolism and 1 aortic aneurysm) (Stolarz-Skrzypek et al., 2011). HRs (95% CI) were 1.12 (0.90–1.41)
(100 events), 1.09 (0.88–1.34) (79 events) and 0.92 (0.74–1.13) (53 events) in the low, medium and
high sex-speciﬁc tertiles of UNa, respectively, compared with the overall risk in the entire cohort (3,681
men and women). The adjusted HRs for fatal CVD events only were 1.41 (0.94–2.12) (50 events),
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0.98 (0.69–1.40) (24 events) and 1.02 (0.71–1.45) (10 events), respectively. This study was judged to
be at moderate RoB (tier 2).
5.5.2.4. Mechanistic considerations
There is a positive relationship between sodium intake and blood pressure (Section 5.5.1), which,
in turn, is an established independent risk factor for CVD, mostly CHD and stroke.
Other mechanisms have been proposed by which sodium intake may affect CVD risk (reviewed by
Farquhar et al. (2015)), including through an effect on endothelial function, arterial stiffness and left
ventricular mass. In a meta-analysis of trials investigating the effect of sodium intake on carotid-
femoral pulse wave velocity (PWV), as a marker of arterial stiffness, D’Elia et al. (2018) reported that
an average reduction in sodium intake of 89.3 mmol/day was associated with a pooled effect of 2.84%
(95% CI: 0.51–5.08, I2 14%; pooling data of 14 cohorts from 11 studies) reduction in PWV. There is
some evidence that the effect of sodium reduction on PWV could, at least in part, be independent of
the changes in blood pressure (D’Elia et al., 2018).
There is uncertainty on the health effects of changes in regulatory hormones associated with
sodium reduction (Section 5.2.3), including how they might affect the risk of stroke at low UNa,
beyond the well-established effect of blood pressure on stroke risk.
5.5.2.5. Conclusions
A small number of observational prospective studies was eligible for the assessment. Three cohorts
(PREVEND, EPOGH/FLEMENGHO and the Finnish cohort) investigated the association between UNa
and risk of stroke (1 in tier 1; 2 in tier 2) and risk of CHD (1 in tier 1; 2 in tier 2). Three cohorts
(EPOGH/FLEMENGHO, InCHIANTI and TOPHI/II) investigated the association between UNa and risk of
CVD (1 in tier 1; 2 in tier 2).
Overall, limited conclusions can be drawn on the relationship between UNa and risk of CVD. The
Panel considers that, over the range of UNa observed in these studies:
• There is some evidence for a positive association between UNa and risk of CHD. The positive
relationship between UNa and blood pressure levels/incidence of hypertension, which is an
established independent risk factor for CHD, supports this association.
• There is some evidence for an inverse association between UNa and risk of stroke. However, the
number of eligible studies available investigating this outcome is small and the mechanisms by
which UNa could be inversely associated with the risk of stroke are unclear, particularly
considering the positive relationship between UNa and blood pressure, which is an established
risk factor for stroke.
• There is some evidence for a positive association between UNa and risk of CVD. The Panel notes
that CVD as a composite outcome combines different diseases that may be differentially affected
by sodium intake. The suggestion of a positive association reported by Cook et al. (2014), in
which MI and coronary revascularisation interventions represented most cases, is consistent with
the evidence for a positive association between UNa and risk of CHD and the positive relationship
between UNa and blood pressure levels/incidence of hypertension.
5.5.3. Bone health
There is consistent evidence that an increase in sodium intake increases urinary calcium excretion,
while a reduction in sodium intake lowers urinary calcium excretion (Afssa, 2001; EFSA, 2005a; IOM,
2005). The increase in urinary calcium excretion with increasing sodium intake may negatively affect
bone calcium balance, even when dietary calcium intake is above the PRI for calcium (see
Section 2.5.3). It is biologically plausible that a long-term increase in urinary calcium excretion leading
to negative bone calcium balance would both lower BMD and increase the risk of osteoporotic bone
fractures. However, evidence for a relationship between sodium intake and bone health was
considered inconclusive in previous assessments (EFSA, 2005a; IOM, 2005).
Two articles were eligible for the assessment (Devine et al., 1995; Ilich et al., 2010)
(Appendix G.2). Study characteristics and results and the outcome of the RoB appraisal are presented
in Appendices L.1 and L.2, respectively.
Although the two eligible studies were primarily designed as RCTs, they have been categorised as
‘prospective cohort studies’ because of the type of analyses conducted. Devine et al. (1995) used data
from a 2-year RCT investigating the effect of supplemental calcium and physical activity on BMD
(Prince et al., 1995). Sodium intake was observed by means of 24-h urine collections at baseline and
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after 1 and 2 years of intervention. Pooled data from all intervention groups were used to explore the
association between sodium intake and change in BMD. Ilich et al. (2010) aimed at investigating the
effect of dietary sodium intake on BMD and other bone-related outcomes in a 3-year RCT in which half
of the participants were assigned to a group instructed to reduce sodium intake (target 1.5 g sodium/
day), while the others maintained their usual diet (~3 g sodium/day). Sodium intake was estimated by
means of 24-h urinary collection every 6 months. With time, some of the participants in the control
group reduced their sodium intake and those in the intervention group did not comply in reducing their
sodium intake. Therefore, in the ﬁnal analyses, all participants were grouped together and data were
pooled to be analysed as a longitudinal observational study, regardless of to which group each subject
was initially assigned.
The two studies involved postmenopausal women, with mean (SD) baseline sodium excretion of
121 (47) mmol (2,783 (1,081) mg)/day (n = 168, in Australia) (Devine et al., 1995) and 105 (42)
mmol (2,404 (963) mg)/day (n = 136, in the USA) (Ilich et al., 2010), respectively. In the study from
Devine et al. (1995), physical activity level and calcium intake varied depending on the intervention
groups, while in the study from Ilich et al. (2010) participants maintained their usual physical activity
and received calcium (~630 mg/day) and vitamin D (~400 IU/day) supplements. BMD was measured
by DEXA at different sites Devine et al. (1995): hip, ankle and lumbar spine; Ilich et al. (2010): hip,
forearm, lumbar spine and total body.
In multivariate analysis, Devine et al. (1995) reported a negative association between average UNa
and 2-year change in BMD at the hip and ankle. No association was found at the lumbar spine. This
study was judged to be at moderate RoB (tier 2) because of concerns about the substantial attrition
rate (124 out of 168 women included in the analysis) without clear reporting about the characteristics
of the subjects excluded, and the lack of information on the quality measures applied for the 24-h
urine collection.
Ilich et al. (2010) reported a positive association between the cumulative average of urinary Na/
creatinine excretion and BMD at 36 months in total body and total forearm (intention-to-treat
analysis). Using random-effects regressions accounting for missing data and repeated measurements,
individuals with higher UNa were found to have higher forearm and lumbar spine BMD at baseline and
subsequent time points. No association was found with total body or femur BMD. This study was
judged to be at low RoB (tier 1).
The Panel notes the limited and inconsistent evidence for an association between sodium intake
and BMD provided by these two studies.
The Panel concludes that these data cannot be used to set DRVs for sodium.
5.5.4. Scope of the review
The conclusions described above are based on the evidence eligible for the assessment. In deﬁning
the inclusion/exclusion criteria of this review, methodological choices were made to minimise the RoB.
In particular, the review was restricted to:
• RCTs and prospective observational studies;
• studies that excluded participants with pre-existing conditions, to minimise the risk of reverse
causality;
• studies that used at least one 24-h urinary collection to estimate sodium intake, to minimise the
RoB related to exposure misclassiﬁcation.
In relation to observational data, the exclusion of studies that relied on dietary questionnaires or
spot urine collections to assess sodium intake resulted in a relatively small number of eligible studies.
This precluded any quantitative integration of the evidence relating sodium intake and disease risk
(e.g. through meta-analyses) and limited the exploration and characterisation of sources of
heterogeneity in the body of evidence.
6. Data on which to base dietary reference values
6.1. Adults
Based on the review of the available evidence, the Panel considers that relevant data to inform the
setting of DRVs for sodium is provided by: (i) balance studies on sodium (Section 5.2); and (ii) studies
informing the relationship between sodium intake and blood pressure level or CVD risk (Sections 5.5.1
and 5.5.2).
Dietary Reference Values for sodium
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The Panel considers that the available evidence cannot be used to determine the sodium
requirement nor its distribution in the population (see Section 5); so, an AR and population reference
intake (PRI) for sodium cannot be established.
Data on the relationship between sodium intake and level of blood pressure or CVD risk could
inform about the levels of sodium intake associated with a reduced risk of chronic diseases. Balance
studies could inform about the levels of sodium intake that are adequate to maintain a null sodium
balance.
Because of the limited evidence available and of the associated uncertainties, it is not possible to
identify such levels of sodium intake with certainty. The Panel therefore used expert judgement to
weigh the available evidence and take account of the associated uncertainties ((a ‘weight of evidence’
approach EFSA Scientiﬁc Committee et al., 2017)). This was achieved by means of a formal EKE
(EFSA, 2014) undertaken with the members of the working group on DRVs for minerals (Appendix M).
The EKE offers several advantages, since:
• It supports experts in making evidence-based judgements about a quantity of interest (typically a
parameter) in a structured way, while limiting bias.
• It allows a representation of the uncertainty about the quantity of interest using a probability
distribution to express judgements about the range of possible values and their relative
likelihoods.
As a result, the probability distribution generated through the EKE reﬂects the uncertainty about
the ‘true’ value of the quantity elicited.
The elicitation was carried out using the roulette method and following the Shefﬁeld protocol (see
section on Data and Methodologies, part C and Appendix M).
In line with the principles for setting DRVs (EFSA NDA Panel, 2010), the Panel aimed at setting
reference values for the general population, excluding diseased populations and subpopulations with
extreme and distinct vulnerabilities due to genetic predisposition or other conditions.
Two separate elicitations were conducted and are reported below.
6.1.1. EKE on the relationship between sodium intake and blood pressure and CVD
Evidence on the relationship between sodium intake and blood pressure or CVD risks could inform
about the levels of sodium intake associated to a reduced risk of chronic diseases.
From the literature reviewed in Section 5, there is strong evidence for a positive relationship between
sodium and blood pressure levels, which is an established risk factor for CVD risk. The meta-regression
dose–response modelling provided evidence for a linear relationship between blood pressure and UNa in
the range covered by the eligible studies (ca. 50–200 mmol/day) (Section 5.5.1.2); any increase in blood
pressure level is considered adverse. Based on eligible prospective observational studies, there is some
evidence for a positive association between UNa and risk of hypertension, CHD and CVD. There is some
evidence for an inverse association between UNa and risk of stroke, with substantial uncertainty as the
number of eligible studies is small and the mechanisms by which UNa could be inversely associated with
the risk of stroke are unclear (Section 5.5.2). So, in view of the available evidence, experts judgement
was elicited on the lowest level of sodium associated with a reduced risk of stroke and CHD integrating all
the relevant evidence, including evidence on blood pressure.
The following question was used for the elicitation: What is the lowest level of sodium intake at
which the risk of chronic disease (i.e. stroke, CHD) is minimised in the majority (≥ 97.5%) of the
general population of adults?
Eligible studies in relation to this source of evidence used UNa as marker of sodium intake. So, the
scale used for the elicitation referred to UNa and was expressed in mmol/24 h.
The empirical probability distribution obtained after the group achieved a consensus is depicted in
Figure 1 and the rationale for the distribution is presented in Table 9. The distribution reﬂects the
uncertainty of the experts about the lowest level of sodium intake at which the risk of chronic disease
(i.e. stroke, CHD) is minimised in the general population.
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UNa: sodium urinary excretion.
EKE question: ‘What is the lowest level of sodium intake at which the risk of chronic disease (i.e. stroke, CHD) is
minimised in the majority (≥ 97.5%) of the general population of adults?’. Experts expressed the probability that
each of the proposed ranges of UNa might include the ‘true’ level of interest. Therefore, the probability distribution
reﬂects the uncertainty about the level elicited. It does NOT represent the probability (or risk) of disease associated
to a given range of UNa. Ranges that did not receive any probability are not retained in the ﬁgure.
Figure 1: Group consensus uncertainty probability distribution on the lowest level of sodium intake at
which the risk of chronic disease (i.e. stroke, CHD) is minimised in the general population
Table 9: Rationale for the group consensus uncertainty probability distribution on the lowest level
of sodium intake at which the risk of chronic disease (i.e. stroke, CHD) is minimised in the
general population
UNa
range
(mmol/
24 h)
Probability(a) Rationale
0–40 1%  Relationship between UNa and blood pressure uncertain in this range (outside
the range of the experimental data)
40–80 44%  Positive relationship between UNa and blood pressure (range 50–200 mmol/24 h),
based on experimental evidence (high conﬁdence) but blood pressure is an
intermediate marker
 Lower risk of hypertension in range ≤ 130 mmol/24 h (TOPH studies)
 No change in CHD risk up to 120 mmol/24 h for women and 150 mmol/24 h for
men (Joosten et al., 2014)
 Indication from Kieneker et al. (2018) that risk of stroke might increase in this
range, with substantial uncertainty
80–120 50%  Positive relationship between UNa and blood pressure (range 50–200 mmol/
24 h), based on experimental evidence (high conﬁdence) but blood pressure is
an intermediate marker
 Lower risk of hypertension in range ≤ 130 mmol/24 h (TOPH studies)
 No change in CHD risk up to 120 mmol/24 h for women and 150 mmol/24 h for
men (Joosten et al., 2014)
 Indication from Kieneker et al. (2018) that risk of stroke might increase below
this range of intake
 Overall, less conﬁdence for causality from prospective cohort studies as
compared with experimental studies and limited number of studies
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6.1.2. EKE on balance studies
As discussed in Section 5.2, balance studies are based on the assumption that a healthy subject on
an adequate diet maintains equilibrium or a null balance, between nutrient intakes and nutrient losses.
At this null balance, the intake matches the requirement determined by the physiological state of the
individual. When losses exceed intakes (negative balance), nutrient stores are progressively depleted,
resulting in deﬁciency in the long term; when intakes exceed losses (positive balance), there is nutrient
accretion. In the case of sodium, a sustained positive balance, albeit small, may lead to a systemic
accumulation overtime with, possibly, adverse implications (Section 2.3.3).
In relation to sodium, the Panel considers that balance studies cannot be used to determine sodium
requirements but could be used to inform about the levels of sodium intake that are adequate to
maintain a null sodium balance (Section 5.2.4).
The following question was used for the elicitation: What is the lowest level of sodium intake which
is adequate (i.e. amount which allows to maintain sodium balance) for the majority (≥ 97.5%) of the
general population of adults?
The group consensus probability distribution elicited in response to the question is depicted in
Figure 2 and the rationale for the distribution is provided in Table 10. The distribution reﬂects the
uncertainty of the experts about the lowest level of sodium intake which allows to maintain sodium
balance for most of the general population.
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UNa
range
(mmol/
24 h)
Probability(a) Rationale
120–200 5%  Studies show CHD risk and incidence of hypertension to increase with Na intake
in this range (Tuomilehto et al., 2001; Joosten et al., 2014)
 Positive relationship between UNa and blood pressure (range 50–200 mmol/24 h)
 Indication of increased risk of CHD and stroke from Stolarz-Skrzypek et al.
(2011) below this level of intake
CHD: coronary heart disease; UNa: sodium urinary excretion; TOPH: Trials of Hypertension Prevention.
(a): Consensus judgement of the expert group about the probability that the corresponding range of UNa includes the ‘true’
level of interest.
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Table 10: Rationale for the group consensus uncertainty probability distribution on the lowest level
of sodium intake which to maintain sodium balance for most of the general population
Sodium intake
range (g/day)
Probability(a) Rationale
0.5–1.0 5%  There is a minimum requirement for sodium, which is unknown.
 Data in Yanomamo Indians indicate that they can sustain a
lifelong sodium intake in the order of a few mmol/day
(INTERSALT Cooperative Research Group, 1988); uncertainty
associated with the generalisability of these observations to the
EU population
1.0–1.5 32.5%  Evidence from the Allsopp study indicates 1.5 g/day (Allsopp,
1997, 1998); good quality study (exposure) but uncertainty due
to single study, short duration, small number of subjects
 Reductions in sodium intake resulting in excretions of 100 to
50 mmol/day (2.3 to 1.2 g/day) and lower has been associated
with a sharp increase in plasma renin activity and aldosterone
concentration in urine
 Distribution of probability in range 1.0–2.5 g/day reﬂects:
 Allsopp indicates 1.5 g/day but uncertainty about the distribution
in the population
 Body constantly adapts to maintain homeostasis in response to
environmental conditions; there is a lack of data on the health
effects of a sustained activation of the sympathetic nervous
system and the RAAS in the general population
 Probability distribution shifted towards range 1.5–2.5 g/day to
cover most of the population and considering the lack of data
from balance studies below 1.5 g/day
1.5–2.0 37.5%
2.0–2.5 20%
EKE question: ‘What is the lowest level of sodium intake that is adequate (i.e. amount which allows to maintain
sodium balance) for the majority (≥ 97.5%) of the general population of adults?’. Experts expressed the probability
that each of the proposed ranges of sodium intake might include the ‘true’ level of interest. Therefore, the
probability distribution reﬂects the uncertainty about the level elicited. It does NOT represent the probability (or
risk) of sodium ‘imbalance’ associated to a given range of sodium intake. Ranges that did not receive any
probability are not retained in the ﬁgure.
Figure 2: Group consensus uncertainty probability distribution on the lowest level of sodium intake
which allows to maintain sodium balance for most of the general population
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6.1.3. Integration of the evidence and conclusions
Parametric distributions were ﬁtted to the group consensus uncertainty empirical probability
distributions. At this stage, UNa values expressed in mmol/24 h were converted into g/day and a
factor of 1.07 was applied to allow for the percentage of dietary sodium excreted through urine. This
conversion factor was chosen based on the meta-analysis of Lucko et al. (2018) that estimated that,
on average, 93% of daily dietary sodium was excreted in 24-h urine (Sections 2.3.4.1 and 2.6.1.1).
The parametric distributions ﬁtted to the centiles of the two group consensus uncertainty
distributions were, respectively: a log-normal distribution with parameters 0.72 (mean) and 0.23
(standard deviation) for the question on sodium intake at which CVD risk is reduced; a log-normal
distribution with parameters 0.5 (mean) and 0.3 (standard deviation) for the question on sodium
balance (Appendix M). Based on the two ﬁtted parametric distributions, cumulative uncertainty density
functions were derived (Figure 3).
The Panel used the cumulative uncertainty density functions to integrate the evidence and
associated uncertainties and derive a reference value for sodium (see Figure 3). The Panel considered
that:
• A sodium intake of 2.0 g/day represents a level of sodium for which there is sufﬁcient conﬁdence
that it is associated within a reduced risk of CVD in the general adult population.
• A sodium intake of 2.0 g/day is likely to allow most of the general population to maintain sodium
balance.
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Sodium intake
range (g/day)
Probability(a) Rationale
2.5–3.5 5%  Uncertainty on the distribution in the population: some people
may achieve null balance in this range (some indication from
Holbrook et al. (1984))
INTERSALT: International Cooperative Study on Salt, Other Factors and Blood Pressure; RAAS: renin–angiotensin–aldosterone
system.
(a): Consensus judgement of the expert group about the probability that the corresponding range of sodium intake includes the
‘true’ level of interest.
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Therefore, the Panel considers that 2.0 g of sodium/day is a safe and adequate intake for the
general EU population of adults. BOX-1 provides an explanation for the terms.
This value provides guidance on a level of sodium intake compatible with good health that can
inform population goals for sodium. However, the value has limited utility for assessing and planning
the diet of individuals. At the individual level, if the usual intake of sodium exceeds this value, it could
be associated with an increased risk of cardiovascular diseases, including concurring risk factors such
as primary hypertension.
The Panel recognised several challenges arising from the integration of the available evidence to set
any sort of advisory level for sodium intake. One is that, due to the limitations of the evidence, there
are substantial uncertainties associated with levels of interest for both sodium balance and stroke/CHD
risk. Another challenge arises from the integration of several outcomes that differ in their nature, i.e.
physiological requirements versus chronic disease risk. The setting of a single value is a pragmatic
choice, which represents a compromise between the different types of evidence and risks.
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Log-normal distributions were ﬁtted to the empirical uncertainty probability distributions elicited through the two
EKEs and used to derive the two cumulative density functions depicted above.
The red curve is the cumulative density function corresponding to the elicitation of the lowest level of sodium intake
at which the risk of chronic disease (i.e. stroke, CHD) is minimised in the general population. As one goes towards the
right of the curve, the uncertainty that the identiﬁed range includes the level of sodium intake that ‘minimises’ the risk
of CHD increases; similarly, as one moves towards the left, the uncertainty that the identiﬁed range includes the level
of sodium intake that ‘minimises’ the risk of stroke increases. The curve integrates experts’ considerations about the
strength of the evidence for the respective outcomes and associated uncertainties. At the median level of the
distribution (red dot), there is equal certainty that the level of sodium that it is associated with a reduction of CVD risk
is neither overestimated (50% probability) nor underestimated (50% probability). So, the Panel considers that there
is sufﬁcient conﬁdence in the data that a sodium intake of 2 g/day is associated with a reduction of CVD risk.
The blue curve is the cumulative density function corresponding to the elicitation of the lowest level of sodium intake
that allows to maintain sodium balance for most of the general population. The curve represents the probability/
certainty that the ‘lowest level of sodium intake that is adequate (i.e. to maintain sodium balance) for the majority
(≥ 97.5%) general population of adults’ is any value from the lower bound of the range up to the identiﬁed value. The
interpretation of the curve is unidirectional: as one goes towards the right, the conﬁdence (certainty) that the
identiﬁed range includes the level of sodium intake that is adequate increases. The Panel considers that a level of
sodium intake of 2 g/day (blue dot) is likely (i.e. with a 75% probability) to be adequate to maintain sodium balance
for most of the general adult population in the EU.
The curves do NOT represent the probability (or risk) of given outcome (i.e. CVD disease, sodium ‘imbalance’)
associated with a given level of sodium intake.
Figure 3: Cumulative uncertainty density functions
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6.2. Pregnant and lactating women
The Panel considers that the requirement for the daily accretion rate of sodium in fetal and
maternal tissues can be met by adaptive changes that maintain sodium homeostasis during pregnancy
(Section 5.3). The Panel also notes that there is no evidence that sodium requirement of lactating
women differs from the requirement of non-lactating women (Section 5.3).
So, the Panel considers that 2.0 g sodium/day is a safe intake and adequate intake for pregnant
and lactating women.
6.3. Infants
There is a lack of data from which an AR could be derived for infants (Section 5.4).
Upwards extrapolation from the estimated sodium intake of fully breast-fed infants during the ﬁrst
6 months of life of 120 mg/day (Section 2.3.4.4), based on ARs for energy of infants aged 3 months
(2.0 MJ/day for men and women (EFSA NDA Panel, 2013a)) and 9 months (2.8 MJ/day for men and
women (EFSA NDA Panel, 2013b)), results in an estimated sodium intake of 168 mg/day.
After rounding to the closest 0.1, an AI of 0.2 g/day is proposed for infants aged 7–11 months.
6.4. Children
There is a lack of data from which an AR could be derived for children (Sections 5.2 and 5.4).
For children, the Panel decided to draw up reference values based on downwards extrapolation
from the reference value for adults, based on the AR for energy (EFSA NDA Panel, 2013b) and
including a growth factor to take into account requirements for growth, as follows:
Valuechild = Valueadult 9 (AR for energy of children/AR for energy of adults aged 18–29 years) 9
(1 + growth factor)
The AR for energy varies with age and physical activity level (PAL) (EFSA NDA Panel, 2013b). For
the calculations, the AR for energy of adults aged 18–29 years was taken as a reference. The values
calculated by using the ARs corresponding to the different PAL values were close (< 0.2 g/day
difference). Therefore, a single value is proposed that applies to all levels of physical activity.
Growth factors are derived from the proportional increase in protein requirement for growth relative
to the maintenance requirement at the different ages (EFSA NDA Panel, 2012a; EFSA, 2017a).
The age categories proposed by the EFSA NDA Panel (2010) were applied. For each age category,
the Panel decided to set a single value for boys and girls and the average of the values calculated for
both sexes was taken (Table 11).
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Table 11: Safe and adequate intake of sodium for children
Safe and adequate intake(a) (g/day)
1–3 years 1.1
4–6 years 1.3
7–10 years 1.7
11–17 years 2.0
BOX 1 – Safe and adequate intake: explanation for the terms
Safe: Although the term ‘safe intake’ is not deﬁned in the principles on deriving and applying DRVs (EFSA
NDA Panel, 2010), the concept of a safe intake has been used in previous assessments regarding a daily
intake of a nutrient which does not give rise to concerns about adverse health effects, in instances when a
tolerable upper intake level (UL) could not be established (SCF, 2000; EFSA NDA Panel, 2012b). The
reference value for sodium is called ‘safe’ because the value proposed takes account of the evidence
describing the relationship between sodium intake and CVD risk in the general population.
Adequate: An adequate intake (AI) is the value estimated when a population reference intake (PRI) cannot
be established because an average requirement (AR) cannot be determined (EFSA NDA Panel, 2010). The AI
is the level of intake that is assumed to be sufﬁcient based on observations from groups of apparently healthy
people. The reference value for sodium is called ‘adequate’ in line with this deﬁnition.
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Conclusions
The Panel concludes that the available evidence cannot be used to derive an AR and a PRI for
sodium. Evidence on the relationship between sodium intake and level of blood pressure and risk of
CVD as well as data from balance studies are used as a basis to determine a safe and adequate intake
of sodium of 2.0 g/day for the general population of adults (Table 12). The Panel proposes that the
reference value for adults also applies to pregnant and lactating women. Reference values for children
are extrapolated from the reference value for adults based on the energy requirements of the age
groups and applying a growth factor. For infants over 6 months of age, an AI is derived by
extrapolating the estimated sodium intake of fully breast-fed infants during the ﬁrst 6 months of life
based on the energy requirement of the respective age groups.
The Panel notes that the mean/median intake of sodium in the European adult populations exceeds
the safe and adequate intakes set for sodium (see Appendices C, D and E). The risk of inadequate
(insufﬁcient) intake in European populations is low. Concerns for European populations instead relate
to ‘excess’ intake of sodium. Therefore, in practice, the values proposed can be used to inform the
setting of population goals for the reduction in sodium intake.
The Panel acknowledges that the concept of a safe and adequate intake is not addressed in the
EFSA’s Scientiﬁc Opinion on the principles for deriving and applying DRVs published in 2010 (EFSA NDA
Panel, 2010). The principles were established when the review of DRVs for European populations was
initiated and was meant as a guidance document. As for other guidance documents in EFSA, it is a
living document that could be updated in the future in the light of the experience gained and new
scientiﬁc and methodological developments in the ﬁeld.
Recommendations for research
There is a need for studies, using robust assessment methods for sodium intake and the outcome
of interest, investigating:
• the moderating effect of energy intake on the relationship between sodium intake and blood
pressure;
• the health effects of sodium and of the Na/K ratio at intakes approximating their respective DRVs;
• the life course effects of sodium intake on blood pressure, in particular the effect of sodium
intake on neurohormonal control during childhood and adolescence, including programming;
• the effect of prolonged exposure to ‘low’ sodium on the effective functioning of its homeostatic
regulation (i.e. SNS and RAAS);
• the effects of sodium intake on bone health in growing and ageing populations;
• the role of sodium intake on the pathogenesis of kidney disease in the general population;
• the characterisation of genes involved in determining ‘salt-sensitive’ phenotypes and of
moderating factors of ‘salt sensitivity’.
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(a): Values for children were derived from the value for adults after adjustment on the basis of differences in average requirement
for energy (EFSA NDA Panel, 2013b) and application of a growth factor (EFSA, 2017a). The average requirements for energy
of adults aged 18 to 29 years was used in the calculations. The average of the values for boys and girls was calculated for
each year of age. For each age category, the proposed value corresponds to the average of the values calculated for each year
of age. A single value for the age categories 11–14 years and 15–17 years was selected. Values are rounded to the closest 0.1.
Table 12: Summary of dietary reference values for sodium
Safe and adequate intake(a) (g/day)
7–11 months 0.2(b)
1–3 years 1.1
4–6 years 1.3
7–10 years 1.7
11–17 years 2.0
≥ 18 years(c) 2.0
(a): Equivalent to: 9 mmol/day for infants 7–11 months, 48 mmol/day for children aged 1–3 years, 57 mmol/day for children
aged 4–6 years, 74 mmol/day for children aged 7–10 years, 87 mmol/day for children aged 11–17 years, 87 mmol for
adults, including pregnant and lactating women.
(b): Adequate intake.
(c): Including pregnant and lactating women.
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Appendix A – Sodium concentration in breast milk from mothers of term infants in Western countries
Reference
N women
(N samples)
Country
Stage of
lactation
Sodium concentration mg/L (mmol/L)
Analytical method
Mean  SD Median
Koo and Gupta
(1982)
45
(5)
(8)
(8)
(9)
(5)
(9)
(9)
(52)
(52)
Australia Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Day 7
Days 8–14
Days 15–28
1,630  262 (70.9  11.4)
1,244  200 (54.1  8.7)
501  71 (21.8  3.1)
651  108 (28.3  4.7)
359  64 (15.6  2.8)
435  92 (18.9  4.0)
398  53 (17.3  2.3)
301  14 (13.1  0.6)
244  14 (10.6  0.6)
Milk expressed manually
Flame photometry
Keenan et al.
(1982)
(14)
(14)
(12)
USA 3.5–6 weeks
8.5–18 weeks
20–32 weeks
182  69 (7.9  3.0)
108  46 (4.7  2.0)
124  30 (5.4  1.3)
Milk expressed using an
electric breast pump
Flame photometry
Parr et al.
(1991)
(71) Hungary 3 months 105  6 (4.6  0.3) Milk expressed using breast
pump
AAS
(29) Sweden 88  17 (3.8  0.7)
Holt (1993) 4 (28) UK 5–16 weeks 107  29 (4.65  1.24) Manual expression
Flame photometry
Wack et al.
(1997)
30 (140) USA 0–60 days
61–120 days
121–180 days
181–240 days
241–300 days
301–360 days
> 360 days
182  83 (7.9  3.6)
129  61(5.6  2.7)
136  76 (5.9  3.3)
139  142 (6.0  6.2)
124  65 (5.4  2.8)
122  123 (5.3  5.3)
126  49 (5.5  2.1)
Manual expression or breast
pump
Plasma emission
spectrophotometry
Motil et al.
(1997)
11 adolescents
(16.5  0.6 years)
USA 6 weeks
12 weeks
18 weeks
24 weeks
136  29 (5.9  1.3)
127  34 (5.5  1.5)
93  31 (4.0  1.3)
116  51 (5.0  2.2)
Milk expressed by manual or
mechanical pumping
AAS
11 adults
(31.1  3.8 years)
USA 6 weeks
12 weeks
18 weeks
24 weeks
94  27 (4.1  1.2)
71  23 (3.1  1.0)
70  16 (3.0  0.7)
75  23 (3.3  1.0)
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Reference
N women
(N samples)
Country
Stage of
lactation
Sodium concentration mg/L (mmol/L)
Analytical method
Mean  SD Median
Fly et al.
(1998)
14 (28) USA 2–8 months Mean  SE
115  11 (5.00  0.48) (at rest)
109  5 (4.73  0.22) (after
exercise)
Milk expressed mechanically
(electric breast pump)
ICP-AES
Gulson et al.
(2001)
17 (68) Australia
(Australian and
migrant
subjects)
Not reported 167.1  62.4 (7  2) 170.0 Not reported
Savilahti and
Saarinen
(2007)
Exclusive breast-
feeding < 0.5 months:
109 (96)
Finland 1–5 days 597 (26) Not reported
Exclusive breast-
feeding > 3.5 months:
119 (106)
Finland 1–5 days 459 (20) Not reported
Manganaro
et al. (2007)
208(a) (208) Italy 3 days 540  25 (23  1) Mode of expression not
reported. Flame photometer.
Bauer and
Gerss (2011)
10 Germany Mixed (1–8 weeks;
samples collected
at weekly intervals
from the ﬁrst to the
eighth week post-
partum)
257  48 (11.2  2.1) Milk expressed mechanically
(electric breast pump)
AAS and colorimetry
Galipeau et al.
(2012)
151 (151) Canada Day 3 982  508 (42.7  22.1) (range: 333–2,758
(14.5–120.0))
Milk expressed manually
Gasometry apparatus
Bjorklund et al.
(2012)
60 (840) Sweden 14–21 days
(samples collected
daily for 7 days)
217  77 (9.4  3.3) 192 (range: 136–
480) (8.3 (range:
5.9–20.9))
Milk sampled using a manual
breast milk pump and/or a
passive breast milk sampler
ICP-MS
Studies were identiﬁed by a comprehensive literature search for publications from January 2010 to January 2014 (LASER Analytica, 2014) and additional searches of the literature before these
dates. If studies did not report whether infants were born at term or not, it was presumed that infants were born at term.
AAS: atomic absorption spectrophotometry; ICP-AES: inductively coupled plasma atomic emission spectroscopy; ICP-MS: inductively coupled plasma mass spectrometry; N: number; SD: standard
deviation; SE: standard error.
(a): Including ﬁve mothers of preterm infants.
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Appendix B – Comparisons of measured 24-h urinary sodium excretions vs 24-h urinary sodium excretions
estimated from equations based on concentrations of sodium in spot urine samples
Reference Population Methods
Estimated 24-h
Na excretion
(extrapolation
method)
Mean  SD
Measured 24-h
Na excretion
(reference)
Mean  SD
Correlation Comparison Bland–Altman analysis
Kawasaki
et al. (1993)
Japan
159 healthy
M and W
(20–79 years)
(Data set used
to derive the
equation)
Collection 3–5 9 2nd
morning voiding urine
collected within 4 h after
the 1st voiding but before
breakfast + Kawasaki
equation to estimate 24 h
Na
Reference:
3–5 9 24-h urine (same
days)
NR NR 0.728
91 healthy
M and W
(40–67 years)
Collection 1 9 2nd
morning voiding urine
collected within 4 h after
the 1st voiding but before
breakfast + Kawasaki
equation to estimate 24-h
Na
Reference:
1 9 24-h urine (same day)
NR NR 0.531 No statistically
signiﬁcant difference
was found between
mean estimated 24-h
Na and measured
24-h Na
15 healthy
M and W
(21–54 years)
Collection 3
successive 9 2nd morning
voiding urine collected
within 4 h after the 1st
voiding but before
breakfast + Kawasaki
equation to estimate 24-h
Na
Reference:
3 successive 9 24-h urine
(same days)
Procedure repeated 4–6
times
NR NR 0.821 No statistically
signiﬁcant difference
was found between
mean estimated 24-h
Na and measured
24-h Na
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Reference Population Methods
Estimated 24-h
Na excretion
(extrapolation
method)
Mean  SD
Measured 24-h
Na excretion
(reference)
Mean  SD
Correlation Comparison Bland–Altman analysis
Tanaka et al.
(2002)
Japan
295 M and
296 W
(20–59 years)
from INTERSALT
(Data set used
to derive the
equation)
1 9 casual spot urine +
Tanaka equation to
estimate 24-h Na
Reference:
1 9 24-h urine collection
(started after the casual
collection)
178.9  36.2
mmol/day
187.2  65.8
mmol/day
0.54 Difference between
measured 24-h Na
and estimated 24-h
Na
8.3 mmol/day
336 M and W
(20–59 years)
(Validation data
set)
1 9 casual spot urine +
Tanaka equation to
estimate 24-h Na
Reference:
1 9 24-h urine collection
(started after the casual
collection)
154.5  32.7
mmol/day
178.5  59.5
mmol/day
0.32 Difference between
mean estimated 24-h
Na and mean
measured 24-h Na,
by quintile of
estimated 24-h Na
Q1: 45.4 mmol/day
Q2: 27.6 mmol/day
Q3: 25.6 mmol/day
Q4: 21.4 mmol/day
Q5: 0.5 mmol/day
Brown et al.
(2013)
15 countries
from North
America and
Europe
(INTERSALT)
2,948 M and W
(20–59 years),
from 29 cities
(Data set used
to derive the
equation)
1 9 casual spot urine +
INTERSALT equation to
estimate 24-h Na
Reference:
1 9 24-h urine collection
(undertaken after the
casual collection)
NR Mean (mix, max)
M:
Belgium, Charleroi:
147.2 mmol/day
Poland, Krakow:
240 mmol/day
W:
Germany, Cottbus:
117.8 mmol/day
Italy, Bassiano:
167.5 mmol/day
M: 0.51
W: 0.52
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Reference Population Methods
Estimated 24-h
Na excretion
(extrapolation
method)
Mean  SD
Measured 24-h
Na excretion
(reference)
Mean  SD
Correlation Comparison Bland–Altman analysis
2,745 M and W
(20–59 years),
from 29 cities
(Validation data
set)
1 9 casual spot urine +
INTERSALT equation to
estimate 24-h Na
Reference:
1 9 24-h urine collection
(undertaken after the
casual collection)
M:
USA, Hawaii:
176.3 mmol/day
Poland, Krakow:
223.6 mmol/day
W:
Iceland, Reykjavik:
126.6 mmol/day
Italy, Bassiano:
178.0 mmol/day
M:
USA, Hawaii:
144.2 mmol/day
Poland, Krakow:
239.7 mmol/day
W:
Iceland, Reykjavik:
115.0 mmol/day
Italy, Bassiano:
170.6 mmol/day
M: 0.50
W: 0.51
Difference between
mean measured 24-h
Na and mean
estimated 24-h Na:
M: 1.6 mmol
W: +2.3 mmol
Bland–Altman showed
overestimation of
excretion at lower levels
and underestimation at
higher levels for both men
and women
Mente et al.
(2014) 11
countries
1,083 M and W
(35–70 years)
1 9 fasting morning
collection + Kawasaki
equation to estimate 24-h
Na
Reference:
1 9 24-h urine collection
(previous day)
4,430  1,253
mg/day
4,116  1,978
mg/day
Intraclass
correlation
coefﬁcient
0.71 (95%
CI: 0.65 to
0.76)
Difference between
estimated 24-h Na
and measured 24-h
Na:
313 (95% CI: 182 to
444) mg/day
Bland–Altman plot
evidenced a systematic
bias towards
overestimation at the
lower end and
underestimation at the
higher end
1 9 fasting morning
collection + INTERSALT
equation to estimate 24-h
Na
Reference:
1 9 24-h urine collection
(previous day)
3,257  860
mg/day
4,116  1,978
mg/day
Intraclass
correlation
coefﬁcient
0.49 (0.29 to
0.62)
Difference between
estimated 24-h Na
and measured 24-h
Na:
872 (728 to
1016) mg/day
Bias signiﬁcantly higher
than Kawasaki equation
1 9 fasting morning
collection + Tanaka
equation to estimate 24-h
Na
Reference:
1 9 24-h urine collection
(previous day)
3,569  782
mg/day
4,116  1,978
mg/day
Intraclass
correlation
coefﬁcient
0.54 (0.42 to
0.62)
Difference between
estimated 24-h Na
and measured 24-h
Na:
548 (408 to
688) mg/day
Bias signiﬁcantly higher
than Kawasaki equation
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Reference Population Methods
Estimated 24-h
Na excretion
(extrapolation
method)
Mean  SD
Measured 24-h
Na excretion
(reference)
Mean  SD
Correlation Comparison Bland–Altman analysis
Pﬁster et al.
(2014) UK
163 M and W
(EPIC-Norfolk
study)
1 9 casual spot urine
sample + INTERSALT
equation to estimate 24-h
Na
Reference:
Mean of up to 6 9 24 h
collections over 1 year
NR NR NR Mean of differences
between measured
and estimated 24-h
Na:
21 mmol/day (95%
CI: 32 to
11 mmol/day)
Variance of the differences
reasonably constant, with
few outliers and most
points lying within the
calculated limits of
agreement
Cogswell
et al. (2013)
USA
407 M and W
(18–39 y, 52%
white)
1 morning spot urine
specimen (ﬁrst specimen
after discarding the ﬁrst
void; 08:30–12:30) +
INTERSALT equation to
estimate 24-h Na
Reference:
1 9 24-h collection (same
day)
3,157  891
mg/day
3,323  1,437
mg/day
0.47 Difference between
estimated and
measured 24-h Na:
–165 mg (95% CI:
295, 36)
Overestimation occurred at
the low levels of 24-h Na
excretion and
underestimation at the
high level
1 afternoon spot urine
specimen (12:31–17:30) +
INTERSALT equation to
estimate 24-h Na
Reference:
1 9 24-h collection (same
day)
3,197  824 mg/
day
3,287  1,408
mg/day
0.49 90 mg (95% CI:
208, 28)
1 evening spot urine
specimen (17:31–23:59) +
INTERSALT equation to
estimate 24-h Na
Reference:
1 9 24-h collection (same
day)
3,178  846 mg/
day
3,298  1,399
mg/day
0.54 120 mg (95% CI:
230, 11)
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Reference Population Methods
Estimated 24-h
Na excretion
(extrapolation
method)
Mean  SD
Measured 24-h
Na excretion
(reference)
Mean  SD
Correlation Comparison Bland–Altman analysis
1 overnight specimen (ﬁrst
void collected the next
morning after the longest
period of sleep (04:00–
12:00)) + INTERSALT
equation to estimate 24-h
Na
Reference:
1 9 24-h collection (same
day)
3,028  809
mg/day
3,295  1,400
mg/day
0.44 267 mg (95% CI:
384, 151)
Morning as above + Tanaka
equation to estimate 24-h
Na
Reference:
1 9 24-h collection
3,574  893
mg/day
3,323  1,437
mg/day
0.50 251 mg (95% CI:
NR)
Overestimation occurred at
the low levels of 24-h Na
sodium excretion and
underestimation at the
high levels
Afternoon as above +
Tanaka equation to
estimate 24-h Na
Reference:
1 9 24-h collection (same
day)
3,655  870
mg/day
3,287  1408
mg/day
0.51 368 mg (95% CI:
NR)
Evening as above + Tanaka
equation to estimate 24-h
Na
Reference:
1 9 24-h collection (same
day)
3,553  820
mg/day
3,298  1399
mg/day
0.59 255 mg (95% CI:
NR)
Overnight as above +
Tanaka equation to
estimate 24-h Na
Reference:
1 9 24-h collection (same
day)
3,272  779
mg/day
3,295  1400
mg/day
0.47 23 mg (95% CI:
141, 95)
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Estimated 24-h
Na excretion
(extrapolation
method)
Mean  SD
Measured 24-h
Na excretion
(reference)
Mean  SD
Correlation Comparison Bland–Altman analysis
Morning as above +
Kawasaki equation to
estimate 24-h Na
Reference:
1 9 24-h collection (same
day)
4,623  1,471
mg/day
3,323  1,437
mg/day
0.52 1,300 mg (95% CI:
1,152, 1,300)
Overestimation appeared
to occur across low to
high levels of 24-h Na
excretion
Ji et al.
(2014)
UK/Italy
915 untreated M
and W (297
white, 326 of
black African
origin and 292
South Asian;
40–59 years old)
1 9 timed morning urine
sample + Tanaka
equation to estimate 24-h
Na
Reference:
1 9 24-h urinary collection
(previous day)
NR NR From 0.055 in
black women
to 0.330 in
white women
Bland–Altman plots
indicated consistent bias
with overestimate for low
and underestimate for
high intakes. The bias was
mainly due to the
inaccuracy of age, weight
and height to predict 24-h
creatinine excretion in the
three ethnic groups,
particularly in those of
African origin
1 9 timed morning urine
sample + arithmetic
extrapolation to 24-h scale
Reference:
1 9 24-h urinary collection
(previous day)
NR NR From 0.116 in
black women
to 0.367 in
white women
Bias was detected with
both Bland–Altman plots
and through quintile
analyses (underestimate at
low levels and
overestimate at high
levels)
148 white M
(mean age
58.3 years), in
Italy
1 9 timed morning urine
sample + Tanaka
equation to estimate 24-h
Na
Reference:
1 9 24-h urinary collection
(previous day)
NR NR 0.499 Bland–Altman plot
indicated overestimated
values in the low 24-h
urinary Na levels and
underestimated values in
the high 24-h urinary Na
levels indicating consistent
bias
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Estimated 24-h
Na excretion
(extrapolation
method)
Mean  SD
Measured 24-h
Na excretion
(reference)
Mean  SD
Correlation Comparison Bland–Altman analysis
1 9 timed morning urine
sample + arithmetic
extrapolation to 24-h scale
Reference:
1 9 24-h urinary collection
NR NR 0.329 Arithmetic extrapolation
produced underestimated
values in the low 24-h
urinary Na levels and
overestimated values in
the high 24-h urinary Na
levels indicating consistent
bias
Polonia et al.
(2017)
Portugal
2,399 M and W
(51% W; aged
18–96 years)
1 9 casual urine sample +
Tanaka equation to
estimate 24-h Na
Reference:
1 9 24-h urinary collection
(1–7 days before)
By quintiles of
measured 24-h Na:
Q1: 3,755  876
Q2: 3,973  862
Q3: 3,986  803
Q4: 4,150  837
Q5: 4,342  801
By quintiles of
measured 24-h Na:
Q1: 2,361  280
Q2: 3,121  192
Q3: 3,825  219
Q4: 4,661  279
Q5: 6,298  921
0.232
Intraclass
correlation
coefﬁcient
0.340 (95%
CI: 0.285,
0.391)
Difference between
measured and
estimated 24-h Na
Overall: 11 mg/day
(95% CI:48.6, 70.6)
By quintiles of
measured 24-h Na:
Q1:1,394  905
Q2:852  875
Q3:161  832
Q4: 511  867
Q5: 1,956  1,140
Bias was detected with
both Bland–Altman plots
and through quintile
analyses (overestimate at
low levels and
underestimate at high
levels). Bland–Altman plots
indicated that formula-
based estimates seem to
have poorer clariﬁcation at
higher levels than lower
levels
2,399 M and W
(51% W; aged
18–96 years)
1 9 casual urine sample +
Kawasaki equation to
estimate 24-h Na
Reference:
1 9 24-h urinary collection
(1–7 days before)
By quintiles of
measured 24-h Na:
Q1: 4,844  1,402
Q2: 5,171  1,414
Q3: 5,240  1,363
Q4: 5,524  1,398
Q5: 5,864  1,365
By quintiles of
measured 24-h Na:
Q1: 2,361  280
Q2: 3,121  192
Q3: 3,825  219
Q4: 4,661  279
Q5: 6,298  921
0.25
Intraclass
correlation
coefﬁcient
0.303 (95%
CI: 0.050,
0.475)
Overall: 1,277 (95%
CI: 1,346.7,
1,206.4)
By quintiles of
measured 24-h Na:
Q1: 2,483  1,409
Q2: 2,050  1,413
Q3: 1,416  1,380
Q4: 864  1,408
Q5: 434  1,533
Bias was detected with
both Bland–Altman plots
and through quintile
analyses (overestimate at
low levels and
underestimate at high
levels)
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Na excretion
(extrapolation
method)
Mean  SD
Measured 24-h
Na excretion
(reference)
Mean  SD
Correlation Comparison Bland–Altman analysis
2,399 M and W
(51% W; aged
18–96 years)
1 9 casual urine sample +
INTERSALT equation to
estimate 24-h Na
Reference:
1 9 24-h urinary collection
(1–7 days before)
By quintiles of
measured 24-h Na:
Q1: 3,019  841
Q2: 3,289  848
Q3: 3,467  901
Q4: 3,677  923
Q5: 3,965  894
By quintiles of
measured 24-h Na:
Q1: 2,361  280
Q2: 3,121  192
Q3: 3,825  219
Q4: 4,661  279
Q5: 6,298  921
0.359
Intraclass
correlation
coefﬁcient
0.457 (95%
CI: 0.337,
0.549)
Overall: 569 (95%
CI: 512.4, 624.7)
By quintiles of
measured 24-h Na:
Q1: 658  852
Q2: 168  857
Q3: 357  914
Q4: 984  930
Q5: 2,333  1,150
Bias was detected with
both Bland–Altman plots
and through quintile
analyses (overestimate at
low levels and
underestimate at high
levels)
Zhou et al.
(2017) China
141 M and W
(27–64 years)
1 morning spot urine
specimen + Kawasaki
equation to estimate 24-h
Na
Reference:
1 9 24-h urinary collection
(started after the spot
collection)
246.1  66.8
mmol/day
220.8  78.5
mmol/day
0.31 Median (95% CI)
difference between
measured and
estimated 24-h Na
6.4 (17.5, 36.8)
mmol/day
The individual
absolute difference
was > 51.3 mmol/day
(3 g salt) in 52.5% of
the participants
1 morning spot urine
specimen + INTERSALT
equation to estimate 24-h
Na
Reference:
1 9 24-h urinary collection
(started after the spot
collection)
143.6  24.7
mmol/day
220.8  78.5
mmol/day
0.25 67.3 (96.5,
46.9) mmol/day
The individual
absolute difference
was > 51.3 mmol/day
(3 g salt) in 63.1% of
the participants
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Measured 24-h
Na excretion
(reference)
Mean  SD
Correlation Comparison Bland–Altman analysis
1 morning spot urine
specimen + Tanaka
equation to estimate 24-h
Na
Reference:
1 9 24-h urinary collection
(started after the spot
collection)
183.7  39.0
mmol/day
220.8  78.5
mmol/day
0.35 42.9 (59.1,
24.8) mmol/day
The individual
absolute difference
was > 51.3 mmol/day
(3 g salt) in 48.3% of
the participants
95% CI: 95% conﬁdence interval; INTERSALT: International Cooperative Study on Salt, Other Factors and Blood Pressure; M: men; Na: Sodium; N/A: not available; NR: not reported; SD: standard
deviation; W: women.
www.efsa.europa.eu/efsajournal 77 EFSA Journal 2019;17(9):5778
Dietary Reference Values for sodium
Appendix C – Daily sodium urinary excretion in children, boys and girls, in European countries
Country Year Methodology
Age
(years)
Participants’
characteristics
Na excreted in urine
(mmol/day)
Mean SD 95% CI
Median
(P50)
IQR
(P25–P75)
Austria (Elmadfa,
2012)
2010–
2012
Casual spot urine samples;
24-h excretion estimated by
multiplying Na concentration
by an average urine volume
of 1.1 L/day in children
7–14 392 boys and girls Boys:
7–9 years: 153
10–12 years: 165
13–14 years: 154
Girls:
7–9 years: 144
10–12 years: 155
13–14 years: 122
N/A Boys:
7–9 years:
133–172
10–12 years:
151–178
13–14 years:
122–187
Girls:
7–9 years:
126–163
10–12 years:
143–167
13–14 years:
93–151
N/A N/A
Iceland
(Kristbjornsdottir
et al., 2012)
2002–
2003
24-h urine collection;
Completeness of urine
collection assessed by PABA
recovery (≥ 85%). For
samples with a PABA
recovery between 50% and
85%, urinary Na excretion
was corrected (formula from
Johansson et al. (1999))
6 30 boys and 28 girls.
A subsample of a
national dietary
survey, including
6-year-old children
living in the greater
Reykjavik area
71 23 N/A N/A N/A
Italy (Campanozzi
et al., 2015)
2008–
2012
24-h urine collection with
control for urine volume and
creatinine
6–18 766 boys and 658
girls
Recruited in
participating National
Health Service
centres in 10 Italian
regions
Boys:
129
Girls:
117
N/A N/A Boys: 120
Girls: 107
Boys: 84–162
Girls: 77–146
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Country Year Methodology
Age
(years)
Participants’
characteristics
Na excreted in urine
(mmol/day)
Mean SD 95% CI
Median
(P50)
IQR
(P25–P75)
Spain (Aparicio
et al., 2017)
2014 24-h urine collection;
Completeness of urine
collection assessed on the
basis of Cr excretion
(samples with Cr excretion
rate < 0.1 mmol/kg/day
considered incomplete
(Remer et al., 2002))
7–11 Boys:
109
Girls:
96
From ﬁve primary
schools in various
Spanish provinces
Boys:
142
Girls:
122
Boys:
57
Girls:
41
N/A Boys:
136
Girls:
119
Boys:
122–177
Girls:
91–154
95% CI: 95% conﬁdence interval; Cr: creatinine; IQR: interquartile range; Na: sodium; N/A: not available; PABA: para-aminobenzoic acid; SD: standard deviation.
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Appendix D – Daily sodium urinary excretion in adult men in European countries
Country
(reference)
Year Methodology
Age
(years)
N and
participants’
characteristics
Na excreted in urine (mmol/day)(a)
Mean SD 95% CI
Median
(P50)
IQR
(P25–P75)(d)
Austria
(Elmadfa, 2012)
2010–
2012
Casual spot urine
samples; 24-h
excretion estimated
by multiplying Na
concentration by an
average urine volume
of 1.75 L/day from a
subsample of 19
people from whom
24-h urine were
collected
18–64
65–80
N/A
(total sample:
419 men and
women aged 18–64
and 196 men and
women aged 65–80)
Sample stratiﬁed by
gender, age and
geographical areas
18–24 years: 187
25–50 years: 191
51–64 years: 204
65–80 years: 183
N/A 18–24 years:
152–226
25–50 years:
178–204
51–64 years:
174–235
65–80 years:
139–204
N/A N/A
Belgium
(Koppen et al.,
2015)
2015 24-h urine collection;
exclusion of samples
with Cr excretion
levels outside the
normal range of
0.177–0.230 mmol/kg
per day for men and
self-reported as
incomplete
23–64 99
Sampled via an
occupational health
survey centre
(random cluster
sampling), spread
over the different
Belgian provinces
179 63 N/A 172 N/A
Belgium 2007–
2008
2 9 24-h urine
collection (1 month
interval);
completeness of urine
collection assessed by
PABA recovery
(≥ 85%). For samples
with a PABA recovery
between 50% and
85%, urinary Na
excretion was
corrected (formula
from Johansson et al.
(1999))
45–65 63 209(b) N/A 195–223 N/A N/A
Czech Republic(c) 58 252(b) 78 N/A 241 P5–P95
149–395
Norway
(De Keyzer et al.,
2015)
62
Subsamples of the
European
EFCOVAL study;
subjects recruited
by convenience
sampling through
advertisements
204(b) N/A 191–218 N/A N/A
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Country
(reference)
Year Methodology
Age
(years)
N and
participants’
characteristics
Na excreted in urine (mmol/day)(a)
Mean SD 95% CI
Median
(P50)
IQR
(P25–P75)(d)
Croatia
(Premuzic et al.,
2010)
2009 24-h urine collection;
Completeness check
not reported
46.3  7.3 N/A
(total sample of
93 men and
women)
From two out-
patient clinics (one
urban, one rural);
‘salt-mapping
survey’
231 74 N/A N/A N/A
Croatia
(Dika et al.,
2009)
2009 Morning spot urine
samples; 24-h Na
excretion estimated
by applying Kawasaki,
INTERSALT and
Tanaka equations
N/A N/A
(total sample of
1,669 men and
women);
Random sample
(door-to-door
method) in the
continental rural
part of Croatia
Kawasaki: 229 80 N/A N/A N/A
INTERSALT: 194 40 N/A N/A N/A
Tanaka: 186 49 N/A N/A N/A
Finland
(Laatikainen
et al., 2006)
2002 24-h urine collection;
exclusion of
incomplete samples
with Cr levels
≤ 5.0 mmol/day or Cr
levels ≤ 6.0 mmol/day
together with a urine
volume < 1,000 mL
25–64 423
North Karelia,
n = 168
Southwestern
Finland, n = 128
Helsinki area,
n = 127
Sampled as part of
the national
FINRISK 2002
study; 10-year age
group and sex-
stratiﬁed subsample
of the population
aged 25–64 years
North Karelia: 163
Southwestern
Finland: 170
Helsinki area: 148
N/A North Karelia:
153–173
Southwestern
Finland:
156–183
Helsinki area:
132–164
N/A N/A
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Country
(reference)
Year Methodology
Age
(years)
N and
participants’
characteristics
Na excreted in urine (mmol/day)(a)
Mean SD 95% CI
Median
(P50)
IQR
(P25–P75)(d)
drawn in north
Karelia,
southwestern
Finland and in the
Helsinki area
Germany
(Johner et al.,
2015)
2008–
2011
Casual spot urine
samples; 24-h Na
excretion estimated
from the Na:Cr ratio
by multiplication with
age- and sex-stratiﬁed
Cr excretion reference
values (Remer et al.,
2002)
18–79 3,340
18–29 years,
n = 507
30–39 years,
n = 403
40–49 years,
n = 586
50–59 years,
n = 630
60–69 years,
n = 671
70–79 years,
n = 543
Random sample, as
part of the German
National Health
Interview and
Examination Survey
2008–2011,
representative
for the German
adult population
N/A N/A Overall:
165–177
18–29 years:
148–173
30–39 years:
163–197
40–49 years:
148–173
50–59 years:
167–189
60–69 years:
165–194
70–79 years:
158–178
Overall: 170
18–29 years:
160
30–39 years:
180
40–49 years:
163
50–59 years:
177
60–69 years:
177
70–79 years:
167
Overall:
117–252
18–29 years:
113–263
30–39 years:
123–264
40–49 years:
110–231
50–59 years:
115–261
60–69 years:
117–252
70–79 years:
118–245
Greece
(unpublished
data)
2013–
2014
For 7 days, the weight
and time of each void
was recorded and a
sample of urine was
collected. For each
day, a sample of
10 mL was
reconstituted from the
individual samples
20–60 89
Participants equally
divided in each
decade of life.
159 51 N/A 148
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Country
(reference)
Year Methodology
Age
(years)
N and
participants’
characteristics
Na excreted in urine (mmol/day)(a)
Mean SD 95% CI
Median
(P50)
IQR
(P25–P75)(d)
based on the ratio of
the volume of each
void to the total
volume of urinary
excretion for the day.
Exclusion of samples
with Cr levels
> 3,500 mg/day
or < 350 mg/day
Greece
(Vasara et al.,
2017)
2015–
2016
24-h urine collection;
exclusion of
incomplete samples
on the basis of (a)
Urinary volume
< 500 mL/24-h, (b)
urinary creatinine less
than 2 SD from the
mean, (c) timing of
collection outside the
range 23–25 h, (d)
self-reporting of
incomplete collection
18–74 114
Salt intake in
northern Greece
(SING) Study –
Regional study
conducted in
Thessaloniki greater
metropolitan area.
Recruitment was
carried out at
various sites and
venues including
churches and
workplaces
194.3 76.8 180.1–208.6 181.9 N/A
Hungary
(unpublished
data)
2010 24-h urine collection;
completeness of the
samples checked on
the basis of
participants’
compliance with the
protocol
Adults
(age not
speciﬁed)
67
Random sample of
the Hungarian adult
population recruited
through primary
care physicians
190 73 N/A N/A N/A
Ireland (Morgan
et al., 2008)
2007 Spot urine samples;
daily Na excretion
estimated through
arithmetic
extrapolation (Na
≥ 18 484
Random sample of
both Irish citizens
and non-Irish
national residents
≥ 18 years: 176
45–64 years: 188
≥ 65 years: 158
≥ 18 years: 85
45–64 years: 88
≥ 65 years: 78
N/A N/A N/A
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Country
(reference)
Year Methodology
Age
(years)
N and
participants’
characteristics
Na excreted in urine (mmol/day)(a)
Mean SD 95% CI
Median
(P50)
IQR
(P25–P75)(d)
concentration
(mmol/L) multiplied
by 1.97 for men)
sampled as part of
the Survey of
Lifestyle, Attitudes
and Nutrition
(SLAN) 2007,
representative of
the general
population in
Ireland
Ireland (Kearney
et al., 2013)
2010–
2011
Morning urine
samples; daily Na
excretion estimated
through arithmetic
extrapolation
(Na concentration
(mmol/L) multiplied
by 1.97 for men)
45–74 999
Registered patients
attending the Living
Health Clinic of
Mitchelstown,
Ireland, sampled as
part of the Cork and
Kerry Diabetes and
Heart Disease Study
Phase II
Overall: 211
45–54 years: 218
55–64 years: 211
65–74 years: 201
Overall: 89
45–54 years: 92
55–64 years: 87
55–74 years: 89
N/A N/A N/A
Italy(e)
(Donfrancesco
et al., 2013;
Cappuccio et al.,
2015)
2009–
2012
24-h urine collection;
A sample if 24-h urine
volume < 500 mL or
creatinine content
referred to body
weight < mean minus
2 SD from the
population mean
35–79 1,962
Random samples of
the Italian adult
population from 20
Italian regions,
stratiﬁed by age and
sex (MINISAL-
GIRCSI Programme)
Overall: 183
35–44 years: 184
45–54 years: 190
55–64 years: 182
65–74 years: 180
75–79 years: 176
Overall: 70
35–44 years: 72
45–54 years: 70
55–64 years: 70
65–74 years: 70
75–79 years: 60
Overall:
180–187
35–44 years:
178–191
45–54 years:
184–197
55–64 years:
176–188
65–74 years:
173–187
75–79 years:
166–185
Overall: 175
35–44 years:
174
45–54 years:
182
55–64 years:
173
65–74 years:
170
75–79 years:
172
N/A
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Country
(reference)
Year Methodology
Age
(years)
N and
participants’
characteristics
Na excreted in urine (mmol/day)(a)
Mean SD 95% CI
Median
(P50)
IQR
(P25–P75)(d)
Slovenia (Ribic
et al., 2010)
2005 24-h urine collection;
exclusion of
incomplete samples
with Cr
level < 120 lmol/kg
bw per day for men
(Osredkar, 1998)
25–65 61
Participants
randomly
sampled from
census data from all
regions,
representative of
the general
population in
Slovenia
221 86 N/A N/A N/A
Spain (Ortega
et al., 2011)
2009 24-h urine collection;
completeness of the
samples assessed by
considering the
correlation between
urinary Cr and FFM of
each subject; FFM
estimated from 24-h
Cr excretion and
result compared with
measured FFM
obtained by electrical
bioimpedance method
(Lopez-Sobaler and
Quintas et al., 2006)
18–60 196
Selected as a
representative
sample of the
Spanish young and
middle-aged adult
population (from 15
randomly selected
provinces; stratiﬁed
by age and sex)
196 82 N/A 196 140–250
Sweden (Hulthen
et al., 2010)
2005 24-h urine collection;
completeness of urine
collection assessed by
PABA recovery
(≥ 85%)
1820 79
Participants
recruited in the city
of Gothenburg, as
part of the
Gothenburg Obesity
and Osteoporosis
Determinants
(GOOD) study
198 69 N/A N/A
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Country
(reference)
Year Methodology
Age
(years)
N and
participants’
characteristics
Na excreted in urine (mmol/day)(a)
Mean SD 95% CI
Median
(P50)
IQR
(P25–P75)(d)
Switzerland
(Chappuis et al.,
2011)
2010–
2011
24-h urine collection;
exclusion of
incomplete samples on
the basis of:
(1) urinary volume
< 300 mL/24 h, (2)
self-reporting of
incomplete collection,
or (3) Cr level
≤ 0.121 mmol/kg bw
per day in men
≥ 15 706
Age- and sex-
stratiﬁed sample in
various cantons of
Switzerland,
randomly selected.
The low
participation rate
was compensated
by recruiting
volunteers
Overall: 185
15–29 years: 171
30–44 years: 190
45–59 years: 194
≥ 60 years: 180
N/A N/A N/A
Netherlands
(Hendriksen
et al., 2014)
2010 24-h urine collection;
exclusion of
incomplete samples
on the basis of (1) Cr
excretion ≤ 5 mmol/
day, or ≤ 6 mmol/day
together with a urine
volume < 1,000 mL or
(2) missing or
overcollection of more
than one urine void
19–70 180
Individuals
participating in an
ongoing long-term
monitoring study on
chronic disease risk
factors (the
Doetinchem Cohort
Study (DCS)) or
randomly drawn
from the municipal
register of
Doetinchem
(General
Doetinchem
Population Sample
(GDPS))
174 63 N/A 163 126–212
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Country
(reference)
Year Methodology
Age
(years)
N and
participants’
characteristics
Na excreted in urine (mmol/day)(a)
Mean SD 95% CI
Median
(P50)
IQR
(P25–P75)(d)
Netherlands
(Hendriksen
et al., 2016)
2015 24-h urine collection;
start and end time of
the urine collection
were recorded.
Participants had to
report urine losses
Based on this data,
the researchers
determined whether
participants had an
incomplete urine
collection
19–70 135
Participants aged
50–70 recruited
from an ongoing
long-term
monitoring study on
chronic disease risk
factors (the
Doetinchem Cohort
Study (DCS));
Participants aged
19–49 randomly
drawn from the
municipal register of
Doetinchem
(General
Doetinchem
Population Sample
(GDPS)); Exclusion
of individuals had
participated in the
24-h urine test in
2006 and 2010 in
the study of
Hendriksen et al.
(2014), kidney
patients and
pregnant women
N/A N/A N/A Overall: 153
19–49 years:
146
50–70 years:
174
Overall:
125–202
19–49 years:
110–195
50–70 years:
138–214
United Kingdom
(Sadler et al.,
2011)
2011 24-h urine collection;
exclusion of samples
on the basis of PABA
recovery (< 70%
(incomplete)
or > 104% (unfeasibly
high); individuals who
19–64 250
Participants from
the England
National Diet and
Nutrition Survey
sample and from a
‘Na boost’ study;
19–34 years: 162
35–49 years: 171
50–64 years: 141
19–34 years: 69
35–49 years: 66
50–64 years: 82
N/A 19–34 years:
159
35–49 years:
165
50–64 years:
133
P2.5–P97.5
19–34 years:
72–296
35–49 years:
73–321
50–64 years:
54–308
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Country
(reference)
Year Methodology
Age
(years)
N and
participants’
characteristics
Na excreted in urine (mmol/day)(a)
Mean SD 95% CI
Median
(P50)
IQR
(P25–P75)(d)
elected not to take
PABA, or did not take
all PABA tablets, but
recorded they had
completed a 24-h
urine collection were
included if recorded
collection time was
collected between 23
and 25 h
stratiﬁed sample
randomly selected in
various regions of
England
bw: body weight; 95% CI: 95% conﬁdence interval; Cr: creatinine; EFCOVAL: European Food Consumption Validation; FFM: fat-free mass; INTERSALT: International Cooperative Study on Salt,
Other Factors and Blood Pressure; IQR: interquartile range; N: number; Na: sodium; N/A: not available; PABA: para-aminobenzoic acid; SD: standard deviation.
(a): For comparison purposes, results provided in g NaCl/day were converted back in mmol/day by multiplying by 0.4 and dividing by 23.
(b): Geometric means; based on two 24-h collection per subject.
(c): The values reported are unpublished data provided by the National Institute of Public Health of the Czech Republic.
(d): Unless indicated otherwise.
(e): The values reported are unpublished data provided by the Italian Instituto Superiore di Sanita.
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Appendix E – Daily sodium urinary excretion in adult women in European countries
Country Year Methodology
Age
(years)
N and participants’
characteristics
Na excreted in urine (mmol/day)(a)
Mean SD 95% CI
Median
(P50)
IQR
(P25–P75)(d)
Austria
(Elmadfa,
2012)
2010–
2012
Casual spot urine
samples; 24-h excretion
estimated by multiplying
Na concentration by an
average urine volume of
1.75 L/day from a
subsample of 19 people
from whom 24-h urine
were collected
18–64
65–80
NA
(total sample:
419 men and women
aged 18–64 and 196
men and women aged
65–80)
Sample stratiﬁed by
gender, age and
geographical areas
18–24 years:
157
25–50 years:
161
51–64 years:
130
65–80 years:
152
N/A 18–24 years:
117–200
25–50 years:
143–178
51–64 years:
104–157
65–80 years:
126–174
N/A N/A
Belgium
(Koppen et al.,
2015)
2015 24-h urine collection;
exclusion of samples
with Cr excretion levels
outside the normal
range of 0.133–
0.177 mmol/kg per day
for women and self-
reported as incomplete
23–64 106;
Sampled via an
occupational health
survey centre (random
cluster sampling),
spread over the
different Belgian
provinces
137 56 N/A 122 N/A
Belgium 2007–
2008
2 9 24-h urine
collection (1 month
interval);
completeness of urine
collection assessed by
PABA recovery (≥ 85%).
For samples with a
PABA recovery between
50% and 85%, urinary
Na excretion was
corrected (formula from
Johansson et al. (1999))
45–65 60 173(b) N/A 161–185 N/A N/A
Czech
Republic(c)
60 182(b) 56 173 P5-P95
101–288
Norway
(De Keyzer
et al., 2015)
62
Subsamples of the
European
EFCOVAL study;
subjects recruited by
convenience sampling
through advertisements
151(b) N/A 141–161 N/A N/A
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Country Year Methodology
Age
(years)
N and participants’
characteristics
Na excreted in urine (mmol/day)(a)
Mean SD 95% CI
Median
(P50)
IQR
(P25–P75)(d)
Croatia
(Premuzic
et al., 2010)
2009 24-h urine collection;
completeness check not
reported
46.3  7.3 N/A
(total sample of
93 men and women);
From two out-patient
clinics (one urban, one
rural); ‘salt-mapping
survey’
177 73 N/A N/A
Croatia
(Dika et al.,
2009)
2009 Morning spot urine
samples; 24-h Na
excretion was estimated
by applying Kawasaki,
INTERSALT and Tanaka
equations
N/A N/A (total sample of
1,669 men and
women);
Random sample (door-
to-door method) in the
continental rural part of
Croatia
Kawasaki:
214
78 N/A N/A
INTERSALT:
222
56 N/A N/A
Tanaka: 178 69 N/A N/A
Finland
(Laatikainen
et al., 2006)
2002 24-h urine collection;
exclusion of incomplete
samples with Cr
levels ≤ 5.0 mmol/day
or Cr levels ≤ 6.0 mmol/
day together with a
urine
volume < 1,000 mL
25–64 486
North Karelia, n = 174
Southwestern Finland,
n = 156
Helsinki area, n = 156
Sampled as part of the
national FINRISK 2002
study; 10-year age
group and sex-stratiﬁed
subsample of the
population aged 25–
64 years drawn in north
Karelia, southwestern
Finland and in the
Helsinki area
North Karelia:
128
Southwestern
Finland: 127
Helsinki area:
119
N/A North Karelia:
120–135
Southwestern
Finland: 119–135
Helsinki area:
111–127
N/A
Germany
(Johner et al.,
2015)
2008–
2011
Casual spot urine
samples; 24-h Na
excretion estimated
from the Na:Cr ratio by
multiplication with age-
18–79 3,622
18–29 years, n = 507
30–39 years, n = 403
40–49 years, n = 586
50–59 years, n = 630
N/A N/A Overall: 138–148
18–29 years:
116–136
30–39 years:
129–153
Overall: 143
18–29 years:
126
30–39 years:
139
Overall: 92–217
18–29 years:
85–184
30–39 years:
96–205
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Country Year Methodology
Age
(years)
N and participants’
characteristics
Na excreted in urine (mmol/day)(a)
Mean SD 95% CI
Median
(P50)
IQR
(P25–P75)(d)
and sex-stratiﬁed Cr
excretion reference
values (Remer et al.,
2002)
60–69 years, n = 671
70–79 years, n = 543
Random sample, as part
of the German National
Health Interview and
Examination Survey
2008–2011,
representative
for the German adult
population
40–49 years:
141–165
50–59 years:
146–167
60–69 years:
134–153
70–79 years:
127–144
40–49 years:
155
50–59 years:
156
60–69 years:
146
70–79 years:
134
40–49 years:
103–226
50–59 years:
96–235
60–69 years:
87–212
70–79 years:
90–223
Greece
(unpublished
data)
2013–
2014
For 7 days, the weight
and time of each void
were recorded and a
sample of urine was
collected. For each day,
a sample of 10 mL was
reconstituted from the
individual samples
based on the ratio of
the volume of each void
to the total volume of
urinary excretion for the
day. Exclusion of
samples on the basis of
Cr excretion
(> 3,500 mg/day or
< 350 mg/day)
20–60 83
Participants equally
divided in each decade
of life
130 48 N/A 124
Greece
(Vasara et al.,
2017)
2015–
2016
24-h urine collection;
exclusion of incomplete
samples on the basis of
(a) urinary
volume < 500 mL/24 h,
(b) urinary creatinine
less than 2 SD from the
18–75 138
Salt intake in northern
Greece (SING) Study –
regional study
conducted in
Thessaloniki greater
metropolitan area.
158.5 64.1 147.7–169.3 151.0
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Country Year Methodology
Age
(years)
N and participants’
characteristics
Na excreted in urine (mmol/day)(a)
Mean SD 95% CI
Median
(P50)
IQR
(P25–P75)(d)
mean, (c) timing of
collection outside the
range 23–25 h and (d)
self-reporting of
incomplete collection
Recruitment was carried
out at various sites and
venues including
churches and
workplaces
Hungary
(unpublished
data)
2010 24-h urine collection;
completeness of the
samples checked on the
basis of participants’
compliance with the
protocol
Adults (age
not
speciﬁed)
86
Random sample of the
Hungarian adult
population recruited
through primary care
physicians
163 71 N/A N/A
Ireland
(Morgan et al.,
2008)
2007 Spot urine samples;
daily Na excretion
estimated through
arithmetic extrapolation
(Na concentration
(mmol/L) multiplied by
1.67 for women)
≥ 18 611
Random sample of both
Irish citizens and non-
Irish national residents
sampled as part of the
Survey of Lifestyle,
Attitudes and Nutrition
(SLAN) 2007,
representative of the
general population in
Ireland
≥ 18 years:
128
45–64 years:
132
≥ 65 years:
116
≥ 18 years:
72
45–64
years: 75
≥ 65 years:
62
N/A N/A N/A
Ireland
(Kearney
et al., 2013)
2010–
2011
Morning urine samples;
daily Na excretion
estimated through
arithmetic extrapolation
(Na concentration
(mmol/L) multiplied by
1.67 for women)
45–74 1,029
Registered patients
attending the Living
Health Clinic of
Mitchelstown, Ireland,
sampled as part of the
Cork and Kerry Diabetes
and Heart Disease Study
Phase II
overall: 129
45–54: 138
55–64: 128
65–74: 125
overall: 64
45–54: 72
55–64: 61
65–74: 59
N/A N/A N/A
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Country Year Methodology
Age
(years)
N and participants’
characteristics
Na excreted in urine (mmol/day)(a)
Mean SD 95% CI
Median
(P50)
IQR
(P25–P75)(d)
Italy(e)
(Donfrancesco
et al., 2013;
Cappuccio
et al., 2015)
2009–
2012
24-h urine collection;
A sample if 24-h urine
volume < 500 mL or
creatinine content
referred to body
weight < mean minus
2 SD from the
population mean
35–79 1,900
Random samples of the
Italian adult population
from 20 Italian regions,
stratiﬁed by age and sex
(MINISAL-GIRCSI
Programme)
Overall: 142
35–44 years:
142
45–54 years:
147
55–64 years:
143
65–74 years:
140
75–79 years:
135
Overall: 57
35–44
years: 61
45–54
years: 58
55–64
years: 54
65–74
years: 55
75–79
years: 56
Overall: 139–145
35–44 years:
136–148
45–54 years:
141–152
55–64 years:
138–148
65–74 years:
135–145
75–79 years:
126–144
Overall: 136
35–44 years:
135
45–54 years:
141
55–64 years:
138
65–74 years:
132
75–79 years:
129
Slovenia (Ribic
et al., 2010)
2005 24-h urine collection;
exclusion of incomplete
samples with Cr
level < 120 lmol/kg bw
per day for men
(Osredkar, 1998)
25–65 82
Participants randomly
sampled from census
data from all regions,
representative of the
general population in
Slovenia
170 74 N/A N/A N/A
Spain (Ortega
et al., 2011)
2009 24-h urine collection;
completeness of the
samples assessed by
considering the
correlation between
urinary Cr and FFM of
each subject; FFM
estimated from 24-h Cr
excretion and result
compared with
measured FFM obtained
by electrical
bioimpedance method
(Lopez-Sobaler and
Quintas et al., 2006)
18–60 222
Selected as a
representative sample of
the Spanish young and
middle-aged adult
population (from 15
randomly selected
provinces; stratiﬁed by
age and sex)
143 66 N/A 131 97–178
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Country Year Methodology
Age
(years)
N and participants’
characteristics
Na excreted in urine (mmol/day)(a)
Mean SD 95% CI
Median
(P50)
IQR
(P25–P75)(d)
Switzerland
(Chappuis
et al., 2011)
2010–
2011
24-h urine collection;
exclusion of incomplete
samples on the basis of:
(1) urinary
volume < 300 mL/24 h,
(2) self-reporting of
incomplete collection, or
(3) Cr
level ≤ 0.082 mmol/kg
bw per day in women
≥ 15 742
Age- and sex- stratiﬁed
sample in various
cantons of Switzerland,
randomly selected. The
low participation rate
was compensated by
recruiting volunteers
Overall: 137
15–29 years:
135
30–44 years:
140
45–59 years:
144
≥ 60 years:
125
N/A N/A N/A N/A
Netherlands
(Hendriksen
et al., 2014)
2010 24-h urine collection;
exclusion of incomplete
samples on the basis of
(1) Cr excretion
≤ 5 mmol/day, or
≤ 6 mmol/day together
with a urine
volume < 1,000 mL or
(2) missing or
overcollection of more
than one urine void
19–70 180
Individuals participating
in an ongoing long-term
monitoring study on
chronic disease risk
factors (the Doetinchem
Cohort Study (DCS)) or
randomly drawn from
the municipal register of
Doetinchem (General
Doetinchem Population
Sample (GDPS))
128 43 N/A 122 96–154
Netherlands
(Hendriksen
et al., 2016)
2015 24-h urine collection;
Start and end time of
the urine collection were
recorded. Participants
had to report urine
losses
Based on this data, the
researchers determined
whether participants
had an incomplete urine
collection
19–70 154
Participants aged 50–70
recruited from an
ongoing long-term
monitoring study on
chronic disease risk
factors (the Doetinchem
Cohort Study (DCS));
Participants aged 19–49
randomly drawn from
the municipal register of
Doetinchem (General
Doetinchem Population
N/A N/A N/A Overall: 120
19–49 years:
122
50–70 years:
113
Overall: 93–146
19–49 years:
103–148
50–70 years:
85–140
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Country Year Methodology
Age
(years)
N and participants’
characteristics
Na excreted in urine (mmol/day)(a)
Mean SD 95% CI
Median
(P50)
IQR
(P25–P75)(d)
Sample (GDPS));
Exclusion of individuals
had participated in the
24-h urine test in 2006
and 2010 in the study
of Hendriksen et al.
(2014), kidney patients
and pregnant women
United
Kingdom
(Sadler et al.,
2011)
2011 24-h urine collection;
exclusion of samples on
the basis of PABA
recovery (< 70%
(incomplete) or > 104%
(unfeasibly high);
individuals who elected
not to take PABA, or did
not take all PABA
tablets, but recorded
they had completed a
24-h urine collection
were included if
recorded collection time
was collected between
23–25 h
19–64 297
Participants from the
England National Diet
and Nutrition Survey
sample and from a
‘sodium boost’ study;
stratiﬁed sample
randomly selected in
various regions of
England
19–34 years:
122
35–49 years:
116
50–64 years:
112
19–34
years: 55
35–49
years: 52
50–64
years: 59
N/A 19–34 years:
120
35–49 years:
104
50–64 years:
108
P2.5–P97.5
19–34 years:
47–261
35–49 years:
57–206
50–64 years:
44–218
bw: body weight; 95% CI: 95% conﬁdence interval; Cr: creatinine; EFCOVAL: European Food Consumption Validation; FFM: fat-free mass; IQR: interquartile range; N: number; Na: sodium; N/A:
not available; PABA: para-aminobenzoic acid, SD: standard deviation.
(a): For comparison purposes, results provided in g NaCl/day were converted back in mmol/day by multiplying by 0.4 and dividing by 23.
(b): Geometric means; based on two 24-h collection per subject.
(c): The values reported are unpublished data provided by the National Institute of Public Health of the Czech Republic.
(d): Unless indicated otherwise.
(e): The values reported are unpublished data provided by the Italian Instituto Superiore di Sanita.
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Appendix F – Balance studies
F.1. Evidence table
Study Subjects Conditions Duration Na intake (mean) Balance (mean  SD) Regulatory
hormones
Limitations
Data in adults
Holbrook
et al. (1984)
12 M/16 F
(20–53 years)
Free living 7 day 9 4
(1 week per
season)
All = 3.4 g (148 mmol)/day
M = 4.2 g (183 mmol)/day
F = 2.7 g (117 mmol)/day
All = +0.47  0.32 g
(+20  14 mmol)/day
M = +0.73  0.83 g
(+32  36 mmol)/day
F = +0.26  0.48 g
(11  21 mmol)/day
Not measured Dermal losses not
measured
Allsopp
(1997);
Allsopp et al.
(1998)
25 M
(18–40 years)
Controlled
25°C + 40°C
3 day + 5 day Low = 1.5 g (65 mmol)/day
Mod = 4 g (174 mmol)/day
High = 8 g (348 mmol)/day
On day 8
+0.04  0.35 g
+0.79  0.64 g
+0.67  1.19 g
Aldosterone ↑/↑
Aldosterone –/↑
Aldosterone –/–
–
Nishimuta
et al. (2012)
131 F
(18–26 years)
(13 studies)
Controlled 2–4 day +
8–12 day
2.5 g (107 mmol)-4.8 g
(209 mmol)/day
+6.07  4.06 mg/kg bw Not measured Sweat loss in ﬁve studies
only
Data in children
Palacios et al.
(2004)
36 adolescent girls
(14 W, 22 B;
12.4  0.3 years)
Semi-
controlled.
Summer
time
3 weeks 9 2
(crossover)
Low intake:
1.31 g/day
High intake:
3.95 g/day
Low intake:
+0.4  0.07 g/day among
blacks (n = 19)
+0.2  0.04 g/day among
whites (n = 12)
High intake:
+1.0  0.14 g/day among
blacks (n = 19)
+0.3  0.09 g/day among
whites (n = 10)
Aldosterone ↑
Aldosterone ↑
Aldosterone –
Aldosterone –
–
B: black; bw: body weight; F: female; M: male; Na: sodium; SD: standard deviation; W: white.
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F.2. Mechanistic data
Table F.1: Effect of sodium intake on blood catecholamines and aldosterone concentrations and renin activity – meta-analyses of trials of at least 4 weeks
Ref
Inclusion criteria Included studies
N
Pooled effect
(95% CI)Study type
Achieved
sodium
difference
between
experimental
groups
Intervention
duration
Participants Co-intervention
M
a
c
G
r
e
g
o
r
e
t
a
l
.
(
1
9
8
2
)
W
a
t
t
e
t
a
l
.
(
1
9
8
3
)
A
n
d
e
r
s
s
o
n
e
t
a
l
.
(
1
9
8
4
)
R
i
c
h
a
r
d
s
e
t
a
l
.
(
1
9
8
4
)
G
r
o
b
b
e
e
e
t
a
l
.
(
1
9
8
7
)
M
a
c
G
r
e
g
o
r
e
t
a
l
.
(
1
9
8
9
)
C
a
r
n
e
y
e
t
a
l
.
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.
(
2
0
0
9
)
H
e
e
t
a
l
.
(
2
0
1
3
)
RCTs
allocating to
a modestly
reduced salt
intake or
usual salt
intake
A reduction in
24-h urinary
sodium within
the range of
40–120 mmol
At least 4 weeks  Adults (≥ 18 years)
(trials in children
or pregnant
women excluded),
irrespective of
ethnicity
 With normal or
raised BP
Trials in patients
with other diseases
than hypertension
were excluded
Studies with
concomitant
interventions (i.e.
non-pharmacological
interventions,
antihypertensive or
other medications)
were excluded
RA X X X X X X X X X X X X X 13 0.26 (0.17,
0.36) ng/mL
per h
ALD X X X X X X X X 8 73.20 (44.92,
101.48) pmol/L
NOR X X X X X X 6 31.67 (6.57,
56.77) pg/mL
ADR X X X X 4 6.70 (0.25,
13.64) pg/mL
G
r
a
u
d
a
l
e
t
a
l
.
(
2
0
1
1
)
RCTs
allocating
subjects to
either a low
or a high
sodium diet
Any Any. Subgroup
analysis
restricted to
studies ≥ 4
weeks
 Any age,
irrespective of
ethnicity
 With normal or
raised BP
Trials in patients
with other diseases
than elevated
blood pressure
were excluded
Studies with
concomitant
interventions were
included if the
co-intervention was
identical during the
low and high sodium
diet
RA(a) ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 14 0.47 (0.35,
0.60)(b)
ALD X X X X X X X X X 9 0.70 (0.37,
1.04)(b)
NOR X X X X X X 6 0.06 (0.19,
0.32)(b)
ADR X X X X X 5 0.24 (0.04,
0.52)(b)
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Ref
Inclusion criteria Included studies
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Pooled effect
(95% CI)Study type
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.
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.
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)
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0
1
)
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.
(
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)
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)
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.
(
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)
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.
(
2
0
0
5
)
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r
e
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l
.
(
2
0
0
7
)
H
e
e
t
a
l
.
(
2
0
0
9
)
W
H
O
(
2
0
1
2
c
)
RCTs which
included an
intervention
that planned
to or
achieved a
reduced
sodium
intake
A reduction in
24-h urinary
sodium > 40
mmol/day
At least 4 weeks  Adults (≥16 years),
irrespective of
ethnicity
 With normal or
raised BP
 Trials in patients
with chronic
conditions (e.g.
overweight or
obesity, diabetes,
chronic
nephrolithiasis)
were included
Studies targeting
patients who
were acutely ill or
infected with HIV
were excluded
Studies with
concomitant
interventions (e.g.
physical activity,
medical treatment
(e.g. diuretics or
beta blockers)) were
included if the co-
intervention was
identical in the
intervention and
control groups
RA Not assessed
ALD Not assessed
NOR X X X X X X X 7 8.23 (27.84,
44.29) pg/mL
ADR X X X X 4 6.90 (2.17,
15.96) pg/mL
ADR: adrenaline; ALD: aldosterone; BP: blood pressure; NOR: noradrenaline; RA: renin activity; RCT: randomised controlled trial.
(a): Through their systematic review, Graudal et al. (2011) retrieved 15 trials lasting ≥ 4 weeks that reported on RA. However, the paper indicates that the pooled analysis for the subgroup of
studies lasting ≥ 4 weeks included 14 trials. The list of references included in the pooled analysis is not provided.
(b): Standardised mean difference, calculated for outcome measures with different units. The difference in effect between two treatments is divided by the standard deviation of the measurements.
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Table F.2: Results from long-term metabolic study from Rakova et al. (2013)
Refs Subjects Conditions
Duration – NaCl
target intake
Na intake
(g/day)
Na excretion(a)
(g/day)
Diff = Na
intake–UNa
(mean  SD)(b)
Regulatory hormones (in urine)
(mean  SD)(b)
Comment
Aldosterone
(lg/day)
Cortisol
(lg/day)
Cortisone
(lg/day)
Rakova
et al.
(2013)
Mars105(c)
4 men
Controlled
(18–25°C;
no rigorous
activities)
105 days, 3
periods:
35 day – 12 g NaCl
35 day – 9 g NaCl
29 day – 6 g NaCl
4.9 g/day
3.6 g/day
2.5 g/day
4.3  0.8 g/day
3.3  0.7 g/day
2.6  0.9 g/day
+0.5  0.9
+0.3  0.7
–0.1  0.9
12.0  4.8
13.5  4.7
15.3  5.5
24.8  10.1
21.6  8.4
18.8  6.6
83.8  21.9
73.3  20.5
72.3  21.1
Weekly and
monthly
rhythms of
body Na
accumulation
and release
correlated
with
ﬂuctuations in
aldosterone,
cortisol and
cortisone –
independent
of Na intake
Mars520(c)
6 men
As above 205 days, 4
periods:
61 day – 12 g NaCl
60 day – 9 g NaCl
60 day – 6 g NaCl
36 day – 12 g NaCl
4.5 g/day
3.3 g/day
2.2 g/day
4.4 g/day
4.2  0.8 g/day
2.9  0.8 g/day
1.9  0.6 g/day
4.1  1.0 g/day
0.2  0.9
0.4  0.9
0.3  0.8
0.3  1.1
11.4  4.8
13.5  4.4
15.4  5.3
9.2  3.6
24.0  7.2
20.1  5.0
17.4  5.4
22.8  7.4
76.3  16.3
63.7  16.4
68.7  18.9
71.7  19.2
Na: sodium; NaCl: sodium chloride; SD: standard deviation; UNa: sodium urinary excretion.
(a): Sweat and faecal losses not measured.
(b): Mean over the last 29 days of each period.
(c): The paper reports on two studies named Mars105 and Mars 520.
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Appendix G – Literature screening and RoB appraisal
G.1. Blood pressure, hypertension and CVD outcomes
G.1.1. PRISMA chart
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G.3. Criteria used to appraise RoB in eligible studies
G.3.1. Randomised controlled trials
Question Rating Explanation for expert judgement
1. Was administered
dose or exposure
level adequately
randomised?
Key question
++ There is direct evidence that subjects (or clusters) were allocated to any study group including controls using a method with a random
component. Acceptable methods of randomisation include: referring to a random number table, using a computer random number
generator, coin tossing, shufﬂing cards or envelopes, throwing dice, or drawing of lots (Higgins and Green, 2011). Restricted
randomisation (e.g. blocked randomisation) to ensure particular allocation ratios will be considered low risk of bias. Similarly, stratiﬁed
randomisation and minimisation approaches that attempt to minimise imbalance between groups on signiﬁcant prognostic factors (e.g.
body weight) will be considered acceptable
+ There is indirect evidence that subjects (or clusters) were allocated to study groups using a method with a random component (i.e.
authors state that allocation was random, without description of the method used)
OR
It is deemed that allocation without a clearly random component during the study would not appreciably bias results. For example,
approaches such as biased coin or urn randomisation, replacement randomisation, mixed randomisation, and maximal randomisation
may require consultation with a statistician to determine risk-of-bias rating (Higgins and Green, 2011)
NR There is insufﬁcient information provided about how subjects (or clusters) were allocated to study groups.
 There is indirect evidence that subjects (or clusters) were allocated to study groups using a method with a non-random component.
NOTE: Non-random allocation methods may be systematic, but have the potential to allow participants or researchers to anticipate the
allocation to study groups. Such ‘quasi-random’ methods include alternation, assignment based on date of birth, case record number, or
date of presentation to study
 – There is direct evidence that subjects (or clusters) were allocated to study groups using a non-random method including judgement of
the clinician, preference of the participant, the results of a laboratory test or a series of tests, or availability of the intervention (Higgins
and Green, 2011)
2. Was allocation to
study groups
adequately
concealed?
++ There is direct evidence that at the time of recruitment the research personnel and subjects did not know what study group subjects
were allocated to, and it is unlikely that they could have broken the blinding of allocation until after assignment was complete and
irrevocable. Acceptable methods used to ensure allocation concealment include central allocation (including telephone, web-based and
pharmacy-controlled randomisation); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque,
sealed envelopes; or equivalent methods
+ There is indirect evidence that the research personnel and subjects did not know what study group subjects were allocated to and it is
unlikely that they could have broken the blinding of allocation until after recruitment was complete and irrevocable
OR
It is deemed that lack of adequate allocation concealment would not appreciably bias results (e.g. some crossover designs)
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Question Rating Explanation for expert judgement
NR There is insufﬁcient information provided about allocation to study groups
 There is indirect evidence that at the time of recruitment it was possible for the research personnel and subjects to know what study
group subjects were allocated to, or it is likely that they could have broken the blinding of allocation before assignment was complete
and irrevocable
NOTE: Inadequate methods include using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes
used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered); alternation or
rotation; date of birth; case record number; or any other explicitly unconcealed procedure. For example, if the use of assignment
envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed
 – There is direct evidence that at the time of recruitment it was possible for the research personnel and subjects to know what study
group subjects were allocated to, or it is likely that they could have broken the blinding of allocation before recruitment was complete
and irrevocable
3. Were the research
personnel and
human subjects
blinded to the study
group during the
study?
++ There is direct evidence that the subjects and research personnel were adequately blinded to study group, AND it is unlikely that they
could have broken the blinding during the study. Methods used to ensure blinding include central allocation; sequentially numbered drug
containers of identical appearance; sequentially numbered, opaque, sealed envelopes; or equivalent methods
+ There is indirect evidence that the subjects and research personnel were adequately blinded to study group, AND it is unlikely that they
could have broken the blinding during the study
OR
There is direct evidence for no blinding during the study (including where it was not possible to implement) AND it is deemed that no
blinding would appreciably bias results BUT bias minimising measures have been adequately implemented
OR
It is deemed that lack of adequate blinding or no blinding during the study would not appreciably bias results (e.g. controls unlikely to
behave differently for factors other than sodium intake) (e.g. cross-over)
NR There is insufﬁcient information provided about blinding to study group during the study (including possible breaking and minimising
measures)
 There is indirect evidence that it was possible for research personnel or subjects to infer the study group AND it is deemed that lack of
adequate blinding or no blinding during the study would appreciably bias results (e.g. no comparable treatment of controls, including not
comparable exposure to factors other than the interventions of interest; differential behaviour) AND no bias minimising measures have
been adequately implemented
 – There is direct evidence for lack of adequate blinding of the study group (including no blinding or incomplete blinding) of research
personnel and subjects AND it is deemed that lack of adequate blinding or no blinding during the study would appreciably bias results
(e.g. no comparable treatment of controls, including not comparable exposure to factors other than the interventions of interest,
differential behaviour) AND no bias minimising measures have been adequately implemented
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4. Were outcome
data complete
without attrition or
exclusion from
analysis?
++ There is direct evidence that there was no loss of subjects during the study and outcome data were complete
OR
Loss of subjects (i.e. incomplete outcome data) was adequately addressed and reasons were documented when human subjects were
removed from a study or analyses. Review authors should be conﬁdent that the participants included in the analysis are exactly those
who were randomised into the trial. Acceptable handling of subject attrition includes: very few missing outcome data (e.g. less than 10%
in each group (Genaidy et al., 2007)) AND reasons for missing subjects unlikely to be related to outcome (for survival data, censoring
unlikely to be introducing bias) AND missing outcome data balanced in numbers across study groups, with similar reasons for missing
data across groups (i.e. unlikely to be related to exposure)
OR
Analyses (such as intention-to-treat analysis) in which missing data have been imputed using appropriate methods (ensuring that the
characteristics of subjects lost to follow up or with unavailable records are described in identical way and are not signiﬁcantly different
from those of the study participants)
NOTE: Participants randomised but subsequently found not to be eligible need not always be considered as having missing outcome
data) (Higgins and Green, 2011
+ There is indirect evidence that loss of subjects (i.e. incomplete outcome data) was adequately addressed and reasons were documented
when human subjects were removed from a study
OR
It is deemed that the proportion lost to follow-up would not appreciably bias results (e.g. less than 20% in each group in parallel studies
(Genaidy et al., 2007)). This would include reports of no statistical differences in characteristics of subjects lost to follow up or with
unavailable records from those of the study participants. Generally, the higher the ratio of participants with missing data to participants
with events, the greater potential there is for bias. For studies with a long duration of follow-up, some withdrawals for such reasons are
inevitable
NB: For crossover designs, this may be less of an issue
NR There is insufﬁcient information provided about numbers of subjects lost to follow-up
 There is indirect evidence that loss of subjects (i.e. incomplete outcome data) was unacceptably large (e.g. greater than 20% in each
group in parallel studies (Genaidy et al., 2007)) and not adequately addressed
 – There is direct evidence that loss of subjects (i.e. incomplete outcome data) was unacceptably large and not adequately addressed (e.g.
greater than 20% in each group in parallel studies (Genaidy et al., 2007)). Unacceptable handling of subject attrition includes: reason for
missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across study
groups (i.e. likely to be related to the exposure); or potentially inappropriate application of imputation
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Question Rating Explanation for expert judgement
5. Can we be
conﬁdent in the
exposure
characterisation?
Key question
++ There is direct evidence that the exposure (including compliance with the treatment, if applicable) was independently characterised AND
that exposure was consistently administered (i.e. with the same method and time-frame) across treatment groups
NOTE: applies to studies that collected single or multiple 24-h urine samples for each time point AND checked the completeness of the
samples (by any kind of method)
+ There is indirect evidence that the exposure (including compliance with the treatment, if applicable) was independently characterised
AND there is indirect evidence that exposure was consistently administered (i.e. with the same method and time-frame) across treatment
groups
NOTE: applies to studies that collected single or multiple 24-h urine samples without completeness check of the urine samples (or not
reported), but there is no evidence for concern
NR There is insufﬁcient information provided to judge the exposure characterisation
 There is indirect evidence that the exposure (including compliance with the treatment, if applicable) was assessed using poorly validated
methods (e.g. FFQs, spot urine etc.)
OR
There is indirect evidence that the exposure assessment was probably biased
NOTE: applies to studies for which 24-h urine samples were collected but there is indirect evidence that the proportion of incomplete
samples included in the analysis was substantial
 – There is direct evidence that the exposure (including compliance with the treatment, if applicable) was assessed using poorly validated
methods (e.g. FFQs, spot urine etc.)
OR
There is direct evidence that the exposure assessment was biased
NOTE: applies to studies for which 24 h urine samples were collected but there is direct evidence that the proportion of incomplete
samples included in the analysis was substantial
6. Can we be conﬁdent
in the outcome
assessment?
Key question
++ There is direct evidence that the outcome was assessed using well-established methods (e.g. for ofﬁce BP: according to a clearly
described methodology, including e.g. repeated measurements per visit, trained technician, resting period before each measurement)
AND
There is direct evidence that the outcome assessors were adequately blinded to the study group, and it is unlikely that they could have
broken the blinding prior to reporting outcomes
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+ There is indirect evidence that the outcome was assessed using acceptable methods (i.e. deemed valid and reliable but not the gold
standard) OR it is deemed that the outcome assessment methods used would not appreciably bias results
AND
There is indirect evidence that the outcome assessors were adequately blinded to the study group, and it is unlikely that they could have
broken the blinding before reporting outcomes OR it is deemed that lack of adequate blinding of outcome assessors would not
appreciably bias results
NR There is insufﬁcient information provided about blinding of outcome assessors or the method of measurement
 There is indirect evidence that the outcome assessment method is an unacceptable method
OR
There is indirect evidence that it was possible for outcome assessors to infer the study group before reporting outcomes
 – There is direct evidence that the outcome assessment method is an unacceptable method
OR
There is direct evidence for lack of adequate blinding of outcome assessors (including study subjects if home BP is the outcome),
including no blinding or incomplete blinding
7. Were all measured
outcomes reported?
++ There is direct evidence that all of the study’s measured outcomes (primary and secondary) outlined in the protocol, methods, abstract,
and/or introduction (that are relevant for the evaluation) have been reported
+ There is indirect evidence that all of the study’s measured outcomes (primary and secondary) outlined in the methods, abstract, and/or
introduction (that are relevant for the evaluation) have been reported
OR
Analyses that had not been planned in advance (i.e. retrospective unplanned subgroup analyses) are clearly indicated as such and it is
deemed that the unplanned analyses were appropriate and selective reporting would not appreciably bias results (e.g. appropriate analyses
of an unexpected effect). This would include outcomes reported with insufﬁcient detail such as only reporting that results were statistically
signiﬁcant (or not)
NR There is insufﬁcient information provided about selective outcome reporting
 There is indirect evidence that all of the study’s measured outcomes (primary and secondary) outlined in the methods, abstract, and/or
introduction (that are relevant for the evaluation) have not been reported
OR
There is indirect evidence that unplanned analyses were included that may appreciably bias result
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– – There is direct evidence that all of the study’s measured outcomes (primary and secondary) outlined in the methods, abstract, and/or
introduction (that are relevant for the evaluation) have not been reported. In addition to not reporting outcomes, this would include
reporting outcomes based on composite score without individual outcome components or outcomes reported using measurements,
analysis methods or subsets of the data (e.g. subscales) that were not pre-speciﬁed or reporting outcomes not pre-speciﬁed, or that
unplanned analyses were included that would appreciably bias results
8. Were there no
other potential
threats to internal
validity?
NOTE: Baseline
characteristics should be
appraised only if Q1
(randomisation) was
rated with ++/+ and Q2
(allocation concealment)
was rated with ++/+/
NR
++ There is evidence that variables, other than the exposure and outcome, did not differ between groups during the course of the
intervention in a way that could bias results
AND, in case randomisation is rated ‘probably low’/‘deﬁnitely low’ RoB and allocation concealment is rated ‘probably low’/‘deﬁnitely low’
RoB or ‘not reported’:
There is no evidence of differences in baseline characteristics
OR
There is no information on both BUT no concern
+ 1. There is evidence that variables, other than the exposure and outcome, differed between groups during the course of the intervention
AND it is deemed that these differences would not appreciably bias results (no concern or adequately addressed by analysis)
AND, in case randomisation is rated ‘probably low’/‘deﬁnitely low’ RoB and allocation concealment is rated ‘probably low’/‘deﬁnitely low’
RoB or ‘not reported’:
There is evidence that reported variables differed between groups at baseline
AND
It is deemed that these differences would not appreciably bias results (no concern or adequately addressed by analysis)
-------
OR
2. There is evidence that variables, other than the exposure and outcome, did not differ between groups during the course of the
intervention in a way that could bias results
AND, in case randomisation is rated ‘probably low’/‘deﬁnitely low’ RoB and allocation concealment is rated ‘probably low’/‘deﬁnitely low’
RoB or ‘not reported’:
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Question Rating Explanation for expert judgement
There is evidence that reported variables differed between groups at baseline.
AND
It is deemed that these differences would not appreciably bias results (no concern or adequately addressed by analysis).
------
OR
3. There is evidence that variables, other than the exposure and outcome, differed between groups during the course of the
intervention.ANDIt is deemed that these differences would not appreciably bias results (no concern or adequately addressed by analysis)
AND, in case randomisation is rated ‘probably low’/‘deﬁnitely low’ RoB and allocation concealment is rated ‘probably low’/‘deﬁnitely low’
RoB or ‘not reported’:
There is no evidence of differences in baseline characteristics.
OR
There is no information BUT no concern
 There is no information on baseline characteristics AND/OR there is no information about differences between groups during the course
of the intervention.
AND
There is concern
 – There is evidence that variables, other than the exposure and outcome, differed between groups during the course of the intervention.
AND
It is deemed that these differences appreciably biased results (there is concern (e.g. not adequately addressed by analysis))
OR, in case randomisation is rated ‘probably low’/‘deﬁnitely low’ RoB and allocation concealment is rated ‘probably low’/‘deﬁnitely low’
RoB or ‘not reported’:
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There is evidence that reported variables differed between groups at baseline.
AND
It is deemed that these differences appreciably biased results (there is concern (e.g. not adequately addressed by analysis))
++: Deﬁnitely low RoB; +: Probably low RoB; NR: Not Reported; –: Probably high RoB; – : Deﬁnitely high RoB.
G.3.2. Prospective observational studies
Question Rating Explanation for expert judgement
Did the study design
or analysis account
for important
confounding?
Key question
++ There is direct evidence that appropriate adjustments or explicit considerations were made for the potential confounders in the ﬁnal
analyses through the study design (e.g. matching, restriction) and/or through the use of statistical models to reduce research-speciﬁc
bias including standardisation, adjustment in multivariate model, stratiﬁcation, propensity scoring, or other methods that were
appropriately justiﬁed
NOTE: Acceptable consideration of appropriate adjustment factors includes cases when the factor is not included in the ﬁnal
adjustment model because: i) there was evidence indicating that a factor did not need to be included as a confounders (e.g. the
author conducted analyses that indicated it did not need to be included; study restricted to males only) OR ii) it is deemed that not
considering the factor would not bias the result
AND
There is direct evidence that confounders were assessed using reliable methods
+ There is indirect evidence that appropriate adjustments were made, OR it is deemed that not considering or only considering a partial
list confounders in the ﬁnal analyses would not substantially bias results
AND
There is evidence (direct or indirect) that confounders were assessed using reliable methods, OR it is deemed that the methods used
would not appreciably bias results (i.e., the authors justiﬁed the validity of the methods from previously published research)
NR There is insufﬁcient information provided about the distribution of potential confounders (record ‘NR’ as basis for answer)
OR
There is insufﬁcient information provided about the methods used to assess confounders (record ‘NR’ as basis for answer)
 There is indirect evidence that the distribution of potential confounders differed between the groups and was not appropriately
adjusted for in the ﬁnal analyses
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 – There is direct evidence that the distribution of confounders differed between the groups, confounding occurred but was not adjusted
for in the ﬁnal analyses
OR
There is direct evidence that confounders were assessed using non-reliable methods
2. Were outcome
data complete
without attrition or
exclusion from
analysis?
++ There is direct evidence that loss of subjects (i.e. incomplete outcome data) was adequately addressed and reasons were documented
when human subjects were lost or removed from a study
NOTE: Acceptable handling of subject attrition includes: very few missing outcome data AND reasons for missing subjects unlikely to
be related to outcome (for survival data, censoring unlikely to be introducing bias) AND missing outcome data balanced in numbers
across study groups, with similar reasons for missing data across groups (i.e. unlikely to be related to exposure)
+ There is indirect evidence that loss of subjects (i.e. incomplete outcome data) was adequately addressed and reasons were
documented when human subjects were removed from a study
OR
It is deemed that the proportion lost to follow-up would not appreciably bias results, due to the similarity between the characteristics
of subjects lost to follow-up and study participants. Generally, the higher the ratio of participants with missing data to participants with
events, the greater potential there is for bias. For studies with a long duration of follow-up, some withdrawals for such reasons are
inevitable
 There is indirect evidence that loss of subjects (i.e. incomplete outcome data) was unacceptably large and not adequately addressed
 – There is direct evidence that loss of subjects (i.e. incomplete outcome data) was unacceptably large and not adequately addressed.
Unacceptable handling of subject attrition includes: reason for missing outcome data likely to be related to true outcome, with either
imbalance in numbers or reasons for missing data across study groups (i.e. likely to be related to the exposure)
3. Can we be
conﬁdent in the
exposure
characterisation?
Key question
++ Sodium intake was assessed through multiple 24-h urinary collection (in a ‘reasonably short time-frame’)
AND
There is direct evidence that quality assurance measures were in place for the collection of 24-h urine (e.g. ﬁrst and last void at the
clinic; careful instructions of the participants) OR incomplete collections were excluded on the basis of any method (e.g. PABA,
creatinine, self-reported, volume. . .)
+ Sodium intake was assessed through a single 24-h urinary collection
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AND
There is direct evidence that quality assurance measures were in place for the collection of 24-h urine (e.g. ﬁrst and last void at the
clinic; careful instructions of the participants) OR incomplete collections were excluded on the basis of any method (e.g. PABA,
creatinine, self-reported, volume. . .)
NR There is insufﬁcient information provided about the method of exposure assessment
– There is indirect evidence that the exposure (including compliance with the treatment, if applicable) was assessed using poorly
validated methods (e.g. FFQs, spot urine etc.)
OR
There is no evidence that quality assurance measures were in place for the collection of 24-h urine (single or multiple) AND no
measures were taken to exclude incomplete samples
 – There is direct evidence that the exposure (including compliance with the treatment, if applicable) was assessed using poorly validated
methods (e.g. FFQs, spot urine etc.)
OR
There is direct evidence for systematic error in the exposure characterisation (exposure misclassiﬁcation)
4. Can we be
conﬁdent in the
outcome
assessment?
Key question
++ There is direct evidence that the outcome was assessed using well-established methods
+ There is indirect evidence that the outcome was assessed using acceptable methods (i.e. deemed valid and reliable but not the gold
standard)
OR
It is deemed that the outcome assessment methods used would not appreciably bias results
NR There is insufﬁcient information provided about the method of measurement
– There is indirect evidence that the outcome assessment method is an unacceptable method
 – There is direct evidence that the outcome assessment method is an unacceptable method
5. Were all measured
outcomes reported?
++ There is direct evidence that all of the study’s measured outcomes (primary and secondary) outlined in the protocol, methods,
abstract, and/or introduction (that are relevant for the evaluation) have been reported. This would include outcomes reported with
sufﬁcient detail to be included in meta-analysis or fully tabulated during data extraction and analyses had been planned in advance
+ There is indirect evidence that all of the study’s measured outcomes (primary and secondary) outlined in the methods, abstract, and/or
introduction (that are relevant for the evaluation) have been reported
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OR
Analyses that had not been planned in advance (i.e. retrospective unplanned subgroup analyses) are clearly indicated as such and it is
deemed that the unplanned analyses were appropriate and selective reporting would not appreciably bias results (e.g. appropriate
analyses of an unexpected effect). This would include outcomes reported with insufﬁcient detail such as only reporting that results
were statistically signiﬁcant (or not)
NR There is insufﬁcient information provided about selective outcome reporting
– There is indirect evidence that all of the study’s measured outcomes (primary and secondary) outlined in the methods, abstract, and/or
introduction (that are relevant for the evaluation) have been reported
OR
There is indirect evidence that unplanned analyses were included that may appreciably bias results
 – There is direct evidence that all of the study’s measured outcomes (primary and secondary) outlined in the methods, abstract, and/or
introduction (that are relevant for the evaluation) have not been reported. In addition to not reporting outcomes, this would include
reporting outcomes based on composite score without individual outcome components or outcomes reported using measurements,
analysis methods or subsets of the data (e.g. subscales) that were not pre-speciﬁed or reporting outcomes not pre-speciﬁed, or that
unplanned analyses were included that would appreciably bias results
6. Were the
statistical methods
applied appropriate?
++ There is direct evidence that the statistical analysis was appropriate
+ There is indirect evidence that the statistical analysis was appropriate
NR There is insufﬁcient information provided about the statistical analysis
– There is indirect evidence that the statistical analysis was not appropriate
 – There is direct evidence that the statistical analysis was not appropriate
++: Deﬁnitely low RoB; +: Probably low RoB; NR: Not Reported; –: probably high RoB; – : Deﬁnitely high RoB.
G.3.3. Algorithm applied to allocate studies to the three tiers of RoB
The judgements to the RoB questions were combined into an overall RoB judgement for each individual study (by outcome). As a result, studies were
classiﬁed as being at low (tier 1), moderate (tier 2) or high (tier 3) RoB. Following the OHAT/NTP guidance (OHAT/NTP, 2015), key questions were identiﬁed
for each type of design (see Table below) and the following algorithm was applied to allocate the studies to the tiers:
Tier 1: study rated as ‘deﬁnitely low’ or ‘probably low’ risk of bias for the key questions AND most other applicable questions answered ‘deﬁnitely low’ or
‘probably low’ risk of bias.
Tier 2: study met neither the criteria for tiers.
Tier 3: study rated as ‘deﬁnitely high’ or ‘probably high’ risk of bias for the key questions AND most other applicable questions answered ‘deﬁnitely high’
or ‘probably high’ risk of bias.
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Bias Domains and Questions RCT Prospective observational
Selection Bias
Was administered dose or exposure level adequately randomised? X*
Was allocation to study groups adequately concealed? X
Confounding Bias
Did the study design or analysis account for important confounding? X*
Performance Bias
Were the research personnel and human subjects blinded to the study group during the study? X
Attrition/Exclusion Bias
Were outcome data complete without attrition or exclusion from analysis? X X
Detection Bias
Can we be conﬁdent in the exposure characterisation? X* X*
Can we be conﬁdent in the outcome assessment? X* X*
Selective Reporting Bias
Were all measured outcomes reported? X X
Other Sources of Bias
Were there no other potential threats to internal validity? X
Were the statistical methods applied appropriate? X
*: Key question.
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Appendix H – Outcome of the systematic review on blood pressure levels in children
H.1. Evidence tables
Experimental studies
References
(country)
Design Subject characteristics at baseline
UNa
(mmol/24 h)
BP measurement
SBP/DBP
(mm Hg)
He et al. (2015)
(China)
School-EduSalt
Study design: cluster-randomised
Run-in type: none
Intervention type: counselling
N participants randomised/completed: 279/274
Duration: 14 weeks
% boys
G1: 47.5
G2: 48.6
Age (mean ± SD, years)
G1: 10.0  0.5
G2: 10.2  0.5
BMI (mean ± SD, kg/m2)
G1: 17.1  3.2
G2: 16.7  2.7
Ethnicity: NR
BP status: NR
24-h UK (mean ± SE, mmol)
G1: 23.5  0.9
G2: 25.4  0.9
Energy intake: NR
Type: multiple 24 h
Mean  SE
Beginning of intervention
G1: 124.2  5.1
G2: 116.7  5.2
End of intervention
G1: 112.2  5.1
G2: 137.2  5.2
Type: point ofﬁce, sitting
Mean  SE
Beginning of intervention
G1: 106.2  1/67.0  1.1
G2: 106.2  1/66.8  1.1
End of intervention
G1: 110  1/69.4  1.1
G2: 110.6  1/70.2  1.1
Miller et al. (1988)
(USA)
Study design: parallel
Run-in type: low sodium diet
Intervention type: feeding
N participants randomised/ completed: 88/NR
Duration: 4 weeks
% boys: NR
Age (years): NR
BP status: NT
Ethnicity: NR
24-h UK (mean, mmol)
G1: 35.3
G2: 36.7
Energy intake: NR
Type: multiple 24 h
Mean
Beginning of intervention
NR
End of intervention
G1: 44.4
G2: 72.1
Type: point ofﬁce, sitting
Mean
Beginning of intervention
NR
End of intervention
G1: 91.7/53.0
G2: 92/52.9
BMI: body mass index; BP: blood pressure; DBP; diastolic blood pressure; G1: group 1 (‘low’ sodium); G2: group 2 (‘high’ sodium); mm Hg: millimetre of mercury; N: number; UNa: sodium urinary
excretion; NR: not reported; NT: normotensive; SBP: systolic blood pressure; SD: standard deviation; SE: standard error; UK: potassium urinary excretion.
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Observational studies
References
(country)
Design
Baseline
characteristics
Na intake
assessment
method
UNa (mmol/24
h)
Outcomes
assessed
Confounders
adjusted for
Results
Shi et al.
(2014)
(Germany)
DONALD
Prospective cohort
N = 1,107 DONALD initial
cohort
N = 435 included in the
analyses (included: at
least 3 BP measurements
with three parallel 24-h
UNa and 3-day weighed
dietary records; excluded:
preterm children, birth
weight and breast-feeding
data missing; taking BP-
lowering treatment;
implausible SBP/DBP
values)
Mean duration: 10 years
Male (%)
51.0
Age (median
(p25–p75), years)
b 6 (4–8)
g 6 (4–7)
BMI (median
(p25–p75), kg/m2)
b 15.7 (15.0–16.8)
g 15.3 (14.7–16.4)
SBP (median
(p25–p75), mm Hg)
b 97.1 (90.8–104.0)
g 97.0 (90.0–102.0)
DBP (median
(p25–p75), mm Hg)
b 57.0 (50.0–65.0)
g 55.0 (49.6–64.1)
24-h UK (median
(p25–p75), mmol)
b 39.1 (29.7–47.8)
g 32.4 (26.2–38.9)
24-h UK UCr
(median (p25–p75),
mmol/kg bw)
b 0.16 (0.14–0.18)
g 0.15 (0.13–0.17)
Energy intake
(median (p25–p75),
MJ/day)
b 6.1 (5.3–7.2)
g 5.3 (4.8–6.3)
Single 24-h urine
sample at yearly
intervals
Median (p25–p75)
First assessment
b 67.4 (50.6–89.9)
g 58.7 (45.9–74.5)
Last assessment
b 131.0 (96.9–
176.0)
g 108.0 (81.7–
133.0)
Longitudinal
change in SBP
and DBP
BP measured
every 2 years
(2 BP readings
averaged at
each visit)
Age, age 2, age 3,
sex, pubertal group,
intraindividual change
in Na
excretion 9 pubertal
group, person-speciﬁc
mean-Na excretion 9
pubertal group, TEI,
TEI 9 pubertal group,
BMI-SDS, height-SDS,
birth weight, full
breast-feeding status,
maternal SBP, FVI,
FVI 9 pubertal group
Change in SBP (mm Hg)/
1 mmol/MJ increase in Na
excretion (b (95% CI)):
Prepubertal group
Between person effect
0.2 (0.4, 0.04) p = 0.1
Within person effect
0.03 (0.2, 0.09)
p = 0.6
Pubertal group
Between person effect
0.1 (0.1, 0.4) p = 0.3
Within person effect
0.1 (0.004, 0.2)
p = 0.06
Age, age 2, age 3,
sex, pubertal group,
intraindividual change
in Na excretion 9
pubertal group,
person-speciﬁc mean-
Na excretion 9
pubertal group, TEI,
TEI 9 pubertal group,
BMI-SDS, height-SDS,
growth velocity, full
breast-feeding status,
maternal SBP, FVI,
FVI 9 pubertal group
and Ca intake
Change in DBP (mm Hg)/
1 mmol/MJ increase in Na
excretion (b (95% CI)):
Prepubertal group
Between person effect
0.1 (0.4,0.07) p = 0.2
Within person effect
0.1 (0.2, 0.03) p = 0.1
Pubertal group
Between person effect
0.2 (0.4, 0.04) p = 0.1
Within person effect
0.1 (0.02, 0.2)
p = 0.09
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References
(country)
Design
Baseline
characteristics
Na intake
assessment
method
UNa (mmol/24
h)
Outcomes
assessed
Confounders
adjusted for
Results
Krupp et al.
(2015)
(Germany)
DONALD
Prospective cohort
N = NR
N = 206 included in the
analyses (‘included:
reached adult age, had a
BP measurement and
assessed in parallel
anthropometrical data
between 18 and
25 years, had ≥ 3 parallel
plausible dietary records
24 h UNa and ≥ 3 BP
measurements during
adolescence
(11–16 years); excluded:
preterm, missing data on
birth weight and
gestational age,
implausible BP data)
Mean duration: 7 years
Male (%)
52.0
Age (median
(p25–p75), years)
b 12.4 (12.1–13.0)
g 12.3 (12.0–13.0)
BMI (mean (SD),
kg/m2)
b 18.9 (2.3)
g 18.7 (2.7)
SBP (mean (SD),
mm Hg)
b 104 (7)
g 103 (8)
DBP (mean (SD),
mm Hg)
b 62 (6)
g 61 (6)
24-h UK (mean
(SD), mmol)
b 56 (14)
g 51 (13)
24-h UK UCr (mean
(SD), mmol/kg bw)
b 0.18 (0.02)
g 0.17 (0.02)
Energy intake
(mean (SD),
MJ/day)
b 9.1 (1.5)
g 7.9 (0.9)
Single 24-h urine
sample at yearly
intervals
Samples with
UCr < 0.1 mmol/
kg BW excluded
from the analysis
NaCl (mean (SD))
b 116 (27)
g 105 (32)
calculated as (Na
(mmol/day) + Cl
(mmol/day))/2
Longitudinal
change in SBP
and DBP
BP measured
every 2 years
(2 blood
pressure
readings
averaged at
each
examination)
Mean pubertal SBP
SDS, adult age,
standardised energy
intake, intake of
saturated fat, height-
SDS, maternal
education, maternal
BP, FVI, adult BMI
Change in SBP (mm Hg)/
1 mmol increase in NaCl
excretion (ß (95% CI)):
b 0.1 (0.03, 0.18)
p = 0.01
g -0.05 (0.11, 0.02)
p = 0.1
Mean pubertal SBP
SDS, adult age,
standardised energy
intake, calcium intake,
birth weight, smoking
in the household,
maternal BP, FVI, adult
BMI
Change in DBP (mm Hg)/
1 mmol increase in NaCl
excretion (ß (95% CI)):
b 0.02 (0.08, 0.04)
p = 0.6
g 0.02 (0.03, 0.08)
p = 0.4
b: boys; BMI: body mass index; BP: blood pressure; bw: body weight; 95% CI: 95% conﬁdence interval; Cl: chloride; DBP: diastolic blood pressure; DONALD: Dortmund Nutritional and
Anthropometrical Longitudinally Designed study FVI: fruit and vegetable intake; g: girls; MJ: megajoule; mm Hg: millimetre of mercury; mmol: millimole; N: number; Na: sodium; NR: not reported;
SBP: systolic blood pressure; SD: standard deviation; SDS: standard deviation score; TEI: total energy intake; UCr: creatinine urinary excretion; UK: potassium urinary excretion; UNa: sodium
urinary excretion.
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H.2. Outcome of the RoB appraisal
Experimental studies
References
Risk of bias domains(a)
Tier(b)
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Miller et al. (1988) + NR  + ++ + + + 1
He et al. (2015) ++ ++ + ++ ++  ++ + 2
(a): Expert judgement was translated into a rating scale for each question to be answered as follows: (++): deﬁnitely low RoB;
(+): probably low RoB; (NR): not reported; (): probably high RoB; (): deﬁnitively high RoB.
(b): The individual rating for each question was combined by an algorithm and translated to an overall tier of reliability for each
individual study (RoB tier 1: low RoB; RoB tier 2: moderate RoB; RoB tier 3: high RoB).
Observational studies
References
Risk of bias domains(a)
Tier(b)
Confounding Attrition Exposure Outcome Reporting Statistics
Krupp et al.
(2015)
++  + ++ ++ ++ 1
Shi et al.
(2014)
++ + + ++ ++ + 1
(a): Expert judgement was translated into a rating scale for each question to be answered as follows: (++): deﬁnitely low RoB;
(+): probably low RoB; (NR): not reported; (): probably high RoB; (): deﬁnitively high RoB.
(b): The individual rating for each question was combined by an algorithm and translated to an overall tier of reliability for each
individual study (RoB tier 1: low RoB; RoB tier 2: moderate RoB; RoB tier 3: high RoB).
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Appendix I – Outcome of the systematic review on blood pressure levels in adults
I.1. Evidence tables
I.1.1. Experimental studies
References
(country)
Design
Subject characteristics at
baseline
UNa
(mmol/24 h)
BP measurement
SBP/DBP
(mm Hg)
Alli et al. (1992)
(Italy)
Study design: cluster-randomised
Run-in type: normal diet
Intervention type: counselling
N participants randomised/completed:
77/56
Duration: 12 months
% men
G1: 35
G2: 50
Age (mean ± SD, years)
G1: 44.3  10.2
G2: 51.7  11
BMI (mean ± SD, kg/m2)
G1: 25  2.5
G2: 24.8  2.8
Ethnicity: NR
BP status: HT
24-h UK (mean ± SD, mmol)
G1: 61.2  18.1
G2: 59.8  16.5
Energy intake: NR
Type: single 24 h
Mean  SD
Beginning of intervention
G1: 178.7  60.5
G2: 168.8  65
End of intervention
G1: 186.5  73
G2: 163.4  60.7
Type: point ofﬁce, supine
Mean  SD
Beginning of intervention
G1: 148.5  13.5/96.2  4.4
G2: 148.2  10.6/97.9  4.9
End of intervention
G1: 144.4  8.1/90.6  8.2
G2: 146.6  15.1/94.5  5.3
ANHMRCDS (1986)
(Australia)
Study design: parallel
Run-in type: normal diet
Intervention type: counselling
N participants randomised/completed:
107/100
Duration: 12 weeks
% men
G1: 83
G2: 89
Age (mean ± SE, years)
G1: 52.3  0.8
G2: 52.3  0.8
BP status: mixed
Ethnicity: NR
24-h UK (mean, mmol)
G1: 66
G2: 71
Energy intake: NR
Type: single 24 h
Mean  SE
Beginning of intervention
G1: 142
G2: 157
End of intervention
G1: 85.8  7.1
G2: 155.6  8.3
Type: point ofﬁce, sitting
Mean
Beginning of intervention
G1: 150/95
G2: 149/95
End of intervention
G1: 144/89
G2: 148/93
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References
(country)
Design
Subject characteristics at
baseline
UNa
(mmol/24 h)
BP measurement
SBP/DBP
(mm Hg)
ANHMRCDS (1989)
(Australia)
Australian National
Health h Medical
Research Council
Dietary Salt Study
Study design: parallel
Run-in type: normal diet
Intervention type: feeding
N participants randomised/completed:
111/108
Duration: 8 weeks
% men
G1: 80
G2: 87
Age (years)
G1: 18 +
G2: 18 +
Ethnicity: NR
BP status: HT
24-h UK (mean ± SE, mmol)
G1: 73  3
G2: 74  3
Energy intake: NR
Type: single 24 h
Mean  SE
Beginning of intervention
G1: 142  6
G2: 134  6
End of intervention
G1: 90  6
G2: 153  6
Type: point ofﬁce, sitting
Mean  SE
Beginning of intervention
G1: 155.2  2.2/95.1  0.6
G2: 152.8  2.1/95.4  0.6
End of intervention
G1: 149.1  1.9/91.4  0.7
G2: 152.2  1.9/94.6  0.9
Benetos et al.
(1992)
(France)
Study design: cross-over
Wash out: 1 week
Intervention type: feeding
N participants randomised/completed:
22/20
Duration: 4 weeks
% men: 45
Age (mean ± SE, years):
41.5 ± 2.4
Ethnicity: NR
BP status: HT
24-h UK (mean ± SE, mmol):
70  3
Energy intake: NR
Type: single 24 h
Mean  SE
Beginning of intervention
173  13
End of intervention
G1: 85  9.6
G2: 163  13.3
Type: point ofﬁce, supine
Mean  SE
Beginning of intervention
154  2.2/96.1  1.5
End of intervention
G1: 142.6  2.6/89.5  1.5
G2: 149.1  2.3/93.2  1.3
Cappuccio et al.
(1997)
(United Kingdom)
Study design: cross-over
Wash out: none
Run-in type: low sodium diet
Intervention type: feeding
N participants randomised/completed:
48/47
Duration: 4 weeks
% men: 51
Age (mean ± SD, years):
66.8  5.3
Ethnicity: mixed
BP status: mixed
24-h UK (mean ± SD, mmol):
66  20
Energy intake: NR
Type: multiple 24 h
Mean  SD
Beginning of intervention
72  40
End of intervention
G1: 94  50
G2: 177  49
Type: point ofﬁce, supine
Mean  SD
Beginning of intervention
154.9  20.4/87.1  9.5
End of intervention
G1: 155.9  21.6/86.9  8.8
G2: 163.2  20.6/90.1  10.5
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References
(country)
Design
Subject characteristics at
baseline
UNa
(mmol/24 h)
BP measurement
SBP/DBP
(mm Hg)
Cobiac et al. (1992)
(Australia)
Study design: parallel
Run-in type: low sodium diet + sodium
tablets
Intervention type: feeding
N participants randomised/completed:
57/54
Duration: 4 weeks
% men
G1: 69
G2: 64
Age (mean ± SE, years)
G1: 67  1
G2: 67  1
BMI (mean ± SE, kg/m2)
G1: 25  1
G2: 25  1
Ethnicity: NR
BP status: mixed
24-h UK (mean ± SE, mmol)
G1: 74  4
G2: 68  6
Energy intake: NR
Type: single 24 h
Mean  SE
Beginning of intervention
G1: 166  10
G2: 166  9
End of intervention
G1: 79  7
G2: 152  10
Type: point ofﬁce, sitting
Mean  SE
Beginning of intervention
G1: 132  2/77  2
G2: 135  3/78  2
End of intervention
G1: 127.8/77.1
G2: 132.5/77.3
Dickinson et al.
(2014)
(Australia)
Study design: cross-over
Wash out: none
Intervention type: feeding
N participants randomised/completed:
50/25
Duration: 6 weeks
% men: 32
Age (years): 18+
BMI (range, kg/m2) : 27–40
Ethnicity: NR
BP status: NT
24-h UK (mean ± SD, mmol):
76  23
Energy intake (mean ± SD, MJ/d):
9.1  2.5
Type: multiple 24 h
Mean  SD
Beginning of intervention
154  58
End of intervention
G1: 113  45
G2: 155  58
Type: point ofﬁce, sitting
Mean  SD
Beginning of intervention
120  13/77  7
End of intervention
G1: 115  10/73  6
G2: 118  16/74  8
Erwteman et al.
(1984)
(Netherlands)
Study design: Parallel
Intervention type: counselling
N participants randomised/completed:
107/94
Duration: 4 weeks
% men
G1: 61
G2: 62
Age (mean ± SD, years)
G1: 45  11
G2: 46.5  9.5
Ethnicity: mixed
BP status: HT
Energy intake: NR
Type: multiple 24 h
mean  SD
Beginning of intervention
NR
End of intervention
G1: 72  31
G2: 130  50
Type: point ofﬁce, supine
Mean  SD
Beginning of intervention
G1: 157  11.4/101.5  5.4
G2: 156.2  11.8/100.5  3.4
End of intervention
G1: 141  15.4/92.9  10.4
G2: 142.9  16.4/94.4  12.0
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References
(country)
Design
Subject characteristics at
baseline
UNa
(mmol/24 h)
BP measurement
SBP/DBP
(mm Hg)
Fotherby and Potter
(1993)
(United Kingdom)
Study design: cross-over
Wash out: none
Run-in type: low sodium diet
Intervention type: feeding
N participants randomised/completed:
18/17
Duration: 5 weeks
% men: 22
Age (mean (range), years):
73 (66–79)
Ethnicity: Caucasian
BP status: HT
24-h UK (mean ± SD, mmol):
66  25
Energy intake: NR
Type: multiple 24 h
Mean  SD
Beginning of intervention
104  59
End of intervention
G1: 95  36
G2: 174  40
Type: point ofﬁce, supine
Mean 
Beginning of intervention
176  17/96  11
End of intervention
G1: 171  21/96  8
G2: 179  18/96  11
Gates et al. (2004)
(USA)
Study design: cross-over
Wash out: none
Intervention type: feeding
N participants randomised/completed:
12/12
Duration: 4 weeks
% men: 50
Age (mean ± SE, years): 63  1
BMI (mean ± SE, kg/m2): 25.1  1
Ethnicity: Caucasian
BP status: HT
24-h UK (mean ± SE, mmol):
72  8
Energy intake (mean ± SE, MJ/d):
9.4  0.7
Type: single 24 h
Mean  SE
Beginning of intervention
134.5  13.4
End of intervention
G1: 60.5  6.8
G2: 150.1  17.9
Type: point ofﬁce, supine
Mean  SE
Beginning of intervention
148.1  2.3/84.0  2.4
End of intervention
G1: 137.1  2.8/79.0  2.1
G2: 144.2  3.7/79.9  2.0
Gijsbers et al.
(2015)
(Netherlands)
Study design: cross-over
Wash out: none
Run-in type: low sodium diet
Intervention type: feeding
N participants randomised/completed:
37/36
Duration: 4 weeks
% men: 67
Age (mean (range), years): 65.8
(40–80)
BMI (mean, kg/m2): 27.2
Ethnicity: Caucasian
BP status: mixed
24-h UK (mean, mmol): 81.8
Energy intake (mean, kcal/d): 2,774
Type: single 24 h
mean  SD
Beginning of intervention
90.8
End of intervention
G1: 105.1  39.7
G2: 202.9  54.8
Type: point ofﬁce, supine
Mean  SD
Beginning of intervention
133.4/75.7
End of intervention
G1: 125.1  15/72.3  7.7
G2: 132.9  17.6/75.7  7.5
Grobbee et al.
(1987)
(Netherlands)
Study design: cross-over
Wash out: none
Run-in type: normal diet
Intervention type: feeding
N participants randomised/completed:
42/40
Duration: 6 weeks
% men: 85
Age (mean ± SD, years): 24  3
Ethnicity: NR
BP status: HT
24-h UK (mean ± SD, mmol):
71  22
Energy intake: NR
Type: multiple 24 h
mean  SE
Beginning of intervention
141  7
End of intervention
G1: 57  4
G2: 129  5
Type: point ofﬁce, supine
Mean  SE
Beginning of intervention
143  2.2/78  1.6
End of intervention
G1: 135.9  1.8/73.7  1.5
G2: 136.8  1.8/73.5  1.8
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References
(country)
Design
Subject characteristics at
baseline
UNa
(mmol/24 h)
BP measurement
SBP/DBP
(mm Hg)
He et al. (2009)
(United Kingdom)
Study design: cross-over
Wash out: none
Run-in type: low sodium diet
Intervention type: feeding
N participants randomised/completed:
185/169
Duration: 6 weeks
% men: 67
Age (mean ± SD, years): 50  11
BMI (mean ± SD, kg/m2) : 29  5
Ethnicity: mixed
BP status: HT
24-h UK (mean ± SD, mmol):
77  26
Energy intake: NR
Type: multiple 24 h
Mean  SD
Beginning of intervention
NR
End of intervention
G1: 110  49
G2: 165  58
Type: point ofﬁce, sitting
Mean  SD
Beginning of intervention
NR
End of intervention
G1: 141  12/88  9
G2: 146  13/91  8
Jablonski et al.
(2013)
(USA)
Study design: cross-over
Wash out: none
Intervention type: feeding
N participants randomised/completed:
11/11
Duration: 5 weeks
% men: 73
Age (mean ± SE, years): 60  2
BMI (mean ± SE, kg/m2):
27.2  1.3
Ethnicity: mixed
BP status: mixed
Energy intake: NR
Type: multiple 24 h
Mean  SE
Beginning of intervention
159  13
End of intervention
G1: 77  9
G2: 144  7
Type: point ofﬁce, supine
mean  SE
Beginning of intervention
139  2/83  2
End of intervention
G1: 127  3/77  2
G2: 138  5/81  2
Kumanyika et al.
(2005)
(USA)
TOHP II
Study design: parallel
Intervention type: counselling
N participants randomised/completed:
1159/1159
Duration: 36 months
% men
G1: 65
G2: 68
Age (mean ± SD, years)
G1: 44.2  6.1
G2: 43.2  6.1
BMI (range, kg/m2)
24.4–37.4
Ethnicity: mixed
BP status: NT
24-h UK (mean ± SD, mmol)
G1: 66.8  28.1
G2: 65.3  26.6
Energy intake: NR
Type: multiple 24 h
Mean  SD
Beginning of intervention
G1: 186.1  80.7
G2: 188.0  80.9
End of intervention
G1: 50.9  86.3
G2: 10.5  88.5
Type: point ofﬁce, sitting
Mean  SD
Beginning of intervention
G1: 127.7  6.6/86.1  1.9
G2: 127.3  6.4/85.8  1.9
End of intervention
G1: 0.7  9.2/3.0  6.5
G2: 0.6  8.5/2.4  7.0
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References
(country)
Design
Subject characteristics at
baseline
UNa
(mmol/24 h)
BP measurement
SBP/DBP
(mm Hg)
Kumanyika et al.
(1993)
(USA)
TOPH I
Study design: parallel
Intervention type: counselling
N participants randomised/completed:
744/744
Duration: 18 months
% men
G1: 71
G2: 72
Age (mean ± SD, years)
G1: 43.4  6.6
G2: 42.6  6.5
BMI (mean ± SD, kg/m2)
G1: 27.1  3.8
G2: 27.1  3.6
Ethnicity: mixed
BP status: NT
24-h UK (mean ± SD, mmol)
G1: 61.8  23.4
G2: 62.8  23.8
Energy intake: NR
Type: single 24 h
Mean  SD
Beginning of intervention
G1: 154.6  59.9
G2: 156.4  60.5
End of intervention
G1: 99.4  60.0
G2: 146.5  79.2
Type: point ofﬁce, sitting
Mean  SD
Beginning of intervention
G1: 124.8  8.5/83.7  2.7
G2: 125.1  8.1/83.9  2.8
End of intervention
G1: 5.08  7.94/4.35  5.65
G2: 3.02  8.31/3.18  5.8
MacGregor et al.
(1982)
(United Kingdom)
Study design: cross-over
Wash out: none
Run-in type: low sodium diet
Intervention type: feeding
N participants randomised/completed:
19/19
Duration: 4 weeks
% men: 74
Age (mean (range), years):
49 (30–66)
Ethnicity: mixed
BP status: HT
24-h UK (mean ± SE, mmol):
59  5
Energy intake: NR
Type: multiple 24 h
Mean  SE
Beginning of intervention
83  11
End of intervention
G1: 86  9
G2: 162  9
Type: point ofﬁce, supine
Mean  SE
Beginning of intervention
142  3/92  1
End of intervention
G1: 144  4/92  1.5
G2: 154  4/97  2.5
MacGregor et al.
(1989)
(United Kingdom)
Study design: cross-over
Wash out: none
Run-in type: low sodium diet
Intervention type: feeding
N participants randomised/completed:
20/20
Duration: 4 weeks
% men: 55
Age (mean (range), years):
57 (42–72)
Ethnicity: mixed
BP status: HT
Energy intake: NR
Type: multiple 24 h
Mean  SE
Beginning of intervention
NR
End of intervention
G1: 49  8
G2: 108  10
G3: 190  11
Type: point ofﬁce, supine
Mean  SE
Beginning of intervention
164  4 / 101  2
End of intervention
G1: 147  4/91  2
G2: 155  3/95  2
G3: 163  4/100  2
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References
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Design
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UNa
(mmol/24 h)
BP measurement
SBP/DBP
(mm Hg)
Meland et al. (1997)
(Norway)
Study design: cross-over
Wash out: none
Run-in type: normal diet
Intervention type: feeding
N participants randomised/completed:
16/16
Duration: 8 weeks
% men: 81
Age (mean (range), years):
50 (20–69)
Ethnicity: NR
BP status: HT
Energy intake: NR
Type: single 24 h
Mean (95% CI)
Beginning of intervention
177 (149, 204)
End of intervention
G1: 125 (104, 146)
G2: 191 (159, 223)
Type: point ofﬁce, sitting
Mean  (95% CI)
Beginning of intervention
146 (140, 153)/95 (92, 98)
End of intervention
G1: 141 (135, 147)/92 (89, 94)
G2: 145 (137, 153)/94 (90, 97)
Melander et al.
(2007)
(Sweden)
Study design: cross-over
Wash out: none
Intervention type: feeding
N participants randomised/completed:
46/39
Duration: 4 weeks
% men: 51
Age (mean ± SD, years): 53  11
BMI (mean ± SD, kg/m2):
26.3  3.1
Ethnicity: NR
BP status: NT
24-h UK (mean ± SD, mmol):
75  22.9
Energy intake: NR
Type: single 24 h
Mean  SD
Beginning of intervention
165  67.4
End of intervention
G1: 50.7  17.3
G2: 140  39.5
Type: point ofﬁce, supine
Mean  SD
Beginning of intervention
136  12.6/78.2  7.8
End of intervention
G1: 125  12.4/73  7.3
G2: 132  14.7/75.2  7.5
Nestel et al. (1993)
(Australia)
Study design: parallel
Run-in type: low sodium diet + sodium
tablets
Intervention type: feeding
N participants randomised/completed:
70/66
Duration: 6 weeks
% men
G1: 50
G2: 50
Age (mean ± SD, years)
G1: 65.5  4
G2: 65.5  4
BMI (mean ± SD, kg/m2)
G1: 24.5  3
G2: 24.5  3
Ethnicity: NR
BP status: NT
24-h UK (mean ± SD, mmol)
G1: 87  26
G2: 76.5  20
Energy intake: NR
Type: single 24 h
Mean  SD
Beginning of intervention
G1: 182.5  48
G2: 162  47
End of intervention
G1: 91.5  41
G2: 156  40
Type: point ofﬁce, sitting
Mean  SD
Beginning of intervention
G1: 126.5  10/72.5  7
G2: 127.5  13/73.5  9
End of intervention
G1: 122.5  9/72  8
G2: 127.5  14/74.5  9
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(mm Hg)
Parijs et al. (1973)
(Belgium)
Study design:
cross-over
Wash out: none
Run-in type: normal diet
Intervention type: feeding
N participants randomised/completed:
22/17
Duration: 4 weeks
% men: 46
Age (mean ± SD, years):
41.2  8.21
Ethnicity: NR
BP status: HT
Energy intake: NR
Type: single 24 h
Mean  SD
Beginning of intervention
NR
End of intervention
G1: 92.8  41.8
G2: 191.1  61.2
Type: point ofﬁce, supine
mean 
Beginning of intervention
179.1  17.8/115.2  10.9
End of intervention
G1: 167.8  24.3/115.5  12.45
G2: 174.5  20.02/112.3  15.17
Puska et al. (1983)
(Finland)
Study design:
parallel
Intervention type: counselling
N participants randomised/completed:
76/72
Duration: 6 weeks
% men: NR
Age (range, years): 30–50
Ethnicity: NR
BP status: mixed
24-h UK (mean ± SE, mmol)
G1: 81  4
G2: 73  3
Energy intake (mean ± SE, kcal/d)
G1: 2,665  120
G2: 2,609  103
Type: single 24 h
Mean  SE
Beginning of intervention
G1: 192  11
G2: 165  9
End of intervention
G1: 77  5
G2: 167  8
Type: point ofﬁce, sitting
Mean  SE
Beginning of intervention
G1: 138.9  2.3/89.6  1.7
G2: 137.8  2/89.3  1.5
End of intervention
G1: 137.2  2.7/86.5  1.8
G2: 136  2.1/86.9  1.5
Richards et al.
(1984)
(New Zealand)
Study design:
cross-over
Wash out: none
Intervention type: feeding
N participants randomised/completed:
16/12
Duration: 5 weeks
% men: 67
Age (range, years): 19–52
Ethnicity: NR
BP status: HT
Energy intake: NR
Type: multiple 24 h
Mean  SE
Beginning of intervention
NR
End of intervention
G1: 94  7.1
G2: 202.8  14.1
Type: point ofﬁce, supine
mean  SE
Beginning of intervention
NR
End of intervention
G1: 144.7  4/90.6  3.6
G2: 149.9  4.2/92.4  3.5
Ruppert et al.
(1993)
(Germany)
Study design:
cross-over
Wash out: none
Intervention type: feeding
N participants randomised/completed:
25/25
Duration: 4 weeks
% men: 40
Age (mean ± SE, years): 47  5
Ethnicity: NR
BP status: NT
Energy intake: NR
Type: single 24 h
Mean  SE
Beginning of intervention
NR
End of intervention
G1: 82  3.4
G2: 199.6  5.3
Type: point ofﬁce, sitting
Mean  SE
Beginning of intervention
NR
End of intervention
G1: 112  2.1/73.3  1.4
G2: 110.3  2.6/72.3  1.8
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Sacks et al. (2001)
(USA)
DASH
Study design:
cross-over
Wash out: none
Run-in type:
high sodium diet
Intervention type: feeding
N participants randomised/completed:
204/192
Duration: 4 weeks
% men: 46
Age (mean ± SD, years): 49  10
BMI (mean ± SD, kg/m2): 30  5
Ethnicity: mixed
BP status: mixed (41% HT)
Energy intake: NR
Type: single 24 h
Mean  SD
Beginning of intervention
152  72
End of intervention
G1: 64  37
G2: 106  44
G3: 141  55
Type: point ofﬁce, sitting
mean 
Beginning of intervention
134.8  9.5/85.7  4.5
End of intervention
G1: 126  10/79.8  6
G2: 130  11.7/82  6.4
G3: 132.7  11.9/83.2  6.9
Santos et al. (2010)
(Portugal)
Study design:
cross-over
Wash out: 6 weeks
Intervention type: feeding
N participants randomised/completed:
17/17
Duration: 7 weeks
% men: 47
Age (range, years): 24–53
Ethnicity: NR
BP status: NT
Energy intake (mean (range) kcal/d):
2,290 (1,461–3,646)
Type: single 24 h
Median (IQR)
Beginning of intervention
NR
End of intervention
G1: 115 (87, 162)
G2: 138 (123, 170)
Type: point ofﬁce, supine
Median (IQR)
Beginning of intervention
NR
End of intervention
G1: 118.3 (89, 124.3)/68 (51.7,
97.7)
G2: 116.7 (92.3, 125)/68.3 (50.3,
81.3)
Schorr et al. (1996)
(Germany)
Study design:
cross-over
Wash out: 2 weeks
Intervention type: feeding
N participants randomised/completed:
21/16
Duration: 4 weeks
% men: 44
Age (mean ± SD, years): 64.1  3.6
BMI (mean ± SD, kg/m2):
26.1  3.6
Ethnicity: NR
BP status: NT
Energy intake: NR
Type: multiple 24 h
Mean  SD
Beginning of intervention
141.8  33.6
End of intervention
G1: 104.6  21.7
G2: 175.2  29.6
Type: point ofﬁce, NR
mean 
Beginning of intervention
132.5  22.2/73.6  12.5
End of intervention
G1: 125.9  17.3/69.5  10.1
G2: 133.6  23.7/71.2  12.2
Swift et al. (2005)
(United Kingdom)
Study design:
cross-over
Wash out: none
Run-in type:
low sodium diet
Intervention type: feeding
N participants randomised/completed:
46/40
Duration: 4 weeks
% men: 43
Age (mean ± SD, years): 50  10
BMI (mean ± SD, kg/m2): 28  4
Ethnicity: African including African
Americans
BP status: HT
24-h UK (mean ± SD, mmol):
63  16
Energy intake: NR
Type: NR
Mean  SD
Beginning of intervention
NR
End of intervention
G1: 89  52
G2: 167  73
Type: point ofﬁce, supine
Mean  SD
Beginning of intervention
NR
End of intervention
G1: 151  13/98  8
G2: 159  13/101  8
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References
(country)
Design
Subject characteristics at
baseline
UNa
(mmol/24 h)
BP measurement
SBP/DBP
(mm Hg)
van Berge-Landry
and James (2004)
(USA)
Study design:
cross-over
Wash out: none
Run-in type: normal diet
Intervention type: counselling
N participants randomised/completed:
48/48
Duration: 4 weeks
% men: 79
Age: middle-aged adults
Ethnicity: mixed
BP status: HT
Energy intake: NR
Type: single 24 h
Mean  SD
Beginning of intervention
NR
End of intervention
G1: 24  13
G2: 309  88
Type: point ofﬁce, NR
Mean  SD
Beginning of intervention
NR
End of intervention
G1: 128  10/85  7
G2: 144  14/93  8
Watt et al. (1983)
(United Kingdom)
Study design:
cross-over
Wash out: none
Run-in type: low sodium diet
Intervention type: feeding
N participants randomised/completed:
20/18
Duration: 4 weeks
% men: 33
Age (mean, range, years):
52 (31–64)
Ethnicity: NR
BP status: HT
24-h UK (mean, mmol): 59.2
Energy intake: NR
Type: single 24 h
Mean
Beginning of intervention
NR
End of intervention
G1: 87.2
G2: 142.8
Type: point ofﬁce, sitting
Mean
Beginning of intervention
NR
End of intervention
G1: 136/82.3
G2: 136.5/82.6
Watt et al. (1985)
(United Kingdom)
High/high
Study design:
cross-over
Wash out: none
Intervention type: feeding
N participants randomised/completed:
75/66
Duration: 4 weeks
% men: 37
Age (mean, years): 22.3
Ethnicity: NR
BP status: mixed
24-h UK (mean ± SD, mmol):
53.8  18.9
Energy intake: NR
Type: single 24 h
Mean  SD
Beginning of intervention
129.7  55.3
End of intervention
G1: 56.3
G2: 130.6
Type: point ofﬁce, sitting
mean 
Beginning of intervention
113.1  13.3/65.2  11.2
End of intervention
G1: 112.2/64.5
G2: 113.6/63.3
Watt et al. (1985)
(United Kingdom)
Low/low
Study design:
cross-over
Wash out: none
Intervention type: feeding
N participants randomised/completed:
75/66
Duration: 4 weeks
% men: 45
Age (mean, years): 22.7
Ethnicity: NR
BP status: mixed
24-h UK (mean ± SD, mmol):
60  18.3
Energy intake: NR
Type: single 24 h
Mean  SD
Beginning of intervention
151.1  63.6
End of intervention
G1: 68.4
G2: 128.4
Type: point ofﬁce, sitting
mean  SD
Beginning of intervention
108.8  11.5/61.9  9.5
End of intervention
G1: 110.2/65
G2: 110.7/63.6
BMI: body mass index; BP: blood pressure; 95% CI: 95% conﬁdence interval; DBP: diastolic blood pressure; G1: group 1 (‘low’ sodium); G2: group 2 (‘high’ sodium); G3: group 3 (‘highest’
sodium, for studies with three sodium intake levels); HT: hypertensive; IQR: interquartile range; mm Hg: millimetre of mercury; N: number; Na: sodium; NR: not reported; NT: normotensive; SBP:
systolic blood pressure; SD: standard deviation; SE: standard error; UK: potassium urinary excretion; UNa: sodium urinary excretion.
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I.1.2. Observational studies
References
(country)
Design
Baseline
characteristics
Na intake
assessment
method
UNa (mmol/24
h)
Outcomes
assessed
Confounders
adjusted for
Results
(Stolarz-Skrzypek
et al., 2011)
(Belgium, Czech
Republic, Italy,
Poland, Russian
Federation)
FLEMENGHO/
EPOGH
Prospective cohort
N = 3,360
FLEMENGHO initial
cohort; N = 1,187
EPOGH initial cohort
N = 1,499 included in
the analyses (‘blood
pressure cohort’)
(excluded:
participants with
treated hypertension,
history of CVD,
missing/inaccurate
24-h UNa at baseline)
Median duration:
6.1 years
Male (%)
47.6
Hypertensive
(untreated) (%)
9.9
Diabetes mellitus
(%)
1.9
Age (mean (SD),
years)
38.3 (14.2)
BMI (mean (SD),
kg/m2)
24.6 (4.0)
Smokers (%)
30.4
SBP (mean (SD),
mm Hg)
120.9 (12.8)
DBP (mean (SD),
mm Hg)
74.6 (8.9)
24-h UK (mean
(SD), mmol)
66.3 (22.4)
24-h UCr (mean
(SD), mmol)
11.9 (3.7)
Single 24-h urine
sample at baseline
and at last follow-
up examination
Inaccurate urine
collections
were deﬁned as a
volume < 300 mL/
24-h, a 24-h
UCr < 4 mmol
or > 25 mmol in
women and
< 6 mmol
or > 30 mmol in
men
Mean (SD)
172.7 (62.5)
Longitudinal change
in SBP and DBP
BP measured at
baseline and follow-
up examinations (5
blood pressure
readings averaged at
each examination)
Study population,
sex, baseline values
of and changes in:
age, BMI,
and alcohol intake,
24-h UK, use of
female sex steroids,
and use of non-
steroidal
anti-inﬂammatory
drugs
Change in SBP (mm
Hg)/ 100 mmol increase
in Na excretion (mean
(95% CI)):
FLEMENGHO: 2.373
(1.154 to 3.392),
p < 0.001
EPOGH: 0.196 (1.409
to 1.801), p = 0.81
All: 1.711 (0.786 to
2.637), p < 0.001
Change in DBP (mm
Hg)/ 100 mmol increase
in Na excretion (mean
(95% CI)):
FLEMENGHO: 0.576
(0.246 to 1.398)
p = 0.17
EPOGH: 0.052
(1.317 to 1.212),
p = 0.94
All: 0.379 (0.313 to
1.070), p = 0.28
BMI: body mass index; BP: blood pressure; 95% CI: 95% conﬁdence interval; CVD: cardiovascular disease; DBP: diastolic blood pressure; EPOGH: European Project on Genes in Hypertension;
FLEMENGHO: Flemish Study on Genes and Health Outcomes; m: men; mm Hg: millimetre of mercury; N: number; Na: sodium; SBP: systolic blood pressure; SD: standard deviation; UCr: creatinine
urinary excretion; UK: potassium urinary excretion; UNa: sodium urinary excretion; w: women.
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I.2. Outcome of the RoB appraisal
I.2.1. Experimental studies
References
Risk of bias domains(a)
Tier(b)
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Alli et al. (1992) +       ++   ++  2
ANHMRCDS (1989) + NR + + + + + + + + + 1
Benetos et al. (1992) + NR + + + + + ++ + 1
Cappuccio et al. (1997) ++ NR + + ++ + ++ ++ ++ 1
ANHMRCDS (1986) + NR  + + + + + + 1
Cobiac et al. (1992) NR NR ++ + ++ + ++ + 2
Dickinson et al. (2014) ++ NR +  + + ++ ++ 1
Erwteman et al. (1984) + NR + + + + + + +  1
Fotherby and Potter (1993) + NR + + + + + ++ ++ 1
Gates et al. (2004) + + + + + + + ++ + + ++ 1
Gijsbers et al. (2015) + + + + + + + + + + + + + + + 1
Grobbee et al. (1987) + NR + ++ + ++  ++ 1
He et al. (2009) ++ + ++ + + ++ ++ ++ 1
Jablonski et al. (2013) ++ + + + + + + + + + ++ 1
Kumanyika et al. (2005) + NR + + + + + + + + + ++ 1
Kumanyika et al. (1993) ++ ++ + ++ + ++ ++ + 1
MacGregor et al. (1982) ++ ++ + ++ + ++ ++ + 1
MacGregor et al. (1989) + NR + + + + + + + + + + 1
Meland et al. (1997) + NR + + + + + + + + + + 1
Melander et al. (2007) + NR + + + + + + + ++ 1
Nestel et al. (1993) + NR + + + + + + + + + + 1
Parijs et al. (1973) NR NR + + + + + + + + + 2
Puska et al. (1983) + NR  + +  + + + 1
Richards et al. (1984) + NR + + + + + + + +  1
Ruppert et al. (1993)    + + + + + 2
Sacks et al. (2001) + NR + + + + ++ ++ 1
Santos et al. (2010) + + + + + + + + + + ++ 1
Schorr et al. (1996) + NR  + + + + + + + 1
Swift et al. (2005) + NR + + + + ++ + 1
van Berge-Landry and James (2004) + NR + + + + + + ++ + + 1
Watt et al. (1983) + NR  + + + NR + + + 2
Watt et al. (1985) + NR + + + + + + + + + 1
(a): Expert judgement was translated into a rating scale for each question to be answered as follows: (++): deﬁnitely low RoB;
(+): probably low RoB; (NR): not reported; (): probably high RoB; (): deﬁnitively high RoB.
(b): The individual rating for each question was combined by an algorithm and translated to an overall tier of reliability for each
individual study (RoB tier 1: low RoB; RoB tier 2: moderate RoB; RoB tier 3: high RoB).
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I.2.2. Observational studies
References
Risk of bias domains(a)
Tier(b)
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Stolarz-Skrzypek et al. (2011)    ++ ++ ++ 2
(a): Expert judgement was translated into a rating scale for each question to be answered as follows: (++): deﬁnitely low RoB;
(+): probably low RoB; (NR): not reported; (): probably high RoB; (): deﬁnitively high RoB.
(b): The individual rating for each question was combined by an algorithm and translated to an overall tier of reliability for each
individual study (RoB tier 1: low RoB; RoB tier 2: moderate RoB; RoB tier 3: high RoB).
I.3. Random-effects meta-analyses of trials of effects of sodium
reduction on SBP and DBP
NOTE: Weights are from random effects analysis.
Overall  (I-squared = 61.9%, p = 0.000)
Nestel (1993)
ANHMRCDS (1989)
Schorr (1996)
Kumanyika (1993) (TOHP I)
Benetos (1992)
van Berge-Landry (2004)
Cobiac (1992)
ANHMRCDS (1986)
Santos (2010)
Alli (1992)
Gates (2004)
Kumanyika (2005) (TOHP II)
Erwteman (1984)
Jablonski (2013)
MacGregor (1989) 100
Melander (2007)
Watt (1985) (low/low)
Fotherby (1993)
He (2009)
Grobbee (1987)
Watt (1985) (high/high)
Sacks (2001) (DASH) 100
Ruppert (1993)
MacGregor (1982)
Sacks (2001) (DASH) 150
Swift (2005)
MacGregor (1989) 200
Cappuccio (1997)
Watt (1983)
Puska (1983)
Meland (1997)
Richards (1984)
Dickinson (2014)
Study
Parijs (1973)
Gijsbers (2015)
-64.5
-63
-70.6
-47.1
-78
-285
-73
-69.8
-23
13.3
-89.6
-42.3
-58
-67
-59
-89.3
-60
-79
-55
-72
-74.3
-42
-117.6
-76
-77
-78
-141
excretion change
-83
-55.6
-90
-66
-108.8
-42
- mmol/d
-98.3
-97.8
UNa
-3.93 (-5.11, -2.76)
-5.00 (-10.65, 0.65)
-3.10 (-8.35, 2.15)
-7.70 (-22.08, 6.68)
-2.40 (-3.61, -1.19)
-6.50 (-13.30, 0.30)
-16.00 (-20.87, -11.13)
-4.70 (-11.86, 2.46)
-4.00 (-6.86, -1.14)
-0.30 (-17.22, 16.62)
-2.20 (-8.44, 4.04)
-7.10 (-16.19, 1.99)
-0.90 (-1.98, 0.18)
-1.90 (-8.33, 4.53)
-11.00 (-22.42, 0.42)
-8.00 (-20.55, 4.55)
-7.00 (-13.04, -0.96)
-0.50 (-2.11, 1.11)
-8.00 (-21.15, 5.15)
-5.00 (-7.67, -2.33)
-0.90 (-5.90, 4.10)
-1.40 (-2.85, 0.05)
-4.00 (-6.60, -1.40)
1.70 (-4.85, 8.25)
-10.00 (-21.06, 1.06)
-6.70 (-9.31, -4.09)
-8.00 (-13.70, -2.30)
-16.00 (-29.59, -2.41)
Mean
-7.30 (-15.83, 1.23)
-0.50 (-3.47, 2.47)
1.20 (-5.48, 7.88)
-4.00 (-13.98, 5.98)
-5.20 (-16.56, 6.16)
-3.00 (-10.40, 4.40)
difference (95% CI)
-6.70 (-22.25, 8.85)
-7.80 (-15.35, -0.25)
100.00
2.76
3.02
0.61
7.07
2.14
3.30
1.99
5.25
0.45
2.42
1.37
7.18
2.32
0.93
0.78
2.53
6.68
0.72
5.48
3.20
6.84
5.56
2.26
0.98
5.54
2.73
0.68
%
1.52
5.13
2.20
1.17
0.94
1.89
Weight
0.53
1.83
Favours low sodium  Favours high sodium 
0-29.6 29.6
Systolic blood pressure - Overall sorted by 24-h UNa between-group difference
95% CI: 95% conﬁdence interval; UNa: sodium urinary excretion.
Figure I.1: sbp – all adults, sorted by 24-h UNa between-group difference
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NOTE: Weights are from random effects analysis.
.
.
.
Overall  (I-squared = 61.9%, p = 0.000)
Melander (2007)
Schorr (1996)
Nestel (1993)
Kumanyika (1993) (TOHP I)
Parijs (1973)
Normotensive
ANHMRCDS 1986
Santos (2010)
Watt (1985) (high/high)
Cobiac (1992)
Kumanyika (2005) (TOHP II)
MacGregor (1989) 200
MacGregor (1982)
van Berge-Landry (2004)
Sacks (2001) (DASH) 100
Cappuccio (1997)
Watt (1983)
Subtotal  (I-squared = 58.2%, p = 0.001)
Swift (2005)
Gijsbers (2015)
Ruppert (1993)
Jablonski (2013)
Watt (1985) (low/low)
Dickinson (2014)
Hypertensive
Grobbee (1987)
Subtotal  (I-squared = 26.3%, p = 0.218)
ANHMRCDS (1989)
Alli (1992)
Mixed
Puska (1983)
Fotherby (1993)
Gates (2004)
He (2009)
MacGregor (1989) 100
Richards (1984)
Study
Sacks (2001) (DASH) 150
Erwteman (1984)
Meland (1997)
Subtotal  (I-squared = 66.8%, p = 0.001)
Benetos (1992)
-3.93 (-5.11, -2.76)
-7.00 (-13.04, -0.96)
-7.70 (-22.08, 6.68)
-5.00 (-10.65, 0.65)
-2.40 (-3.61, -1.19)
-6.70 (-22.25, 8.85)
-4.00 (-6.86, -1.14)
-0.30 (-17.22, 16.62)
-1.40 (-2.85, 0.05)
-4.70 (-11.86, 2.46)
-0.90 (-1.98, 0.18)
-16.00 (-29.59, -2.41)
-10.00 (-21.06, 1.06)
-16.00 (-20.87, -11.13)
-4.00 (-6.60, -1.40)
-7.30 (-15.83, 1.23)
-0.50 (-3.47, 2.47)
-5.61 (-8.08, -3.14)
-8.00 (-13.70, -2.30)
-7.80 (-15.35, -0.25)
1.70 (-4.85, 8.25)
-11.00 (-22.42, 0.42)
-0.50 (-2.11, 1.11)
-3.00 (-10.40, 4.40)
Mean
-0.90 (-5.90, 4.10)
-1.98 (-3.27, -0.68)
-3.10 (-8.35, 2.15)
-2.20 (-8.44, 4.04)
1.20 (-5.48, 7.88)
-8.00 (-21.15, 5.15)
-7.10 (-16.19, 1.99)
-5.00 (-7.67, -2.33)
-8.00 (-20.55, 4.55)
-5.20 (-16.56, 6.16)
difference (95% CI)
-6.70 (-9.31, -4.09)
-1.90 (-8.33, 4.53)
-4.00 (-13.98, 5.98)
-3.53 (-5.40, -1.65)
-6.50 (-13.30, 0.30)
100.00
2.53
0.61
2.76
7.07
0.53
5.25
0.45
6.84
1.99
7.18
0.68
0.98
3.30
5.56
1.52
5.13
36.91
2.73
1.83
2.26
0.93
6.68
1.89
%
3.20
24.75
3.02
2.42
2.20
0.72
1.37
5.48
0.78
0.94
Weight
5.54
2.32
1.17
38.34
2.14
Favours low sodium  Favours high sodium 
0-29.6 29.6
Systolic blood pressure – Blood pressure status
95% CI: 95% conﬁdence interval.
Figure I.2: SBP – all adults, subgroups by blood pressure status
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Overall  (I-squared = 61.9%, p = 0.000)
Erwteman (1984)
Subtotal  (I-squared = 48.9%, p = 0.014)
Age >= 50 years old
MacGregor (1982)
Watt (1985) (low/low)
Ruppert (1993)
Swift (2005)
ANHMRCDS (1989)
Subtotal  (I-squared = 50.4%, p = 0.007)
Age < 50 years old
Sacks (2001) (DASH) 100
Melander (2007)
Gates (2004)
Cappuccio (1997)
Schorr (1996)
He (2009)
Alli (1992)
Cobiac (1992)
Grobbee (1987)
Richards (1984)
Watt (1985) (high/high)
Nestel (1993)
Watt (1983)
Jablonski (2013)
ANHMRCDS (1986)
Dickinson (2014)
Puska (1983)
Meland (1997)
Kumanyika (2005) (TOHP II)
Santos (2010)
Study
MacGregor (1989) 100
MacGregor (1989) 200
Fotherby (1993)
van Berge-Landry (2004)
Sacks (2001) (DASH) 150
Benetos (1992)
Kumanyika (1993) (TOHP I)
Gijsbers (2015)
Parijs (1973)
-3.93 (-5.11, -2.76)
-1.90 (-8.33, 4.53)
-2.23 (-3.34, -1.12)
-10.00 (-21.06, 1.06)
-0.50 (-2.11, 1.11)
1.70 (-4.85, 8.25)
-8.00 (-13.70, -2.30)
-3.10 (-8.35, 2.15)
-6.13 (-8.15, -4.10)
-4.00 (-6.60, -1.40)
-7.00 (-13.04, -0.96)
-7.10 (-16.19, 1.99)
-7.30 (-15.83, 1.23)
-7.70 (-22.08, 6.68)
-5.00 (-7.67, -2.33)
Mean
-2.20 (-8.44, 4.04)
-4.70 (-11.86, 2.46)
-0.90 (-5.90, 4.10)
-5.20 (-16.56, 6.16)
-1.40 (-2.85, 0.05)
-5.00 (-10.65, 0.65)
-0.50 (-3.47, 2.47)
-11.00 (-22.42, 0.42)
-4.00 (-6.86, -1.14)
-3.00 (-10.40, 4.40)
1.20 (-5.48, 7.88)
-4.00 (-13.98, 5.98)
-0.90 (-1.98, 0.18)
-0.30 (-17.22, 16.62)
difference (95% CI)
-8.00 (-20.55, 4.55)
-16.00 (-29.59, -2.41)
-8.00 (-21.15, 5.15)
-16.00 (-20.87, -11.13)
-6.70 (-9.31, -4.09)
-6.50 (-13.30, 0.30)
-2.40 (-3.61, -1.19)
-7.80 (-15.35, -0.25)
-6.70 (-22.25, 8.85)
100.00
2.32
56.31
0.98
6.68
2.26
2.73
3.02
43.69
5.56
2.53
1.37
1.52
0.61
5.48
%
2.42
1.99
3.20
0.94
6.84
2.76
5.13
0.93
5.25
1.89
2.20
1.17
7.18
0.45
Weight
0.78
0.68
0.72
3.30
5.54
2.14
7.07
1.83
0.53
Favours low sodium Favours high sodium 
0-29.6 29.6
Systolic blood pressure – Age < and >= 50 years old
95% CI: 95% conﬁdence interval.
Figure I.3: SBP – all adults, subgroups by age < or ≥ 50 years
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Overall  (I-squared = 61.9%, p = 0.000)
Santos (2010)
Puska (1983)
2–3 months
Gijsbers (2015)
Grobbee (1987)
1 month
He (2009)
Erwteman (1984)
ANHMRCDS (1986)
Subtotal  (I-squared = 39.6%, p = 0.191)
Ruppert (1993)
Melander (2007)
Richards (1984)
Schorr (1996)
Meland (1997)
Fotherby (1993)
ANHMRCDS (1989)
Kumanyika 1993 (TOHP I)
1 year or longer
Jablonski (2013)
Watt (1985) (high/high)
Sacks (2001) (DASH) 100
Swift (2005)
Dickinson (2014)
Watt (1985) (low/low)
Sacks (2001) (DASH) 150
Alli 1992
Nestel (1993)
Cobiac (1992)
Parijs (1973)
Benetos (1992)
Study
MacGregor (1982)
van Berge-Landry (2004)
Cappuccio (1997)
Kumanyika 2005 (TOHP II)
MacGregor (1989) 100
Watt (1983)
MacGregor (1989) 200
Subtotal  (I-squared = 0.0%, p = 0.755)
Gates (2004)
Subtotal  (I-squared = 72.4%, p = 0.000)
-3.93 (-5.11, -2.76)
-0.30 (-17.22, 16.62)
1.20 (-5.48, 7.88)
-7.80 (-15.35, -0.25)
-0.90 (-5.90, 4.10)
-5.00 (-7.67, -2.33)
-1.90 (-8.33, 4.53)
-4.00 (-6.86, -1.14)
-1.63 (-2.83, -0.44)
1.70 (-4.85, 8.25)
-7.00 (-13.04, -0.96)
-5.20 (-16.56, 6.16)
-7.70 (-22.08, 6.68)
-4.00 (-13.98, 5.98)
-8.00 (-21.15, 5.15)
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Figure I.4: SBP – all adults, subgroups by trial duration
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NOTE: Weights are from random effects analysis.
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Figure I.5: DBP – all adults, sorted by 24-h UNa between-group difference
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NOTE: Weights are from random effects analysis.
.
.
.
Overall  (I-squared = 60.6%, p = 0.000)
Alli (1992)
Watt (1985) (low/low)
Gijsbers (2015)
Melander (2007)
Ruppert (1993)
Schorr (1996)
Meland (1997)
Normotensive
Jablonski (2013)
Mixed
He (2009)
Subtotal  (I-squared = 75.2%, p = 0.000)
Richards (1984)
MacGregor (1989) 100
Watt (1985) (high/high)
Erwteman (1984)
Benetos (1992)
Gates (2004)
Puska (1983)
Sacks (2001) (DASH) 150
Subtotal  (I-squared = 8.5%, p = 0.365)
Sacks (2001) (DASH) 100
Kumanyika (2005) (TOHP II)
Nestel (1993)
Watt (1983)
Cappuccio (1997)
Dickinson (2014)
Fotherby (1993)
MacGregor (1989) 200
MacGregor (1982)
Santos (2010)
Swift (2005)
van Berge-Landry (2004)
ANHMRCDS (1989)
ANHMRCDS (1986)
Study
Subtotal  (I-squared = 47.3%, p = 0.016)
Hypertensive
Parijs (1973)
Grobbee (1987)
Kumanyika (1993) (TOHP I)
Cobiac (1992)
-1.98 (-2.75, -1.21)
-3.90 (-7.58, -0.22)
1.40 (-0.36, 3.16)
-3.40 (-6.91, 0.11)
-2.20 (-5.48, 1.08)
1.00 (-3.47, 5.47)
-1.70 (-9.46, 6.06)
-2.00 (-6.28, 2.28)
-4.00 (-9.52, 1.52)
-3.00 (-4.82, -1.18)
-1.75 (-3.31, -0.18)
-1.80 (-11.64, 8.04)
-4.00 (-10.76, 2.76)
1.20 (-0.62, 3.02)
-1.50 (-6.03, 3.03)
-3.70 (-7.58, 0.18)
-0.90 (-6.58, 4.78)
-0.40 (-4.98, 4.18)
-3.40 (-4.95, -1.85)
-0.88 (-1.55, -0.20)
-2.20 (-3.70, -0.70)
-0.30 (-1.13, 0.53)
-3.00 (-7.10, 1.10)
-0.30 (-1.87, 1.27)
-3.20 (-7.12, 0.72)
-1.00 (-4.92, 2.92)
0.00 (-6.47, 6.47)
-9.00 (-15.76, -2.24)
-5.00 (-10.71, 0.71)
Mean
4.50 (-3.03, 12.03)
-3.00 (-6.51, 0.51)
-8.00 (-11.01, -4.99)
-3.20 (-5.44, -0.96)
-4.00 (-5.73, -2.27)
difference (95% CI)
-2.89 (-4.18, -1.60)
3.20 (-6.38, 12.78)
0.20 (-4.40, 4.80)
-1.40 (-2.25, -0.55)
-0.20 (-5.75, 5.35)
100.00
2.67
5.03
2.82
3.05
2.07
0.86
2.19
1.52
4.95
36.14
0.56
1.09
4.94
2.03
2.50
1.45
2.00
5.35
24.30
5.42
6.33
2.32
5.32
2.47
2.47
1.18
1.09
1.44
%
0.91
2.83
3.35
4.33
5.09
Weight
39.56
0.59
1.99
6.30
1.50
Favours low sodium  Favours high sodium 
0-15.8 15.8
Diastolic blood pressure – Blood pressure status
95% CI: 95% conﬁdence interval.
Figure I.6: DBP – all adults, subgroups by blood pressure status
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NOTE: Weights are from random effects analysis
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Figure I.7: DBP – all adults, subgroups by age < or ≥ 50 years
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NOTE: Weights are from random effects analysis.
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Figure I.8: DBP – all adults, subgroups by trial duration
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Table I.1: Pooled estimates of the effect of sodium reduction on SBP (mean difference expressed in
mm Hg)
N studies N particip.
Mean
diff.
95% CI I2 p
All Adults 35 3,407 3.9 5.1 2.8 62% < 0.001
BP Hypertensive 17 721 5.6 8.1 3.1 58% 0.001
Mixed 10 770 3.5 5.4 1.7 67% 0.001
Normotensive 8 1,916 2.0 3.3 0.7 26% 0.218
Age Adults < 50 years 16 632 2.2 3.3 1.1 49% 0.014
Adults ≥ 50 years 19 2,775 6.1 8.2 4.1 50% 0.007
Sex > 55% men 14 2,430 4.5 6.5 2.6 74% < 0.001
4555% both genders 14 761 4.7 7.0 2.5 55% 0.007
> 55% women 7 216 1.8 3.6 0.0 20% 0.277
BMI < 25 1 66 5.0 10.6 0.6 – –
2529 10 1,132 4.6 6.3 2.8 26% 0.207
≥ 30 2 384 5.3 8.0 2.7 52% 0.151
NR 22 1,825 3.1 4.7 1.6 62% < 0.001
Ethnicity Caucasian 3 65 7.6 12.9 2.3 0% 0.991
African (including AA) 1 40 8.0 13.7 2.3 – –
Mixed 12 2,540 5.7 8.0 3.4 82% < 0.001
NR 19 762 1.7 2.5 0.8 0% 0.578
Potassium ≤ 60 mmol/day 4 103 1.0 2.1 0.1 9% 0.346
> 60≤ 70 mmol/day 8 2,008 3.0 4.6 1.4 52% 0.043
> 70≤ 80 mmol/day 7 442 4.3 6.2 2.5 0% 0.743
> 80 mmol/day 3 174 3.8 8.7 1.2 41% 0.183
NR 13 680 6.4 9.5 3.3 59% 0.004
Design Parallel 8 2,217 2.0 3.1 1.0 20% 0.272
Crossover 26 1,134 5.0 6.8 3.3 67% < 0.001
Cluster-randomised 1 56 2.2 8.4 4.0 – –
Speciﬁc
design
Run-in – normal diet 7 380 5.2 9.6 0.9 75% 0.001
Run-in – low Na diet 9 386 5.8 8.6 2.9 43% 0.083
Run-in – high Na diet 4 504 5.3 7.0 3.6 0% 0.552
No run-in 15 2,137 1.6 2.5 0.8 18% 0.254
Trial
duration
1 month 20 1,005 5.1 7.0 3.1 72% < 0.001
2–3 months 12 618 4.0 5.5 2.5 0% 0.755
≥ 1 year 3 1784 1.6 2.8 0.4 40% 0.191
Intervention
type
Feeding 28 1,309 4.0 5.3 2.7 44% 0.007
Counselling 7 2,098 3.7 6.2 1.1 85% < 0.001
Position Supine 17 517 5.6 7.5 3.6 0% 0.762
Seated 16 2,826 2.5 3.6 1.5 57% 0.003
NR 2 64 14.7 20.6 8.8 13% 0.284
UNa
difference
≤ 50 mmol 6 2,018 2.0 3.0 0.9 23% 0.26
5175 mmol 14 773 2.4 3.6 1.2 27% 0.169
76100 mmol 11 511 6.5 8.3 4.7 0% 0.814
> 100 mmol 4 105 8.6 19.0 1.7 85% < 0.001
Tier Tier 1 30 3,171 3.3 4.4 2.2 50% 0.001
Tier 2 5 236 6.9 12.8 1.1 75% 0.003
BP: blood pressure; 95% CI: 95% conﬁdence interval; diff.: difference; N: number; Na: sodium; NR: not reported; particip.:
participants; SBP: systolic blood pressure; UNa: sodium urinary excretion.
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Table I.2: Pooled estimates of the effect of sodium reduction on DBP (mean difference expressed
in mm Hg)
N studies N particip.
Mean
diff.
95% CI I2 p
All Adults 35 3,407 2.0 2.8 1.2 61% < 0.001
BP Hypertensive 17 721 2.9 4.2 1.6 47% 0.016
Mixed 10 770 1.7 3.3 0.2 75% < 0.001
Normotensive 8 1,916 0.9 1.6 0.2 9% 0.365
Age Adults < 50 years 16 632 1.0 2.0 0.0 61% 0.001
Adults ≥ 50 years 19 2,775 2.9 4.0 1.9 40% 0.036
Sex > 55% men 14 2,430 2.7 3.9 1.5 70% < 0.001
4555% both genders 14 761 1.9 3.3 0.5 53% 0.01
> 55% women 7 216 0.6 2.0 0.8 33% 0.173
BMI < 25 1 66 3.0 7.1 1.1 – –
2529 10 1,132 1.9 2.6 1.2 0% 0.739
≥ 30 2 384 2.8 4.0 1.6 16% 0.276
NR 22 1,825 1.7 2.8 0.5 69% < 0.001
Ethnicity Caucasian 3 65 2.2 4.9 0.5 0% 0.579
African (including AA) 1 40 3.0 6.5 0.5 – –
Mixed 12 2,540 3.0 4.2 1.7 74% < 0.001
NR 19 762 1.2 2.3 0.0 54% 0.003
Potassium ≤ 60 mmol/day 4 103 0.4 1.1 1.9 51% 0.105
> 60≤ 70 mmol/day 8 2,008 2.2 3.4 0.9 66% 0.005
> 70≤ 80 mmol/day 7 442 2.4 3.5 1.3 0% 0.742
> 80 mmol/day 3 174 2.5 4.8 0.2 0% 0.573
NR 13 680 2.9 4.5 1.2 51% 0.017
Design Parallel 8 2,217 1.8 3.0 0.7 63% 0.009
Crossover 26 1,134 2.0 3.1 0.9 61% < 0.001
Cluster-randomised 1 56 3.9 7.6 0.2 – –
Speciﬁc
design
Run-in – normal diet 7 380 3.6 5.4 1.7 55% 0.036
Run-in – low Na diet 9 386 2.7 4.1 1.2 38% 0.119
Run-in – high Na diet 4 504 2.7 3.7 1.7 0% 0.57
No run-in 15 2137 0.5 1.3 0.3 30% 0.131
Duration 1 month 20 1,005 2.1 3.4 0.8 67% < 0.001
2–3 months 12 618 2.8 3.7 1.9 0% 0.501
≥ 1 year 3 1,784 1.1 2.3 0.1 66% 0.052
Intervention
type
Feeding 28 1,309 1.7 2.6 0.9 46% 0.004
Counselling 7 2,098 2.7 4.4 1.0 83% < 0.001
Position Supine 17 517 2.7 3.8 1.5 0% 0.66
Seated 16 2,826 1.4 2.3 0.5 70% < 0.001
NR 2 64 5.9 11.7 0.1 55% 0.138
UNa
difference
≤ 50 mmol 6 2,018 1.3 2.3 0.2 52% 0.063
5175 mmol 14 773 1.5 2.8 0.2 64% 0.001
76100 mmol 11 511 2.9 3.9 1.9 0% 0.869
> 100 mmol 4 105 4.6 10.1 0.8 76% 0.006
Tier Tier 1 30 3,171 1.7 2.4 0.9 56% < 0.001
Tier 2 5 236 4.1 7.0 1.2 52% 0.081
BP: blood pressure; 95% CI: 95% conﬁdence interval; diff.: difference; N: number; Na: sodium; NR: not reported; particip.:
participants; DBP: diastolic blood pressure; UNa: sodium urinary excretion.
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I.4. Dose–response modelling
Table I.3: Multivariable mixed-effects meta-regression model on SBP, only ﬁxed effects reported
Covariate b coefﬁcient Std. Err. p > |z| 95% CI
Mean UNa – per 100 mmol/day 5.3 0.8 < 0.001 (3.6 to 6.9)
Age at baseline
Age < 40 years old(a) 0
Age 40–49 years old 18.2 4.4 < 0.001 (9.6 to 26.9)
Age 50–59 years old 11.6 4.7 0.013 (2.4 to 20.7)
Age ≥ 60 years old 12.4 4.2 0.003 (4.3 to 20.6)
Blood pressure status
Normotensive(a) 0
Hypertensive 11.4 4.5 0.011 (2.6 to 20.1)
UNa at baseline(b)
< 100 mmol/day(a) 0
100–149 mmol/day 25.2 6.3 < 0.001 (12.7 to 37.6)
≥150 mmol/day 18.7 6.4 0.004 (6.0 to 31.3)
Not reported 13.4 5.3 0.012 (3.0 to 23.8)
BP measurement method
Point ofﬁce, supine(a) 0
Point ofﬁce, sitting 13.2 3.2 < 0.001 (19.6 to 6.9)
Speciﬁc trial design
No Run-in(a) 0
Run-in, Normal diet 11.9 3.4 < 0.001 (5.3 to 18.5)
Run-in, Low Na diet 19.7 5.1 < 0.001 (9.7 to 29.8)
Constant 95.5 6.8 < 0.001 (82.2 to 108.8)
95% CI: 95% conﬁdence interval; Std. Err.: standard error; UNa: sodium urinary excretion.
(a): Reference category.
(b): UNa at baseline: corresponds to UNa at the start of the intervention (i.e. after run-in, where applicable).
Model centred at 49 mmol/day sodium excretion (minimum mean UNa observed in the data set); total heterogeneity (random
effects on trial) estimated from null model = 275.2 (95% CI: 161.4–468.9), residual heterogeneity from full model = 33.4 (95%
CI: 13.3–53.5).
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Circles represents mean SBP by arm and their size is proportional to weights from the mixed-effects model. The
slope from the full model with moderators did not differ substantially (UNa unadjusted coefﬁcient: 5.2 mm Hg per
100 mmol/day, 95% CI: 3.6–6.9).
Figure I.9: Linear dose–response relationship between mean urinary sodium excretion and mean SBP
(mm Hg) from meta-regression modelling of trials’ arms (crude model)
Table I.4: Multivariable mixed-effects meta-regression model on DBP, only ﬁxed effects reported
Covariate b coefﬁcient Std. Err p > |z| 95% CI
Mean UNa – per 100 mmol/day 2.6 0.5 < 0.001 (1.6 to 3.7)
Age at baseline
Age < 40 years old(a) 0
Age 40–49 years old 18.2 3.2 < 0.001 (11.9 to 24.6)
Age 50–59 years old 11.8 3.5 0.001 (5.1 to 18.6)
Age ≥ 60 years old 7.8 3.1 0.011 (1.8 to 13.8)
Blood pressure status
Normotensive(a) 0
Hypertensive 8.7 3.3 0.008 (2.3 to 15.1)
UNa at baseline(b)
< 100 mmol/day(a) 0
100–149 mmol/day 10.4 4.5 0.022 (1.5 to 19.3)
≥ 150 mmol/day 10.2 4.7 0.028 (1.1 to 19.4)
Not reported 10.4 3.8 0.007 (2.9 to 17.9)
BP measurement method
Point ofﬁce, supine(a) 0
Point ofﬁce, sitting 6.6 2.4 0.005 (11.3 to 2.0)
Speciﬁc trial design
No Run-in(a) 0
Run-in, Normal diet 7.9 2.5 0.002 (3.0 to 12.7)
Run-in, Low Na diet 7.7 3.7 0.037 (0.5 to 15.0)
Constant 55.4 4.8 < 0.001 (45.9 to 64.8)
BP: blood pressure; 95% CI: 95% conﬁdence interval; Std. Err: standard error; UNa: sodium urinary excretion.
(a): Reference category.
(b): UNa at baseline: corresponds to UNa at the start of the intervention (i.e. after run-in, where applicable).
Model centred at 49 mmol/day sodium excretion (minimum mean UNa observed in the data set); total heterogeneity (random
effects on trial) estimated from null model = 129.1 (95% CI: 76.1–218.8), residual heterogeneity from full model = 18.8 (95%
CI: 8.1–29.4).
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Circles represents mean DBP by arm and their size is proportional to weights from the mixed-effects model.
The slope from the full model with moderators did not differ substantially (UNa unadjusted coefﬁcient: 2.6 mm
Hg per 100 mmol/day, 95% CI: 1.6–3.7).
Figure I.10: Linear dose–response relationship between mean urinary sodium excretion and mean
DBP (mm Hg) from meta-regression modelling of trials’ arms (crude model)
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Appendix J – Outcome of the systematic review on incidence of hypertension
J.1. Evidence tables
J.1.1. Experimental studies
References
(country)
Design
Subjects characteristics
at
baseline
Na intake
assessment
method
UNa (mmol/24 h)
Outcomes
assessed
Results
Whelton et al.
(1997)
(USA)
TOPH I
RCT (parallel)
G1: sodium reduction
counselling
(goal < 80 mmol/24 h)
(N = 326)
G2: usual care
(N = 417)
Recruitment criteria:
aged 35–54 years, with
high-normal DBP
Duration: 18 months
Sex (male,%)
G1: 70.9
G2: 71.7
Age (years, mean ± SD)
G1: 43.4  6.6
G2: 42.6  6.0
Ethnicity (White,%)
G1: 78.0
G2: 76.5
bw (kg, mean ± SD)
G1: 82.7  14.3
G2: 82.8  14.0
SBP (mm Hg, mean ± SD)
G1: 124.8  8.5
G2: 125.1  8.1
DBP (mm Hg, mean ± SD)
G1: 83.7  2.7
G2: 83.9  2.8
Average of two 24-h
urine collection at
baseline single 24-h
urine collection at
the 6-, 12- and 18-
month follow-up visits
Mean  SD
Baseline
G1: 154.6  77.9
G2: 156.4  60.5
Diff: –1.8
At 18 month
G1: 99.4  60.0
G2: 146.5  79.2
Diff: –47.2
Incident hypertension
Hypertension diagnosed
when mean of 9 DBP
measurements ≥ 90 mm
Hg or antihypertensive
drug therapy prescribed
Incidence of hypertension
during follow-up
G1: 8.6%
G2: 11.3%
RR = 0.76 (95% CI 0.49,
1.18)
The Trials of
Hypertension
Collaborative
Research
Group (1997)
(USA)
TOPH II
RCT (parallel)
G1: sodium reduction
counselling
(goal < 80 mmol/24 h)
(N = 594)
G2: usual care
(N = 596)
Recruitment criteria:
aged 30–54 years, with
high-normal DBP,
overweight
Sex (male,%)
G1: 64.8
G2: 68.3
Age (years, mean ± SD)
G1: 44.2  6.1
G2: 43.2  6.1
Ethnicity (White, %)
G1: 81.1
G2: 79.5
bw (kg, mean ± SD)
G1: 94.0  14.3
G2: 93.6  13.5
Average of two 24-h
urine collection at
baseline single 24-h
urine collection at
the 18-, 36-month
follow-up visits
Mean  SD
Baseline
G1: 186.1  80.7
G2: 188.0  80.9
Diff: –1.9
At 36 month (change
from baseline)
G1: 50.9  86.3
G2: 10.5  88.5
Diff: 40.4
Incident hypertension
Hypertension diagnosed
when mean of 9 DBP
measurements ≥ 90 mm
Hg or
mean of 9 SBP
measurements ≥ 140 mm
Hg or antihypertensive
drug therapy prescribed
Incidence of hypertension
At 18 month (cases, %)
G1: 108 (18.6)
G2: 124 (21.1)
RR = 0.88 (p = 0.28)
At 36 month (cases, %)
G1: 198 (34.4)
G2: 229 (39.2)
RR = 0.88 (p = 0.09)
At 48 month (cases, %)
G1: 211 (38.1)
G2: 248 (44.4)
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References
(country)
Design
Subjects characteristics
at
baseline
Na intake
assessment
method
UNa (mmol/24 h)
Outcomes
assessed
Results
Duration: 36 to
48 months
SBP (mm Hg, mean ± SD)
G1: 127.7  6.6
G2: 127.3  6.4
DBP (mm Hg, mean ± SD)
G1: 86.1  1.9
G2: 85.8  1.9
RR = 0.86 (p = 0.04)
bw: body weight; 95% CI: 95% conﬁdence interval; DBP: diastolic blood pressure; Diff: difference; G1: group 1 (‘low’ sodium); G2: group 2 (‘high’ sodium); mm Hg: millimetre of mercury; N: number;
Na: sodium; RCT: randomised controlled trial; RR: relative risk; SBP: systolic blood pressure; SD: standard deviation; TOPH: Trials of Hypertension Prevention; UNa: sodium urinary excretion.
J.1.2. Observational studies
References
(country)
Design Baseline characteristics
Na intake
assessment
method
UNa
(mmol/24 h)
Outcomes
assessed
Confounders
adjusted for
Results
Forman et al.
(2012)
(Netherlands)
PREVEND
Prospective cohort
N = 8,592 initial
cohort; IMDM and
pregnant women
excluded;
oversampling of
subjects with
elevated albumin
excretion
(> 10 mg/L)
N = 5,556 included
(excluded:
participants with
hypertension,
missing 24-h UNa
at baseline)
Median duration:
6.4 years
Male (%)
Q1 32.5 Q2 43.5 Q3 48.1 Q4
58.4
Age (median (IQR), years)
Q1 43 (36–52) Q2 43
(36–52) Q3 43 (36–51) Q4
44 (37–52)
BMI (median (IQR), kg/m2)
Q1 23.7 (21.7–26.2) Q2 24.2
(22.2–26.7) Q3 24.9 (22.6–
27.3) Q4 25.7
(23.5–28.4)
Smoking status (never, %)
Q1 31.5 Q2 30.5 Q3 31.5 Q4
29.4
SBP (median (IQR), mm Hg)
Q1 116 (108–126) Q2 118
(110–127) Q3 119
(111–128) Q4 121
(112–129)
DBP (median (IQR), mm Hg)
Two 24-h
urine specimens
collected at baseline
(1997–1998), two
24-h urine specimens
collected during
follow-up ﬁrst
examination (2001–
2003) and two 24-h
urine specimens
collected during
follow-up second
examination (2003–
2006)
Median (IQR)
Overall 137
(106–171)
Q1 97
(79–110)
(n = 1,389)
Q2 142
(132–153)
(n = 1,389)
Q3 188
(176–203)
(n = 1,389)
Q4 271
(242–316)
(n = 1,389)
Incident
hypertension
BP measured at
baseline and at
follow-up
Hypertension was
deﬁned as a
SBP > 140 mm Hg,
a DBP > 90 mm Hg,
or both or the use
of antihypertensive
medications
Age, BMI, sex,
alcohol intake,
smoking status,
family history of
hypertension,
estimated GFR,
serum levels of
glucose ad
cholesterol, and 24-h
UK, 24-h UCa and
24-h UCr
HR for incident
hypertension
By 1 g (43 mmol)
increase in UNa
HR (95% CI) = 1.05
(1.00–1.10) (878
cases)
By quartile of UNa:
Q1 (reference)
(incidence 13.9%)
Q4 HR (95%
CI) = 1.21
(0.98–1.51)
(incidence 19.7%)
Effect modiﬁcation
by serum uric acid
and UAlbumin
excretion
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References
(country)
Design Baseline characteristics
Na intake
assessment
method
UNa
(mmol/24 h)
Outcomes
assessed
Confounders
adjusted for
Results
Q1 69 (64–74) Q2 70
(65–75) Q3 70 (65–75) Q4
71 (66–76)
UK (median (IQR), mmol/
24 h)
Q1 56 (43–72) Q2 73
(59–91) Q3 87 (71–109)
Q4 114 (87–144)
24-h UCr (median (IQR), g)
Q1 1.1 (0.9–1.3) Q2 1.3
(1.1–1.5) Q3 1.4 (1.2–1.7)
Q4 1.6 (1.3–1.9)
24-h UAlbumin (median
(IQR), mg)
Q1 7.3 (5.3–11.7) Q2 7.9
(5.8–12.5) Q3 8.4 (6.1–13.6)
Q4 8.7 (6.4–13.9)
Stolarz-
Skrzypek
et al. (2011)
(Belgium,
Czech
Republic,
Italy, Poland,
Russian
Federation)
FLEMENGHO/
EPOGH
Prospective cohort
N = 3,360
FLEMENGHO initial
cohort; N = 1,187
initial EPOGH initial
cohort
N = 2,096 included
in the analyses
(‘hypertension
cohort’) (excluded:
participants with
treated/untreated
hypertension at
baseline, history of
CVD, missing/
inaccurate 24-h
UNa at baseline)
Male (%)
T1 45.8 T2 46.0 T3 45.9
Hypertensive (%)
none
Diabetes mellitus
w T1 1.9 T2 1.6 T3 1.9
m T1 1.9 T2 2.4 T3 1.9
Age (mean (SD), years)
w T1 38.9 (15.3) T2 38.7
(14.1) T3 36.7 (13.1)
m T1 39.3 (16.0) T2 40.1
(15.4) T3 38.2 (13.4)
BMI (mean (SD), kg/m2)
w T1 23.6 (4.2) T2 24.1
(4.1) T3 25.0 (4.6)
m T1 24.6 (3.4) T2 24.9
(3.3) T3 25.2 (3.6)
Smokers (%)
w T1 32.3 T2 23.6 T3 23.9
m T1 37.7 T2 39.0 T3 32.8
Single 24-h urine
sample at baseline
and at last follow-up
examination
Inaccurate urine
collections
were deﬁned as a
volume < 300 mL/
24-h, a 24-h
UCr < 4 mmol
or > 25 mmol in
women and
< 6 mmol
or > 30 mmol in
men
Mean (SD)
Overall 174.2
(74.1)
Women
T1 94.4 (21.5)
(n = 375)
T2 147.4
(14.3)
(n = 385)
T3 222.1
(47.2)
(n = 373)
Men
T1 121.3
(27.9)
(n = 318)
T2 185.3
(16.1)
(n = 328)
T3 282.2
Incident
hypertension
BP measured at
baseline and
follow-up
Hypertension was
deﬁned as
SBP ≥ 140 mm Hg
or DBP ≥ 90 mm
Hg use of
antihypertensive
drugs.
Study population,
sex, age, BMI, SBP,
24-h UK, drinking
alcohol and
educational
attainment
HR for incident
hypertension
By tertile of UNa
(whole population as
reference)
T1 HR (95%
CI) = 1.00 (0.87,
1.16) (incidence
27.0%, 187 cases)
T2 HR (95%
CI) = 1.02 (0.89,
1.16) (incidence
26.6%, 190 cases)
T3 HR (95%
CI) = 0.98 (0.86,
1.12) (incidence
25.4%, 175 cases)
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References
(country)
Design Baseline characteristics
Na intake
assessment
method
UNa
(mmol/24 h)
Outcomes
assessed
Confounders
adjusted for
Results
Median duration:
6.5 years
Alcohol intake (5 g/day,%)
w T1 8.8 T2 9.9 T3 12.9
m T1 35.2 T2 32.9 T3 39.8
Higher education (%)
w T1 10.7 T2 14.3 T3 16.9
m T1 13.8 T2 12.5 T3 17.7
SBP (mean (SD), mm Hg)
w T1 115.6 (11.2) T2 115.6
(10.7) T3 116.8 (10.0)
m T1 121.8 (9.7) T2 121.8
(8.7) T3 122.0 (9.3)
DBP (mean (SD), mm Hg)
w T1 71.3 (8.0) T2 72.1
(7.6) T3 73.0 (8.0)
m T1 74.8 (8.2) T2 74.0
(7.9) T3 75.5 (7.7)
24-h UK (mean (SD), mmol)
w T1 51.2 (17.2) T2 62.9
(21.1) T3 69.4 (23.4)
m T1 62.5 (26.3) T2 73.5
(23.4) T3 84.1 (28.8)
24-h UCr (mean (SD), mmol)
w T1 8.6 (2.2) T2 9.6 (2.0)
T3 10.8 (2.5)
m T1 12.2 (3.1) T2 14.1
(3.2) T3 16.1 (3.4)
(56.4)
(n = 317)
BMI: body mass index; BP: blood pressure; 95% CI: 95% conﬁdence interval; CVD: cardiovascular disease; DBP: diastolic blood pressure; EPOGH: European Project on Genes in Hypertension;
FLEMENGHO: Flemish Study on Genes and Health Outcomes; GFR: glomerular ﬁltration rate; HR: hazard ratio; IMDM: insulin-mediated diabetes mellitus; IQR: interquartile range; m: men; mm Hg:
millimetre of mercury; N: number; Na: sodium; SBP: systolic blood pressure; PREVEND: Prevention of Renal and Vascular End-stage Disease; SD: standard deviation; UAlbumin: albumin urinary
excretion; UCa: calcium urinary excretion; UCr: creatinine urinary excretion; UK: potassium urinary excretion; UNa: sodium urinary excretion; w: women.
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J.2. Outcome of the RoB appraisal
J.2.1. Experimental studies
References
Risk of bias domains(a)
Tier
(b)
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Whelton et al. (1997) (TOPH I) ++ ++ + ++ + ++ ++ + 1
The Trials of Hypertension Collaborative
Research Group (1997) (TOPH II)
++ ++ + ++ + ++ ++ + 1
(a): Expert judgement was translated into a rating scale for each question to be answered as follows: (++): deﬁnitely low RoB;
(+): probably low RoB; (NR): not reported; (): probably high RoB; (): deﬁnitively high RoB.
(b): The individual rating for each question was combined by an algorithm and translated to an overall tier of reliability for each
individual study (RoB tier 1: low RoB; RoB tier 2: moderate RoB; RoB tier 3: high RoB).
J.2.2. Observational studies
References
Risk of bias domains(a)
Tier(b)
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Forman et al. (2012) +  ++ ++ + ++ 1
Stolarz-Skrzypek et al. (2011)    ++ ++ + 2
(a): Expert judgement was translated into a rating scale for each question to be answered as follows: (++): deﬁnitely low RoB;
(+): probably low RoB; (NR): not reported; (): probably high RoB; (): deﬁnitively high RoB.
(b): The individual rating for each question was combined by an algorithm and translated to an overall tier of reliability for each
individual study (RoB tier 1: low RoB; RoB tier 2: moderate RoB; RoB tier 3: high RoB).
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J.3. Descriptive forest plot
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Note
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Incidence of hypertension – HRs categorical and continuous
95% CI: 95% conﬁdence interval; HR: hazard ratio.
A hazard ratio > 1 indicates an increased risk of outcome with higher sodium intake.
Figure J.1: Descriptive forest plot of the eligible observational and experimental studies on the incidence of hypertension
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Appendix K – Outcome of the systematic review on risk of CVD
K.1. Evidence tables
References
(country)
Design
Baseline
characteristics
Na intake
assessment
method
UNa
(mmol/24 h)
Outcomes
assessed
Confounders
adjusted for
Results
Cook et al.
(2014)
(USA)
TOPH I/TOPH
II
Prospective
cohort
N = 2,974
TOPH I/TOPH II
participants not
in active Na
intervention
eligible for
follow-up
N = 2,275
included in the
analyses
(excluded: CVD
event during
trial period,
missing 24-h
UNa)
Duration:
10 years
(TOPH I)/
15 years
(TOPH II)
Men (%)
TOPH I 71, TOPH II 67
Hypertensive (treated/
untreated): none
Age (mean, years)
TOPH I
w Q1 44.6 Q2 44.7 Q3
43.0 Q4 42.7
m Q1 42.1 Q2 42.8 Q3
43.3 Q4 42.7
TOPH II
w Q1 44.4 Q2 43.8 Q3
43.1 Q4 44.0
m Q1 42.7 Q2 43.6 Q3
43.6 Q4 42.5
bw (mean, lb)
TOPH I
w Q1 151.3 Q2 162.4
Q3 174.1 Q4 183.7
m Q1 175.8 Q2 185.4
Q3 198.1 Q4 211.4
TOPH II
w Q1 172.7 Q2 181.4
Q3 192.0 Q4 203.1
m Q1 202.4 Q2 207.5
Q3 213.8 Q4 229.2
Ethnicity (%, black)
w Q1 19.8 Q2 22.6
Q3 28.8 Q4 30.4
m Q1 14.8 Q2 6.5
Q3 8.8 Q4 7.7
TOPH II
3 to 7 24-h collection
scheduled over
18 months in TOPH I
and over 3 to
4 years in TOPH II
To adjust for
potential inaccuracy
in collection,
controlled for UCr/bw
in multivariate model
or excluded subjects
with CVs of UCr/
bw ≥ 20% or 30%
(sensitivity analyses)
Men and women
Q1 < 100
Q2 100–156
Q3 157–208
Q4 ≥ 209
CVD death or event,
including MI, stroke,
coronary artery
bypass graft,
percutaneous
transluminal
coronary angioplasty.
Standardised
questionnaires sent
at 2-year intervals;
medical records
reviewed by study
physician (non-fatal
events); search for
National Death Index
(fatal events)
Age, sex, race/
ethnicity, clinic and
treatment assignment,
education status,
baseline weight,
alcohol se, smoking,
exercise, UK, family
history of CVD, change
in bw, change in
smoking and change
in exercise during trial
periods
HR (95% CI) for fatal
and non-fatal CVD
events
By continuous UNa (by
1 g (43-mmol)/day
increase):
1.17 (1.00–1.36) (193
cases, n = 2,275)
By quantiles of UNa:
Q1 0.68 (0.34–1.37)
(TOPH I 15 events/189
total, TOPH II 2
events/47 total)
Q2 0.75 (0.50–1.11)
(TOPH I 48 events/590
total, TOPH II 13
events/303 total)
Q3 1.00 (reference)
(TOPH I 40 events/427
total, TOPH II 34
events/341 total)
Q4 1.05 (0.68–1.62)
(TOPH I 23 events/191
total, TOPH II 18
events/224 total)
No signiﬁcant deviation
from linearity
(restricted cubic
spline).
Sensitivity analyses:
exclusion of subjects
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References
(country)
Design
Baseline
characteristics
Na intake
assessment
method
UNa
(mmol/24 h)
Outcomes
assessed
Confounders
adjusted for
Results
w Q1 34.5 Q2 30.4
Q3 28.1 Q4 18.2
m Q1 11.1 Q2 10.6
Q3 9.5 Q4 7.9
Smokers (%, current)
TOPH I
w Q1 14.8 Q2 10.6
Q3 11.0 Q4 21.7
m Q1 10.2 Q2 10.7
Q3 10.5 Q4 10.1
TOPH II
w Q1 10.3 Q2 8.7
Q3 13.5 Q4 9.1
m Q1 22.2 Q2 7.0
Q3 8.3 Q4 8.9
Alcohol intake (≥ 1
drink/wk,%)
TOPH I
w Q1 41.6 Q2 28.8
Q3 23.3 Q4 39.1
m Q1 63.6 Q2 55.2
Q3 52.5 Q4 42.9
TOPH II
w Q1 13.8 Q2 19.9
Q3 14.6 Q4 27.3
m Q1 55.6 Q2 42.2
Q3 44.0 Q4 40.1
College degree (%)
TOPH I
w Q1 46.5 Q2 46.2
Q3 42.5 Q4 39.1
m Q1 84.1 Q2 71.2
Q3 68.8 Q4 66.7
TOPH II
w Q1 62.1 Q2 50.3
Q3 44.9 Q4 45.4
m Q1 100.0 Q2 72.5
based on the CV for
UCr/bw: little change
in estimated
coefﬁcients
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References
(country)
Design
Baseline
characteristics
Na intake
assessment
method
UNa
(mmol/24 h)
Outcomes
assessed
Confounders
adjusted for
Results
Q3 67.1 Q4 62.9
SBP (mm Hg, mean)
TOPHI
W Q1 125.2 Q2 125.7
Q3 125.3 Q4 123.9
M Q1 124.3 Q2 124.2
Q3 125.2 Q4 125.3
TOPH II
W Q1 128.2 Q2 128.4
Q3 128.2 Q4 130.0
M Q1 127.7 Q2 127.5
Q3 126.7 Q4 127.6
DBP (mm Hg, mean)
TOPH I
W Q1 83.7 Q2 83.7 Q3
84.5 Q4 83.6
M Q1 84.0 Q2 83.7 Q3
84.0 Q4 83.7
TOPH II
W Q1 85.7 Q2 85.7 Q3
85.8 Q4 86.2
M Q1 85.8 Q2 86.1 Q3
85.9 Q4 86.2
24-h UK (mean, mmol)
TOPH I
w Q1 42 Q2 49 Q3 58
Q4 67
m Q1 51 Q2 60 Q3 68
Q4 78
TOPH II
w Q1 39 Q2 50 Q3 56
Q4 68
m Q1 56 Q2 60 Q3 69
Q4 75
24-h UCr (mean, g)
TOPH I
W Q1 0.9 Q2 1.1 Q3 1.3
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References
(country)
Design
Baseline
characteristics
Na intake
assessment
method
UNa
(mmol/24 h)
Outcomes
assessed
Confounders
adjusted for
Results
Q4 1.5
M Q1 1.3 Q2 1.5 Q3 1.7
Q4 2.0
TOPH II
W Q1 1.0 Q2 1.2 Q3 1.4
Q4 1.5
M Q1 1.5 Q2 1.7 Q3 1.9
Q4 2.2
Stolarz-
Skrzypek
et al. (2011)
(Belgium,
Czech
Republic,
Italy, Poland,
Russian
Federation)
FLEMENGHO/
EPOGH
Prospective
cohort
N = 3,360
FLEMENGHO
initial cohort;
N = 1,187 initial
EPOGH initial
cohort
N = 3,681
included in the
analyses
(‘outcome
cohort’)
(excluded:
participants with
history of CVD,
missing/
inaccurate 24-h
UNa at baseline)
Median duration:
7.9 years
Men (%)
T1 47.1 T2 47.4 T3 47.3
Hypertensive (treated)
(%)
w T1 14.9 T2 12.5 T3
16.6
m T1 11.1 T2 7.4 T3 8.9
Diabetes mellitus
w T1 3.3 T2 2.9 T3 4.9
m T1 5.0 T2 4.4 T3 4.5
Age (mean (SD), years)
w T1 42.5 (17.6) T2
41.0 (16.0) T3 39.2
(14.7)
m T1 41.8 (18.1) T2
41.3 (16.4) T3 39.5
(14.4)
BMI (mean (SD), kg/m2)
w T1 24.6 (5.1) T2 24.9
(4.6) T3 25.9 (5.3)
m T1 24.7 (3.8) T2 25.2
(3.8) T3 26.1 (4.3)
Smokers (%)
w T1 25.9 T2 22.2 T3
22.1
m T1 35.1 T2 37.3 T3
29.1
Alcohol intake (5 g/day,
%)
Single 24-h urine
sample at baseline
and at last follow-up
examination
Inaccurate urine
collections
were deﬁned as a
volume < 300 mL/
24-h, a 24-h
UCr < 4 mmol
or > 25 mmol in
women and
< 6 mmol
or > 30 mmol in men
Mean (SD)
Women
T1 95.1 (22.0)
(n = 645)
T2 150.2 (15.0)
(n = 658)
T3 231.7 (50.9)
(n = 638)
Men
T1 120.1 (28.4)
(n = 575)
T2 188.8 (17.6)
(n = 592)
T3 290.5 (56.2)
(n = 573)
CHD events included
fatal and non-fatal
MI and coronary
revascularisation.
Fatal and non-fatal
CVD events
comprised CHD
events, stroke, fatal
and non-fatal left
ventricular HF, aortic
aneurysm, cor
pulmonale and
pulmonary or arterial
embolism.
Hospitalisations for
unstable angina
coded as IHD.
Standardised
questionnaire at
follow-up visits.
Physicians
ascertained the
diseases reported on
the death certiﬁcates
or by the
questionnaires
against medical
records
Study population, sex,
and baseline variables:
age, BMI, 24-h UK,
antihypertensive drug
treatment, smoking
and drinking alcohol,
diabetes, total
cholesterol and
educational attainment
HRs expressed the risk
in each tertile of UNa
compared with the
overall risk in whole
group
HR (95% CI) for fatal
CVD events
T1 1.41 (0.94, 2.12)
(50 events, n = 1,220)
T2 0.98 (0.69, 1.40)
(24 events, n = 1,250)
T3 1.02 (0.71, 1.45)
(10 events,
n = 1,211)
HR (95% CI) for non-
fatal CVD events
T1 1.12 (0.90, 1.41)
(100 events,
n = 1,220)
T2 1.09 (0.89, 1.34)
(79 events, n = 1,250)
T3 0.92 (0.74, 1.13)
(53 events,
n = 1,211)
HR (95% CI) for non-
fatal CHD events
T1 1.41 (0.99, 2.01)
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References
(country)
Design
Baseline
characteristics
Na intake
assessment
method
UNa
(mmol/24 h)
Outcomes
assessed
Confounders
adjusted for
Results
w T1 10.7 T2 10.3 T3
14.0
m T1 34.3 T2 35.6 T3
44.0
Higher education (%)
w T1 11.6 T2 15.1 T3
19.3
m T1 15.3 T2 13.0 T3
19.7
SBP (mean (SD), mm
Hg)
w T1 123.3 (19.4)
T2 121.0 (16.8)
T3 121.7 (15.8)
m T1 128.7 (17.9)
T2 126.6 (14.9)
T3 128.1 (15.3)
DBP (mean (SD), mm
Hg)
w T1 74.7 (11.0) T2
74.6 (9.7) T3 75.4
(10.2)
m T1 77.8 (11.0) T2
76.6 (10.4) T3 79.0
(10.9)
24-h UK (mean (SD),
mmol)
w T1 51.6 (17.8) T2
61.0 (20.5) T3 69.1
(24.0)
m T1 61.6 (26.3) T2
71.6 (27.1) T3 84.5
(29.2)
24-h UCr (mean (SD),
mmol)
(45 events, n = 1,220)
T2 1.15 (0.87, 1.52)
(34 events, n = 1,250)
T3 0.87 (0.66, 1.15)
(19 events, n = 1,211)
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References
(country)
Design
Baseline
characteristics
Na intake
assessment
method
UNa
(mmol/24 h)
Outcomes
assessed
Confounders
adjusted for
Results
w T1 8.4 (2.2) T2 9.5
(2.0) T3 10.6 (2.5)
m T1 12.1 (3.2) T2 13.9
(3.4) T3 16.1 (3.8)
HR (95% CI) for non-
fatal stroke events
T1 1.05 (0.56, 1.96)
(13 events, n = 1,220)
T2 1.28 (0.75, 2.17)
(13 events, n = 1,250)
T3 0.78 (0.46, 1.33)
(7 events, n = 1,211)
Joosten et al.
(2014)
(Netherlands)
PREVEND
Prospective
cohort
N = 8,592 initial
cohort; IMDM
and pregnant
women
excluded;
oversampling of
subjects with
elevated albumin
excretion
(> 10 mg/L)
N = 7,543
included
(excluded:
participants with
CVD, renal
disease requiring
dialysis,
malignancies,
missing values of
covariates at
baseline)
Men (%)
Q1 48.7 Q2 48.7 Q3
48.7 Q4 48.7
Age (mean ± SD, years)
Q1 50  13 Q2 49  13
Q3 48  12 Q4 47  11
BMI (mean ± SD, kg/
m2)
Q1 25.0  3.7 Q2
25.5  3.7 Q3
26.1  4.1 Q4
27.5  4.8
Smoking status (never,
%)
Q1 30.1 Q2 32.1 Q3
28.6 Q4 29.9
SBP (mean ± SD, mm
Hg)
Q1 129  22 Q2
128  20 Q3 128  20
Q4 129  20
DBP (mean ± SD, mm
Hg)
Q1 74  10 Q2 74  10
Q3 74  10 Q4 74  9
Two 24-h
urine specimens
collected at baseline
(1997–1998)
Sensitivity analyses
excluding 24-h urine
samples with
possible over- or
undercollections (i.e.
samples
upper and lower
2.5% of the
difference between
the estimated and
measured volume of
a subject’s 24-h urine
sample.)
Men
Q1 < 122
Q2 122–154
Q3 155–190
Q4 > 190
Women
Q1 < 95
Q2 95–121
Q3 122–151
Q4 > 151
CHD deﬁned as MI,
acute and subacute
IHD and coronary
artery bypass
grafting or
percutaneous
transluminal
coronary angioplasty.
Data from Dutch
bureau of statistics
(fatal events) and
Dutch national
registry of hospital
discharge diagnoses
(non-fatal events)
Age, sex, body mass
index, smoking status,
alcohol intake,
parental history of
coronary heart
disease, type 2
diabetes mellitus, total
to HDL cholesterol
ratio, and 24-h UK,
magnesium and
creatinine excretion
HR (95% CI) for fatal
and non-fatal CHD
By continuous UNa (by
1 g (43-mmol)/day
increase):
1.07 (0.98–1.18)
p = 0.15 (452 cases;
71,491 person-years)
By sex-speciﬁc
quintiles of UNa:
Q1 (reference) (123
cases, 17,738 person-
years)
Q2 0.99 (0.76–1.29)
(111 cases, 17,975
person-years)
Q3 1.09 (0.83–1.44)
(112 cases, 17,878
person-years)
Q4 1.19 (0.88–1.62)
(106 cases, 18,000
person-years)
No signiﬁcant deviation
from linearity (restricted
cubic spline).
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References
(country)
Design
Baseline
characteristics
Na intake
assessment
method
UNa
(mmol/24 h)
Outcomes
assessed
Confounders
adjusted for
Results
Median duration:
10.5 years (IQR
9.9–10.8)
Antihypertensive drugs
(%)
Q1 14.3 Q2 12.6 Q3
12.4 Q4 12.7
24-h UK (median (IQR),
mmol)
Q1 59 (47–73) Q2 67
(56–81) Q3 73 (61–86)
Q4 80 (66–95)
24-h UCr (median
(IQR), mmol)
Q1 10.3 (8.4–12.7) Q2
11.5 (9.5–13.8) Q3 12.3
(10.1–15.1) Q4 13.6
(11.1–16.8)
24-h UAlbumin (median
(IQR), mmol)
Q1 8.1 (5.5–14.7) Q2
9.1 (6.3–16.4) Q3 9.4
(6.4–17.1) Q4 10.3
(7.0–19.3)
Evidence for effect
modiﬁcation bymean
arterial pressure
(Pinteraction = 0.08) and
plasma NT-proBNP
concentration (Pinteraction
= 0.002).
Sensitivity analyses:
exclusion of subjects
with potential under- or
overcollections in 24-h
urine samples: results
unchanged
restricted to subjects
with
UAlbumin > 10 mg/L:
results unchanged
Kieneker
et al. (2018)
(Netherlands)
PREVEND
Prospective
cohort
N = 8,592 initial
cohort
N = 7,330
included
(excluded:
participants with
CVD, renal
disease requiring
dialysis, missing
values of
covariates at
baseline)
Men (%)
Q1 48.6 Q2 48.6 Q3
48.6 Q4 48.6 Q5 48.6
Age (mean ± SD, years)
Q1 50.5  13.0 Q2
50.1  12.9 Q3
49.2  12.5 Q4
48.2  12.0 Q5
47.0  11.1
BMI (mean ± SD, kg/m2)
Q1 25.0  3.8 Q2
25.3  3.6 Q3
25.7  4.0 Q4
26.3  4.0 Q5
27.8  4.9
Ethnicity (% white)
Two 24-h
urine specimens
collected at baseline
(1997–1998) and two
24-h urine specimens
collected during
follow-up (2001–
2003)
Men
Q1 < 116 (712)
Q2 116–142
(713)
Q3 143–167
(713)
Q4 168–201
(713)
Q5 > 201 (713)
Women
Q1 < 89 (753)
Q2 89–110 (754)
Q3 111–132
(753)
Q4 133–160
(753)
Haemorrhagic,
ischaemic,
unspeciﬁed stroke,
fatal and non-fatal
events
Data from municipal
registers (fatal
events) and Dutch
national registry of
hospital discharge
diagnoses (non-fatal
events)
Age, sex, height,
weight, race/ethnicity,
smoking status,
alcohol consumption,
education, type 2
diabetes, and total to
HDL cholesterol ratio,
24-h UK, magnesium,
creatinine and albumin
and estimated GFR
HR (95% CI) for fatal
and non-fatal stroke
By continuous UNa (by
51 mmol/24 h
decrease):
1.44 (1.14–1.82) (183
cases; 83,189 person-
years)
By sex-speciﬁc
quintiles of UNa:
Q1 1.45 (0.92–2.29)
(57 cases, 16,272
person-years)
Q2 1.13 (0.71–1.79)
(49 cases, 16,515
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References
(country)
Design
Baseline
characteristics
Na intake
assessment
method
UNa
(mmol/24 h)
Outcomes
assessed
Confounders
adjusted for
Results
Oversampling of
subjects with
elevated albumin
excretion
(> 10 mg/L)
Median duration:
12.5 years (IQR
11.9–12.9)
Q1 93.9 Q2 95.2 Q3
96.5 Q4 96.1 Q5 96.0
Smoking status (current,
%)
Q1 39.0 Q2 33.1 Q3
33.9 Q4 31.6 Q5 32.3
Education (higher
vocational education or
university, %)
Q1 31.1 Q2 32.9 Q3
32.2 Q4 31.4 Q5 26.5
SBP (mean ± SD, mm
Hg)
Q1 129  21 Q2
129  20 Q3 128  20
Q4 128  20 Q5
129  18
DBP (mean ± SD, mm
Hg)
Q1 74  10 Q2 74  10
Q3 74  10 Q4 73  10
Q5 74  9
Antihypertensive drugs
(%)
Q1 14.7% Q2 12.0% Q3
12.2% Q4 12.3% Q5
13.0%
24-h UK (median (IQR),
mmol)
Q1 57 (46–72) Q2 66
(55–79) Q3 70 (58–83)
Q4 74 (62–88) Q5 81
(68–96)
24-h UCr (median
(IQR), mmol)
Q1 10.0 (8.3–12.6) Q2
11.2 (9.3–13.6) Q3 11.8
Q5 > 160 (753) person-years)
Q3 (reference)
(33 cases, 16,774
person-years)
Q4 1.04 (0.64–1.71)
(25 cases, 16,720
person-years)
Q5 0.81 (0.46–1.41)
(19 cases, 16,908
person-years)
Adjustment for
potential mediators
(SBP and
antihypertensive
medication, plasma
renin, aldosterone, and
sodium levels) did not
change the result.
No evidence for effect
modiﬁcation by age,
sex, BMI,
hypertension, and UK
(all Pinteraction > 0.10).
Sensitivity analyses:
excluding individuals
who were taking
antihypertensive drugs
at baseline (n = 6,388,
126 cases): results
unchanged.
excluding individuals
with malignancies,
type 2 diabetes, or
chronic kidney disease
at baseline (n = 6,054,
112 cases): results
unchanged.
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References
(country)
Design
Baseline
characteristics
Na intake
assessment
method
UNa
(mmol/24 h)
Outcomes
assessed
Confounders
adjusted for
Results
(9.8–14.3) Q4 12.5
(10.3–15.6) Q5 13.8
(11.3–16.8)
24-h UAlbumin (median
(IQR), mmol)
Q1 8.0 (5.5–14.4) Q2
8.9 (6.1–16.0) Q3 9.1
(6.3–16.2) Q4 9.5
(6.5–18.1) Q5
10.5 (7.0–19.9)
Lelli et al.
(2018)
(Italy)
InCHIANTI
Prospective
cohort
N = 1,170 initial
cohort
N = 514
included
(excluded:
younger than
65 years,
participants with
CVD at baseline)
Median duration:
9 years
NR for the subcohort Single 24-h
urine specimen
collected at baseline
(1998–2000)
NR for the
subcohort
Non-fatal CVD event,
including angina
pectoris, MI, heart
failure, stroke
Standardised
questionnaire at
follow-up visits;
clinical
documentation
reviewed
Age, sex, education,
CKD-EPI, SBP, pack/
years, hypertension,
diabetes, BMI, caloric
intake/bw, and
antihypertensive drugs
and diuretics)
RR (95% CI) for non-
fatal CVD events
By continuous UNa (By
NR mmol/day
increase):
0.96 (0.90–1.02)
(169 cases, n = 514)
Tuomilehto
et al. (2001)
(Finland)
Prospective
cohort
N = 3,607 initial
cohort
Non-fatal CHD
analysis
Age (mean ± SD, years)
w Q1 45.7  11.6 Q2
45.4  11.8 Q3
44.8  11.1 Q4
45.6  11.3
m Q1 45.4  11.6 Q2
45.3  11.0 Q3
46.2  10.4 Q4
Single 24-h
urine specimens
collected at baseline
Participants reporting
incomplete collection
excluded from the
analysis
Median (min–
max)
Male
205 (25–552)
Female
154 (12–512)
Coronary deaths,
non-fatal coronary
events, stroke
events,
cardiovascular
deaths
Statistics Finland
(fatal events) and
Age, study year,
smoking, serum total
and HDL cholesterol,
SBP and BMI
HR (95% CI) for non-
fatal CHD events
By 100 mmol/24-h
increase in UNa
Men
1.34 (1.06–1.70)
(98 cases, n = 1145)
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References
(country)
Design
Baseline
characteristics
Na intake
assessment
method
UNa
(mmol/24 h)
Outcomes
assessed
Confounders
adjusted for
Results
N = 2,402
(prevalent cases
of CHD also
excluded)
Non-fatal stroke
analysis
N = 2,420
(prevalent cases
of stroke also
excluded)
Duration: up to
14 years
45.4  10.6
BMI (mean ± SD, kg/
m2)
w Q1 24.6  4.2 Q2
25.1  4.0 Q3
26.3  4.6 Q4
27.8  5.4
m Q1 25.5  2.4 Q2
26.4  3.3 Q3
26.9  3.3 Q4
28.1  4.2
Smoking (current,%)
w Q1 15% Q2 20% Q3
18% Q4 16%
m Q1 31% Q2 40% Q3
33% Q4 44%
SBP (mean ± SD, mm
Hg)
w Q1 141  22
Q2 140  22
Q3 141  22
Q4 142  22
m Q1 144  22
Q2 145  19
Q3 148  20
Q4 147  19
DBP (mean ± SD, mm
Hg)
w Q1 83  12
Q2 83  12
Q3 83  12
Q4 85  22
m Q1 86  11
Q2 86  12
Q3 89  13
Q4 90  13
national hospital
discharge register
(non-fatal events)
Women
1.35 (0.77–2.35)
(30 cases, n = 1257)
Men + Women
1.34 (1.08–1.67)
(128 cases,
n = 2,402)
HR for non-fatal stroke
events
By 100 mmol/24-h
increase in UNa
Men
1.00 (0.68–1.47)
(43 cases, n = 1161)
Women
1.34 (0.87–2.07)
(41 cases, n = 1259)
Men + Women
1.13 (0.84–1.51)
(84 cases, n = 2,420)
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BMI: body mass index; BP: blood pressure; bw: body weight; 95% CI: 95% conﬁdence interval; CKD-EPI: estimated creatinine clearance; CHD: coronary heart disease; CVD: cardiovascular
disease; DBP: diastolic blood pressure; EPOGH: European Project on Genes in Hypertension; FLEMENGHO: Flemish Study on Genes and Health Outcomes; GFR: glomerular ﬁltration rate; HDL: high
density lipoprotein; HF: heart failure; HR: hazard ratio; IHD: ischaemic heart disease; IMDM: insulin-mediated diabetes mellitus; IQR: interquartile range; m: men; mm Hg: millimetre of mercury;
MI: myocardial infarction; N: number; Na: sodium; NR: not reported; NT-proBNP: N-terminal pro-B-type natriuretic peptide; RR: relative risk; SBP: systolic blood pressure; SD: standard deviation;
TOPH: Trials of Hypertension Prevention; UAlbumin: urinary albumin; UCr: creatinine urinary excretion; UK: potassium urinary excretion; UNa: sodium urinary excretion; w: women.
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K.2. Outcome of the RoB appraisal
K.2.1. Observational studies
References Outcomes
Risk of bias domains(a)
Tier(b)
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e
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Lelli et al. (2018) Non-fatal CVD (any)  ++ +  ++  2
Joosten et al. (2014) Fatal and non-fatal CHD + NR ++ ++ ++ ++ 1
Kieneker et al. (2018) Fatal and non-fatal stroke + NR + + ++ + 1
Stolarz-Skrzypek et al. (2011) Fatal CVD
Fatal and non-fatal CVD
Fatal and non-fatal CHD
Fatal and non-fatal stroke
+   + ++  2
Cook et al. (2014) Fatal and non-fatal CVD (any) ++ + ++ ++ ++ ++ 1
Tuomilehto et al. (2001) Non-fatal stroke
Non-fatal CHD
 ++ + + ++  2
CHD: coronary heart disease; CVD: cardiovascular disease
(a): Expert judgement was translated into a rating scale for each question to be answered as follows: (++): deﬁnitely low RoB;
(+): probably low RoB; (NR): not reported; (): probably high RoB; (): deﬁnitively high RoB.
(b): The individual rating for each question was combined by an algorithm and translated to an overall tier of reliability for each
individual study (RoB tier 1: low RoB; RoB tier 2: moderate RoB; RoB tier 3: high RoB).
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K.3. Descriptive forest plots
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3681
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95% CI: 95% conﬁdence interval; HR: hazard ratio; HTN: hypertensive; UNa: sodium urinary excretion.
A hazard ratio > 1 indicates an increased risk of outcome with higher sodium intake.
Figure K.1: Descriptive forest plot of the eligible observational studies on stroke
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CHD: coronary heart disease; 95% CI: 95% conﬁdence interval; HR: hazard ratio; HTN: hypertensive; UNa: sodium urinary excretion.
A hazard ratio > 1 indicates an increased risk of outcome with higher sodium intake.
Figure K.2: Descriptive forest plot of the eligible observational studies on coronary heart disease
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Figure K.3: Descriptive forest plot of the eligible observational studies on cardiovascular disease
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Appendix L – Outcome of the systematic review on bone health
L.1. Evidence table
References
(country)
Design
Baseline
characteristics
mean  SD (N)
Na intake
assessment
method
UNa (mg/day)
Mean  SD
(N)
Outcomes
assessed
Confounders
adjusted for
Key ﬁndings
Devine et al.
(1995); Prince
et al. (1995)
(Australia)
RCT in postmenopausal
women (≥ 10 years after
menopause)
Group 1: Ca suppl.
(1 g/day)
Group 2: Ca suppl.
(1 g/day) + exercise
programme
Group 3: Placebo
Group 4: ~200 mL milk/
day (1 g Ca/day)
N = 196 screened
N = 168 randomised
(42/group)
Duration: 2 years
Age: 63 (168)
bw: 66  10 (191)
Nutrient intakes based
on 4-day weighed diet
records (190):
Protein: 76  16 g/day
Ca (food only): 805
 320 mg/day
P: 1,269  311 mg/day
Energy:
1,632  348 kcal/day
Single 24-h urine
samples collected
at baseline, year 1
and year 2;
excretions
averaged over the
2-year period.
No information on
instructions to
participants or on
measures to
check
completeness of
collections.
Baseline UNa:
2,783  1,081
(196)
Average year 1
and 2 UNa:
3,049  808
(127)
BMD (total hip,
intertrochanter,
femoral neck,
ultradistal ankle,
lumbar spine)
By DEXA at
baseline, 1 year
and 2 years
Body weight,
change in METs/day
over the 2-year
period, average
daily Ca intake
Multiple regression
analysis:
Negative associations
between average
UNa and 2-year
change in BMD for
total hip (SRC =
0.20, p = 0.002)
and ultradistal ankle
(SRC = 0.18,
p = 0.016)
Ilich et al.
(2010)
(USA)
RCT in postmenopausal
women (≥ 5 years after
menopause); all
supplemented with Ca
(630 mg/day) and
vitamin D (~ 400 IU/day)
Group 1: instructed to
reduce Na intake to
1,500 mg/day
Age: 68.6  7.1 (136)
bw: 68.0  11.3 (136)
BMI: 26.0  3.8 (136)
Nutrient intakes based
on 4-day weighed diet
records (136):
Protein: 70.6  18.6
g/day
Ca (food only): 872
 365 mg/day
P: 1,077  351 mg/day
Single 24-h urine
samples collected
every 6 months.
Cumulative Na/Cr
used as variable.
Careful
instructions to
participants and
use of Cr to
screen for errors
Baseline UNa:
2,404  963
(136)
Baseline UNa/g
Cr:
2,465  903
(136)
BMD (composite
femur, forearm,
lumbar spine,
total body)
By DEXA at
baseline and
every 6 months
Age, height,
cumulative lean
and/or fat tissue,
cumulative total
calcium intake and
cumulative modes
of physical activity
Multiple regression
analysis (ITT):
Positive associations
between cumulative
UNa/Cr and BMD at
36 months at LS
(Coeff. = 5.85e5,
p = 0.056), at
forearm (Coeff. =
8.12e5, p = 0.076)
and total body BMD
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References
(country)
Design
Baseline
characteristics
mean  SD (N)
Na intake
assessment
method
UNa (mg/day)
Mean  SD
(N)
Outcomes
assessed
Confounders
adjusted for
Key ﬁndings
Group 2: usual Na intake
(~ 3,000 mg/day)
N = 136 randomised
(68/group)
N = 97 completed
Duration: 3 years
Energy:
1,691  382 kcal/day
or incomplete
collection
(Coeff. = 2.81e5,
p = 0.041)
Random-effects
regression analysis
(accounting for
repeated measures
and missing data):
Main effect of UNa in
the forearm: higher
UNa associated with
higher BMD at
baseline and
subsequent time
points (t = 2.63,
p = 0.0089). Similar
observation in the
spine. No effect on
total body or femoral
BMD
BMD: bone mineral density; BMI: body mass index; bw: body weight; Ca: calcium; Cr: creatinine; DEXA: dual-energy X-ray technology; MET: metabolic equivalent activity; IU: international unit;
N: number; Na: sodium; NR: not reported; P: phosphorus; RCT: randomised controlled trial; SD: standard deviation; SRC: standardised regression coefﬁcient; UNa: urinary sodium excretion.
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L.2. Outcome of the RoB
L.2.1. Observational evidence
References
Risk of bias domains(a)
Tier(b)
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Devine et al. (1995) +   ++ ++ ++ 2
Ilich et al. (2010) ++ + + ++ + + 1
(a): Expert judgement was translated into a rating scale for each question to be answered as follows: (++): deﬁnitely low RoB;
(+): probably low RoB; (NR): not reported; (): probably high RoB; (): deﬁnitively high RoB.
(b): The individual rating for each question was combined by an algorithm and translated to an overall tier of reliability for each
individual study (RoB tier 1: low RoB; RoB tier 2: moderate RoB; RoB tier 3: high RoB).
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Appendix M – Expert knowledge elicitation
In 2014, EFSA published a guidance on expert knowledge elicitation (EKE) in food and feed safety
risk assessment (EFSA, 2014). The reader is referred to the guidance for general information about the
objectives, procedures and methods of EKE methods. Appendix M details the speciﬁc process used for
the two EKEs that were conducted to inform the setting of DRVs for sodium.
M.1. Principle
EKE refers to the drawing out of knowledge from one or more experts, following a transparent,
structured and comprehensivemethod based on rigorous probabilistic judgement techniques (EFSA, 2014).
Through the EKE, experts can be asked for judgements about an uncertain quantity of interest.
The method aims at obtaining from the experts not only their ‘best judgement’ of the quantity of
interest based on the available evidence, but also a representation of the uncertainty surrounding it.
M.2. The Shefﬁeld protocol
The Shefﬁeld protocol is an EKE method that is based on behavioural aggregation, i.e. judgements
of several experts are combined via a moderated discussion (EFSA, 2014).14
The main steps of the protocol are illustrated in Figure M.1. It is characterised by two rounds of
judgements from the experts. In the ﬁrst round, experts answer the elicitation question privately, by
deriving their individual uncertainty probability distribution. The individual judgements, together with
their rationale (see Sections M.3 and M.4 below), are then discussed by the group. In the second round,
the group agrees on a consensus judgement through a moderated group discussion. To that end, the
group is requested to express the reasonable judgement of an impartial expert informed by the range of
judgements and rationales expressed in the ﬁrst round. The ﬁnal outcome of the EKE is an uncertainty
probability distribution that represents the experts aggregated judgement about the quantity of interest.
The protocol requires an experienced facilitator to manage the experts, and to address possible
sources of bias in group interactions.
STEP 0
•Formulaon of the elicitaon queson and preparaon of the evidence dossier(a) 
STEP 1
•Collecve review of the 'evidence dossier'(a) by the experts
STEP 2
•Elicitaon of separate uncertainty probability distribuons from each expert in 
parallel(b)
STEP 3
•Collecve discussion about the individual judgements and their raonale
STEP 4
•Elicitaon of the consensus distribuon (aggregated probability curve)(c)
STEP 5
•Documentaon of the process, discussion and decisions 
(a): The evidence dossier documents all the evidence and related uncertainties relevant to the formulation of
the expert judgement (see Section M.3 below).
(b): In this step, each expert answered the EKE questions individually. To that end, experts had to express the
probability that each of the proposed ranges of sodium intake/excretion would include the ‘true’ level of
interest (roulette method, see Section M.4 below). As a result, each expert provides his/her own uncertainty
probability distribution.
(c): Following the collective discussion, a consensus uncertainty probability distribution is elicited from the group of
experts, which reﬂect the aggregated view of the experts on the parameter of interest and related uncertainty.
Figure M.1: Main steps of the EKE process following the Shefﬁeld method
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M.3. Preparatory phase: elicitation questions and evidence dossier
Based on the review of the available evidence, it was considered that (i) data on the relationship
between sodium intake and level of blood pressure or CVD risk could inform about the levels of sodium
intake associated to a reduced risk of chronic diseases; and (ii) balance studies could inform about the
levels of sodium intake that are adequate to maintain a null sodium balance. Because of the limited
evidence available and of the associated uncertainties, it was not possible to identify such levels of
sodium intake with certainty. Two questions were formulated to elicit evidence-based judgement of the
experts about the levels of interest:
EKE question 1: What is the lowest level of sodium intake at which the risk of chronic disease (i.e.
stroke, CHD) is minimised in the majority (≥ 97.5%) of the general population of adults?
EKE question 2: What is the lowest level of sodium intake which is adequate (i.e. amount which
allows to maintain sodium balance) for the majority (≥ 97.5%) of the general population of adults?
Through the EKE, experts are required to formulate evidence-based judgements, providing a
rationale. An evidence dossier was prepared before the EKE meeting, which assembled all the relevant
evidence into a single document, in the form of structured tables and graphical representations (BOX 2).
During the process, the experts are requested to provide their rationales behind their probability
assessments by referring to the dossier.
The two EKEs were conducted with the seven experts of the EFSA working group on DRVs for
minerals,15 who had been in charge of selecting, reviewing and appraising the available evidence. All
experts received a training on the method before starting the elicitation process.
BOX 2 – Content of the evidence dossier
EKE question 1:
a) All relevant evidence on the relationship between sodium and blood pressure, including:
• The outcome of the meta-regression modelling of sodium and blood pressure
• The data from the eligible randomised studies on the incidence of hypertension
• The data from the eligible prospective cohort study on blood pressure
• The data from the eligible prospective cohort studies on the incidence of hypertension
• Considerations about the reliability, external validity and consistency of each source of
evidence
b) All relevant evidence on the relationship between sodium and risk of CVD, including:
• The data from the eligible prospective cohort studies on risk of stroke
• The data from the eligible prospective cohort studies on risk of coronary heart disease
• The data from the eligible prospective cohort studies on risk of CVD
• Considerations about the reliability, external validity and consistency of each source of
evidence
• The outcome of the risk of bias assessment for each individual study
• Graphical representations of the dose-responses from the eligible observational studies on
coronary heart disease and stroke
• A summary of relevant mechanistic data
EKE question 2:
• The data from the eligible balance studies
• Considerations about the reliability, external validity and consistency of the available evidence
• A summary of relevant mechanistic data
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M.4. Elicitation of the uncertainty probability distributions: the
roulette method
For illustrative purposes, the uncertain quantity of interest is denoted X. The objective of the EKE is
to elicit a probability distribution for X from the experts. The roulette method was used for the EKEs
on sodium (Johnson et al., 2010; EFSA, 2014). The range of possible values for X was divided into
ﬁxed intervals (bins) (Figure M.2). In answering the elicitation questions, experts were asked to
distribute 20 chips into the bins, with the probability of X lying in a particular bin interpreted as the
proportion of chips allocated into that bin. As the total number of chips was 20, each chip represented
5% probability.
In the ﬁrst round of judgements, one histogram was obtained from each expert, representing his/her
uncertainty probability distribution. In the second round of judgements, the experts built a group
histogram, i.e. consensus uncertainty probability distribution, through discussion. The group consensus
uncertainty probability distributions elicited in response to the two EKE questions are provided in
Figures 1 and 2. The rationales for the distributions were documented and are reported in Tables 9
and 10.
M.5. Derivation of parametric distributions from the group consensus
uncertainty probability distributions
Parametric distributions were ﬁtted to the group consensus uncertainty probability distributions to
derive probability density functions. This allows the derivation of probabilities for values within the
range of each bin used for the elicitation. Several parametric distributions (e.g. normal, log-normal,
truncated normal, gamma, Weibull and logistic) have been considered as possible candidates to
estimate the probability density functions that better ﬁt the centiles obtained through the EKE process.
Log-normal distributions were ﬁnally chosen based on indicators of goodness of ﬁt (Akaike Information
Criterion and Bayesian Information Criterion), with the following parameters: 0.72 (mean) and 0.23
(standard deviation) for the question on sodium intake at which CVD risk is reduced; 0.5 (mean) and
0.3 (standard deviation) for the question on sodium balance.
Based on the two probability density functions, cumulative uncertainty density functions were
derived (Figure 3) and served as the basis to inform the setting of the reference value for sodium.
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Figure M.2: Illustration of the roulette method. In this example, a range of possible values for X has
been set between 5 and 13. Each orange rectangle represents one chip. For instance, by
placing four of their 20 chips in the bin (6,7) the expert expresses a probability of 4/20
(20%) that the ‘true value’ of X lies in that bin. The probability that the range 6 to 12
includes the ‘true value’ of X is 100%.
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Annex A – Protocol for sections 5.5 and 6 of the scientiﬁc opinion on DRVs
for sodium: Assessment of the relationship between sodium intake and
pre-speciﬁed health outcomes, including dose–response relationships, and
integration of different lines of evidence for setting DRVs for sodium
Annex A can be found in the online version of this output (‘Supporting information’ section):
https://doi.org/10.2903/j.efsa.2019.5778
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Annex B – Analysis of evidence from published scientiﬁc literature as
preparatory work for the setting of Dietary Reference Values for Sodium
Annex B can be found in the online version of this output (‘Supporting information’ section):
https://doi.org/10.2903/j.efsa.2019.5778
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